

# Plasminogen Activators, Tissue Degradation, and Cancer

Advances in Cancer Research

44, 139-266

DOI: [10.1016/s0065-230x\(08\)60028-7](https://doi.org/10.1016/s0065-230x(08)60028-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. <i>British Journal of Dermatology</i> , 1985, 113, 257-263.	1.4	30
2	Plasminogen activator in mouse and rat oocytes: Induction during meiotic maturation. <i>Cell</i> , 1985, 43, 551-558.	13.5	162
3	Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. <i>FEBS Letters</i> , 1986, 196, 269-273.	1.3	59
4	Local synthesis of plasminogen by the seminiferous tubules of the testis. <i>FEBS Letters</i> , 1986, 204, 193-197.	1.3	24
5	Plasminogen activator inhibitor type-1 : reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. <i>FEBS Letters</i> , 1986, 209, 213-218.	1.3	195
6	Transforming growth factor $\beta^2$ alters plasminogen activator activity in human skin fibroblasts. <i>Experimental Cell Research</i> , 1986, 164, 399-407.	1.2	109
7	Normal and malignant cells, including neurons, deposit plasminogen activator on the growth substrata. <i>Experimental Cell Research</i> , 1986, 166, 31-46.	1.2	43
8	Degradation of insulin and glucagon by a factor associated with Walker 256 carcinosarcoma cells. <i>Cancer Letters</i> , 1986, 31, 77-85.	3.2	1
9	Interactions of serine proteases with cultured fibroblasts. <i>Journal of Cellular Biochemistry</i> , 1986, 32, 281-291.	1.2	17
10	Hormonal regulation of extracellular plasminogen activators and Mr $\approx$ 54000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies. <i>Molecular and Cellular Endocrinology</i> , 1986, 45, 137-147.	1.6	68
11	Species differences in the detection of high molecular weight urinary plasminogen activators. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1986, 84, 287-293.	0.2	9
12	A gliia-derived neurite promoting factor with protease inhibitory activity belongs to the protease nexins. <i>Cell</i> , 1986, 47, 687-693.	13.5	302
13	An anticatalytic monoclonal antibody to avian plasminogen activator: Its effect on behavior of RSV-transformed chick fibroblasts. <i>Cell</i> , 1986, 45, 905-915.	13.5	119
14	Suppression of plasminogen activator activity by dexamethasone in cultured cardiac myocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 1986, 18, 1117-1124.	0.9	10
15	Cell Interactions during the Seminiferous Epithelial Cycle. <i>International Review of Cytology</i> , 1986, 104, 115-151.	6.2	140
16	Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells.. <i>EMBO Journal</i> , 1986, 5, 855-861.	3.5	73
17	Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells. <i>Biochemical Journal</i> , 1986, 239, 497-503.	1.7	101
18	Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 6776-6780.	3.3	374

#	ARTICLE	IF	CITATIONS
19	Human tumor cells synthesize and secrete alpha-2-macroglobulin in vitro. <i>International Journal of Cancer</i> , 1986, 37, 81-88.	2.3	26
20	Identification and localization of urokinase-type plasminogen activator in human NK-cells. <i>International Journal of Cancer</i> , 1986, 38, 355-360.	2.3	13
21	Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. <i>International Journal of Cancer</i> , 1986, 38, 719-727.	2.3	94
22	The receptor for urokinase-plasminogen activator. <i>Journal of Cellular Biochemistry</i> , 1986, 32, 179-186.	1.2	79
23	Characterization of plasminogen activator from two human renal carcinoma cell lines. <i>Journal of Cellular Physiology</i> , 1986, 126, 435-443.	2.0	10
24	Tissue-type plasminogen activator in rat adrenal medulla. <i>Histochemistry</i> , 1986, 85, 431-436.	1.9	47
25	Tumors: Wounds That Do Not Heal. <i>New England Journal of Medicine</i> , 1986, 315, 1650-1659.	13.9	3,899
26	Effect of oxygen on the tetrazolium reaction for glucose 6-phosphate dehydrogenase in cryosections of human breast carcinoma, fibrocystic disease and normal breast tissue. <i>Vigiliae Christianae</i> , 1986, 50, 13-25.	0.1	9
27	Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta.. <i>Journal of Cell Biology</i> , 1986, 103, 2403-2410.	2.3	444
28	Enzyme-Linked Immunosorbent Assay for Human Urokinase-Type Plasminogen Activator and its Proenzyme Using a Combination of Monoclonal and Polyclonal Antibodies. <i>Journal of Immunoassay</i> , 1986, 7, 209-228.	0.3	45
29	Plasminogen activator in mammalian skeletal muscle: characteristics of effect of denervation on urokinase-like and tissue activator.. <i>Journal of Cell Biology</i> , 1986, 103, 1415-1421.	2.3	39
30	Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissue-type plasminogen activator.. <i>Journal of Cell Biology</i> , 1987, 105, 977-981.	2.3	78
31	Production of plasminogen activators and inhibitor by serially propagated endothelial cells from adult human blood vessels.. <i>Arteriosclerosis (Dallas, Tex )</i> , 1987, 7, 389-400.	4.9	97
32	Intraocular Fibrinolysis With Recombinant Human Tissue Plasminogen Activator. <i>JAMA Ophthalmology</i> , 1987, 105, 1277.	2.6	76
33	Tissue-Type Plasminogen Activator in Somatostatin Cells of Rat Pancreas and Hypothalamus*. <i>Endocrinology</i> , 1987, 121, 2238-2244.	1.4	28
34	Role of transforming growth factor-beta in the development of the mouse embryo.. <i>Journal of Cell Biology</i> , 1987, 105, 2861-2876.	2.3	752
35	Scaling and Structure-Function Relationships. <i>Annual Review of Physiology</i> , 1987, 49, 105-106.	5.6	4
36	Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. <i>Journal of Cell Biology</i> , 1987, 104, 801-804.	2.3	613

#	ARTICLE	IF	CITATIONS
37	The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells.. Journal of Cell Biology, 1987, 105, 957-963.	2.3	374
38	Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.. Journal of Cell Biology, 1987, 104, 705-712.	2.3	142
39	Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface.. Journal of Cell Biology, 1987, 104, 1281-1289.	2.3	127
40	Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells.. Journal of Cell Biology, 1987, 105, 2535-2541.	2.3	264
41	Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. Journal of Cell Biology, 1987, 104, 1085-1096.	2.3	298
42	Mechanisms of Tumour Cell Metastasis. Journal of Cell Science, 1987, 1987, 181-197.	1.2	17
43	Dexamethasone Inhibition of Tissue-Type Plasminogen Activator (tPA) Activity: Paradoxical Induction of Both tPA Antigen and Plasminogen Activator Inhibitor*. Molecular Endocrinology, 1987, 1, 97-101.	3.7	42
44	Plasminogen Activators in Human Xenografted Oro-pharyngeal Squamous Cell Carcinomas. Acta Oto-Laryngologica, 1987, 104, 568-572.	0.3	5
45	Inhibition of protein synthesis in LLC-PK1 cells increases calcitonin-induced plasminogen-activator gene transcription and mRNA stability. Biochemical Journal, 1987, 242, 387-392.	1.7	65
46	Glycosaminoglycans on fibroblasts accelerate thrombin inhibition by protease nexin-1. Biochemical Journal, 1987, 245, 543-550.	1.7	58
47	Chapter 35 Plasminogen activators and inhibitors: roles in muscle and neuromuscular regeneration. Progress in Brain Research, 1987, 71, 423-431.	0.9	22
48	Binding of urokinase to specific receptor sites on human breast cancer membranes. British Journal of Cancer, 1987, 55, 13-16.	2.9	45
49	Stage-Specific Regulation of Plasminogen Activator Secretion in the Rat Seminiferous Epithelium*. Endocrinology, 1987, 120, 142-145.	1.4	35
50	Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 8548-8552.	3.3	127
51	Induction of urokinase-type plasminogen activator by UV light in human fetal fibroblasts is mediated through a UV-induced secreted protein.. Molecular and Cellular Biology, 1987, 7, 622-631.	1.1	66
52	Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells.. Molecular and Cellular Biology, 1987, 7, 3021-3025.	1.1	56
53	Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 2776-2780.	3.3	137
54	The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class pai-2 inhibitor (minactivin). Thrombosis Research, 1987, 46, 755-766.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Poly-d-lysine dependent inactivation of tissue plasminogen activator by a class pai-2 inhibitor (minactivin). <i>Thrombosis Research</i> , 1987, 46, 767-777.	0.8	7
56	Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies. <i>Thrombosis Research</i> , 1987, 46, 411-423.	0.8	10
57	Effect of urokinase on the proliferation of primary cultures of human prostatic cells. <i>Thrombosis Research</i> , 1987, 48, 291-298.	0.8	30
58	Regulation and Localization of Plasminogen Activators in the Rat Seminiferous Epithelium. <i>Annals of the New York Academy of Sciences</i> , 1987, 513, 310-311.	1.8	2
59	The Growth Factor Module of Urokinase is the Binding Sequence for Its Receptor. <i>Annals of the New York Academy of Sciences</i> , 1987, 511, 192-195.	1.8	23
60	Distribution of Tissue Plasminogen Activator in Human and Monkey Eyes. <i>Ophthalmology</i> , 1987, 94, 1434-1438.	2.5	47
61	Plasminogen activator activity and composition in human colorectal carcinomas. <i>Fibrinolysis</i> , 1987, 1, 57-62.	0.5	15
62	Amiloride selectively inhibits the urokinase-type plasminogen activator. <i>FEBS Letters</i> , 1987, 214, 187-191.	1.3	348
63	cDNA cloning and expression in <i>E.coli</i> of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell. <i>FEBS Letters</i> , 1987, 210, 11-16.	1.3	50
64	Dose effects of transfected c-Ha-rasVal 12 oncogene in transformed cell clones. <i>Experimental Cell Research</i> , 1987, 168, 518-530.	1.2	63
65	Antagonist effect of RU 486 on transcription of glucocorticoid-regulated genes. <i>Experimental Cell Research</i> , 1987, 173, 425-430.	1.2	35
66	Degradation of muscle basement membrane zone by locally generated plasmin. <i>Experimental Neurology</i> , 1987, 95, 44-55.	2.0	30
67	Dexamethasone coordinately inhibits plasminogen activator gene expression and enzyme activity in porcine kidney cells. <i>Biochemical and Biophysical Research Communications</i> , 1987, 143, 329-336.	1.0	27
68	Expression of urokinase-type plasminogen activator in the mucosal lesions of inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 517-523.	1.4	17
69	Increased expression of urokinase-type plasminogen activator in colorectal carcinoma and in adenomatous polyps. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 103-111.	1.4	2
70	Proteolysis and physiological regulation. <i>Molecular Aspects of Medicine</i> , 1987, 9, 173-287.	2.7	33
71	Photoaffinity labeling of human plasmin and plasminogen. , 1987, 34, 335-348.		4
72	Tissue plasminogen activator in avascular tissues of the eye: a quantitative study of its activity in the cornea, lens, and aqueous and vitreous humors of dog, calf, and monkey. <i>Experimental Eye Research</i> , 1987, 44, 55-63.	1.2	35

#	ARTICLE	IF	CITATIONS
73	The placental type plasminogen activator inhibitor, PAI 2. <i>Fibrinolysis</i> , 1987, 1, 203-208.	0.5	88
74	Differences between the F10, BL6 and F1 sublines of the B16 melanoma in the enhancement of plasminogen activator and plasminogen activator inhibitor secretion by phorbol myristate acetate. <i>Cancer Letters</i> , 1987, 35, 27-38.	3.2	8
75	Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1987, 924, 473-482.	1.1	61
76	Modulation of secreted plasminogen activator activity of human renal carcinoma cells by dimethylsulfoxide, butyrate and retinoate. <i>Cancer Letters</i> , 1987, 34, 305-316.	3.2	4
78	Characterisation of fibronectin fragments and plasminogen activators released by RSV-transformed cells. <i>Fibrinolysis</i> , 1987, 1, 183-187.	0.5	5
79	Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 213-222.	0.9	17
80	Gonadotropin regulation of tissue-type and urokinase-type plasminogen activators in rat granulosa and theca-interstitial cells during the periovulatory period. <i>Molecular and Cellular Endocrinology</i> , 1987, 54, 221-229.	1.6	80
81	Regulation of plasminogen activator and plasminogen activator-inhibitor production by tissue culture cells: Evidence for independent induction and regulation. <i>Fibrinolysis</i> , 1987, 1, 109-116.	0.5	3
82	Treatment of mouse L-cells with phorbol myristate acetate induces the secretion of a plasminogen activator inhibitor which binds to human and mouse urokinase and human tissue plasminogen activator. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1987, 88, 277-283.	0.2	2
83	A covalent molecular weight .apprx.92,000 hybrid plasminogen activator derived from human plasmin fibrin-binding and tissue plasminogen activator catalytic domains. <i>Biochemistry</i> , 1987, 26, 4661-4667.	1.2	33
84	Treatment of Experimental Intravitreal Fibrin with Tissue Plasminogen Activator. <i>American Journal of Ophthalmology</i> , 1987, 104, 619-623.	1.7	57
85	The murine urokinase-type plasminogen activator gene. <i>Biochemistry</i> , 1987, 26, 8270-8279.	1.2	54
86	Proliferation of a human epidermal tumor cell line stimulated by urokinase. <i>FASEB Journal</i> , 1987, 1, 125-128.	0.2	132
87	Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.. <i>EMBO Journal</i> , 1987, 6, 1281-1286.	3.5	229
88	Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. <i>Blood</i> , 1987, 70, 721-728.	0.6	188
89	Invasiveness of human glioma cell lines in vitro: Relation to tumorigenicity in athymic mice. <i>Acta Neuropathologica</i> , 1987, 72, 207-213.	3.9	40
90	Cutaneous infiltrates of histiocytosis X contain plasminogen activator-bearing epidermotropic dendritic cells different from Langerhans cells. <i>Archives of Dermatological Research</i> , 1987, 279, S88-S91.	1.1	2
91	Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay. <i>International Journal of Cancer</i> , 1987, 40, 823-829.	2.3	0

#	ARTICLE	IF	CITATIONS
92	Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors. <i>Journal of Cellular Physiology</i> , 1987, 132, 509-516.	2.0	124
93	Proteolytic degradation of extracellular matrix in tumor invasion. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1987, 907, 191-217.	3.3	237
94	Chromosomal assignments of genes for tissue plasminogen activator and urokinase in mouse. <i>Somatic Cell and Molecular Genetics</i> , 1987, 13, 581-586.	0.7	21
95	Involvement of Urokinase-Type Plasminogen Activator in Acantholysis Induced by Pemphigus IgG. <i>Journal of Investigative Dermatology</i> , 1987, 89, 474-477.	0.3	81
96	Immunohistochemical Localization of Urokinase- and Tissue-Type Plasminogen Activators in Psoriatic Skin. <i>Journal of Investigative Dermatology</i> , 1987, 88, 28-32.	0.3	99
97	Plasminogen activators during differentiation of the human kidney. <i>Differentiation</i> , 1987, 34, 131-138.	1.0	13
98	Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid. <i>European Journal of Clinical Investigation</i> , 1988, 18, 595-599.	1.7	15
99	Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. <i>FEBS Journal</i> , 1988, 175, 33-39.	0.2	136
100	The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family. <i>FEBS Journal</i> , 1988, 176, 609-616.	0.2	71
101	Transforming growth factor $\alpha$ 21 is a potent inducer of plasminogen activator inhibitor type $\alpha$ 1 in human glioblastoma and carcinoma cell lines. <i>Apmis</i> , 1988, 96, 845-849.	0.9	8
102	Plasma tetranectin is reduced in cancer and related to metastasia. <i>Cancer</i> , 1988, 62, 869-872.	2.0	55
103	High frequency of plasminogen activator secretion by malignant human lymphoid cell lines of T-cell type origin. <i>Cancer</i> , 1988, 62, 1952-1957.	2.0	9
104	Tissue plasminogen activator binding to mouse cerebellar granule neurons. <i>Journal of Neuroscience Research</i> , 1988, 21, 420-425.	1.3	36
105	Modulation of urokinase-type plasminogen activator messenger rna levels in human synovial fibroblasts by interleukin-1, retinoic acid, and a glucocorticoid. <i>Arthritis and Rheumatism</i> , 1988, 31, 1046-1051.	6.7	37
106	Fibrin autography of plasminogen activator by electrophoretic transfer into fibrin agar gels. <i>Analytical Biochemistry</i> , 1988, 168, 411-416.	1.1	10
107	Inhibition of plasminogen activators and the growth of cultured human tumour cells. <i>International Journal of Biochemistry &amp; Cell Biology</i> , 1988, 20, 817-822.	0.8	7
108	Plasminogen activator expression and steroid hormone receptors in female breast cancer: A multifactorial study. <i>International Journal of Cancer</i> , 1988, 41, 798-804.	2.3	11
109	Selective enhancement of metastatic capacity in mouse bladder carcinoma cells after transfection with dna from liver metastases of human colon carcinoma. <i>International Journal of Cancer</i> , 1988, 41, 840-846.	2.3	22

#	ARTICLE	IF	CITATIONS
110	Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas. <i>International Journal of Cancer</i> , 1988, 42, 59-63.	2.3	39
111	Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: Quantitative expression of active and proenzyme. <i>International Journal of Cancer</i> , 1988, 42, 483-488.	2.3	40
112	Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas. <i>International Journal of Cancer</i> , 1988, 42, 627-632.	2.3	32
113	Heparanases and tumor metastasis. <i>Journal of Cellular Biochemistry</i> , 1988, 36, 157-167.	1.2	299
114	Localization of protease nexin-1 on the fibroblast extracellular matrix. <i>Journal of Cellular Physiology</i> , 1988, 134, 179-188.	2.0	68
115	Secretion of plasminogen activators by human colorectal and gastric tumor explants. <i>Clinical and Experimental Metastasis</i> , 1988, 6, 431-450.	1.7	31
116	Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line. <i>Journal of Neuro-Oncology</i> , 1988, 6, 277-283.	1.4	11
117	Differences between preneoplastic cells, neoplastic cells and their normal counterparts. <i>Journal of Oral Pathology and Medicine</i> , 1988, 17, 257-265.	1.4	13
118	Pharmacodynamic and Systemic Fibrinolytic Effects of Plasminogen Activators in Man. <i>Journal of Interventional Cardiology</i> , 1988, 1, 149-159.	0.5	1
119	Epidermal Plasminogen Activator is Abnormal in Cutaneous Lesions. <i>Journal of Investigative Dermatology</i> , 1988, 90, 777-782.	0.3	76
120	Urokinase- and Tissue-Type Plasminogen Activators in Keratinocytes During Wound Reepithelialization In Vivo. <i>Journal of Investigative Dermatology</i> , 1988, 90, 790-795.	0.3	205
121	Keratinocyte Urokinase-Type Plasminogen Activator is Secreted as a Single Chain Precursor. <i>Journal of Investigative Dermatology</i> , 1988, 90, 823-828.	0.3	23
122	Development and characterization of a human cell line from an ovarian mixed mullerian tumor (carcinosarcoma). <i>In Vitro Cellular &amp; Developmental Biology</i> , 1988, 24, 965-971.	1.0	7
123	A surface receptor for urokinase plasminogen activator: a link between the cytoskeleton and the extracellular matrix. <i>Protoplasma</i> , 1988, 145, 95-98.	1.0	4
124	Production of an active urokinase by leukemia cells: A novel distinction from cell lines of solid tumors. <i>Leukemia Research</i> , 1988, 12, 419-422.	0.4	53
125	Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1988, 948, 67-85.	3.3	138
126	Effects of human interferon on cellular response to UV in UV-sensitive human cell strains. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1988, 198, 207-214.	0.4	35
127	Urokinase-catalysed plasminogen activation. Effects of ligands binding to the AH-site of plasminogen. <i>BBA - Proteins and Proteomics</i> , 1988, 957, 258-265.	2.1	15



#	ARTICLE	IF	CITATIONS
128	Tumor-Targeted Cell Killing with 8-Hydroxyquinolyl-Glucuronide. <i>Radiation Research</i> , 1988, 115, 373.	0.7	11
129	Monoclonal antibodies to human fibroblast procollagenase. Inhibition of enzymatic activity, affinity purification of the enzyme, and evidence for clustering of epitopes in the amino-terminal end of the activated enzyme. <i>Biochemistry</i> , 1988, 27, 6751-6758.	1.2	88
130	Bovine plasminogen activator inhibitor 1: Specificity determinations and comparison of the active, latent, and guanidine-activated forms. <i>Biochemistry</i> , 1988, 27, 2911-2918.	1.2	84
131	Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. <i>Archives of Biochemistry and Biophysics</i> , 1988, 262, 199-210.	1.4	155
132	Immunohistochemical localization of urokinase-type plasminogen activator in sertoli cells and tissue-type plasminogen activator in spermatogenic cells in the rat seminiferous epithelium. <i>Developmental Biology</i> , 1988, 126, 150-155.	0.9	45
133	Anti-sense inhibition of tissue plasminogen activator production in differentiated F9 teratocarcinoma cells. <i>Developmental Biology</i> , 1988, 129, 408-416.	0.9	12
134	Plasminogen activator activity of cultured murine macrophages and effects of isopropylmethylphosphonofluoridate (sarin). <i>Biochemical Pharmacology</i> , 1988, 37, 2139-2143.	2.0	9
135	Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells*1. <i>Experimental Cell Research</i> , 1988, 179, 385-395.	1.2	102
136	Modulation of extracellular proteolytic activity and anchorage-independent growth of cultured cells by sarcoma cell-derived factors: Relationships to transforming growth factor- $\beta$ 2. <i>Experimental Cell Research</i> , 1988, 176, 297-308.	1.2	6
137	Heterogeneity of human tissue-type plasminogen activator. <i>FEBS Letters</i> , 1988, 238, 129-134.	1.3	6
138	Determination of intermediates, products and cleavage site in the reaction between plasminogen activator inhibitor type-2 and urokinases. <i>FEBS Letters</i> , 1988, 230, 51-56.	1.3	18
139	Tissue plasminogen activator mRNA in murine tissues. <i>FEBS Letters</i> , 1988, 229, 100-106.	1.3	44
140	Tumor invasion: A consequence of destructive and compositional matrix alterations. <i>Human Pathology</i> , 1988, 19, 628-639.	1.1	144
141	Susceptibility of plasminogen activators to suicide inactivation. <i>Thrombosis Research</i> , 1988, 50, 35-44.	0.8	3
142	Enhanced expression of urokinase activity on U 937 cell line by 1,25-Dihydroxyvitamin D3 induction. <i>Thrombosis Research</i> , 1988, 50, 57-63.	0.8	0
143	Role of Degradative Enzymes in Wound Healing. , 1988, , 497-523.		10
144	Susceptibility of plasminogen activators to suicide inactivation. <i>Thrombosis Research</i> , 1988, 49, 35-44.	0.8	0
145	Enhanced expression of urokinase activity on U 937 cell line by 1,25-dihydroxyvitamine D3 induction. <i>Thrombosis Research</i> , 1988, 49, 57-63.	0.8	2

#	ARTICLE	IF	CITATIONS
146	Distribution of plasminogen activators in human kidney and male genital organs using a highly sensitive enzyme immunoassay. <i>Thrombosis Research</i> , 1988, 51, 453-459.	0.8	19
147	Cell-Associated Plasminogen Activation: Regulation and Physiological Functions. <i>Annual Review of Cell Biology</i> , 1988, 4, 93-120.	26.0	789
148	Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. <i>Gene</i> , 1988, 73, 459-468.	1.0	139
149	Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activator. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1988, 967, 183-194.	1.1	75
150	Cloning and Characterization of a cDNA for Rat Tissue-Type Plasminogen Activator. <i>DNA and Cell Biology</i> , 1988, 7, 671-677.	5.1	55
151	Specific cleavage of diphtheria toxin by human urokinase. <i>Biochemical and Biophysical Research Communications</i> , 1988, 157, 747-754.	1.0	17
152	Parallel induction of fibrinolysis and receptors for plasminogen and urokinase by interferon gamma on U937 cells. <i>Biochemical and Biophysical Research Communications</i> , 1988, 155, 418-422.	1.0	35
153	Surface receptors for urokinase plasminogen activator. <i>Fibrinolysis</i> , 1988, 2, 73-84.	0.5	184
154	Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. <i>Comparative Biochemistry and Physiology Part B: Comparative Biochemistry</i> , 1988, 90, 691-708.	0.2	48
155	Plasminogen activator secretion in relation to Schwann cell activities. <i>International Journal of Developmental Neuroscience</i> , 1988, 6, 483-493.	0.7	13
156	Plasminogen activator inhibitor type 1: cell-specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay. <i>Molecular and Cellular Endocrinology</i> , 1988, 60, 43-53.	1.6	49
157	Urokinase and tissue-type plasminogen activators are present in breast cyst fluids. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1988, 24, 985-989.	0.9	2
158	Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. <i>Cell</i> , 1988, 52, 321-328.	13.5	178
159	What's New in the Ultrastructure of Tumor Invasion in vivo?. <i>Pathology Research and Practice</i> , 1988, 183, 792-808.	1.0	23
160	Purification and partial characterization of a plasminogen activator inhibitor from the human glioblastoma, U138. <i>Biochemistry and Cell Biology</i> , 1988, 66, 1270-1277.	0.9	19
161	Rat Testicular Peritubular Cells in Culture Secrete an Inhibitor of Plasminogen Activator Activity1. <i>Biology of Reproduction</i> , 1988, 38, 359-371.	1.2	46
162	Expression of Plasminogen Activator (PA) and a PA Inhibitor in Human Granulosa Cells From Preovulatory Follicles*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 67, 857-860.	1.8	29
163	A Critical Appraisal of the Role of Proteolytic Enzymes in Cancer Invasion: Emphasis on Tumor Surface Proteinases. <i>Cancer Investigation</i> , 1988, 6, 219-231.	0.6	40

#	ARTICLE	IF	CITATIONS
164	Plasminogen Activation: Biochemistry, Physiology, and Therapeutics. Critical Reviews in Biotechnology, 1988, 8, 131-148.	5.1	23
165	Stromal Involvement In Malignant Growth. Advances in Cancer Research, 1988, 50, 159-196.	1.9	198
166	An upstream enhancer and a negative element in the 5' flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Research, 1988, 16, 10699-10716.	6.5	108
167	Intravitreal Clearance of Tissue Plasminogen Activator in the Rabbit. JAMA Ophthalmology, 1988, 106, 969-972.	2.6	38
168	In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.. Journal of Cell Biology, 1988, 107, 2437-2445.	2.3	271
169	The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene. Nucleic Acids Research, 1988, 16, 2805-2824.	6.5	82
170	[27] Tissue-type plasminogen activator and fast-acting plasminogen activator inhibitor in plasma. Methods in Enzymology, 1988, 163, 302-309.	0.4	6
171	Multiple nuclear factors interact with promoter sequences of the urokinase-type plasminogen activator gene. Nucleic Acids Research, 1988, 16, 7527-7544.	6.5	24
172	Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. Journal of Cell Biology, 1988, 106, 451-459.	2.3	122
173	Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.. Journal of Cell Biology, 1988, 106, 971-978.	2.3	160
174	Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.. Journal of Cell Biology, 1988, 106, 1659-1665.	2.3	910
175	Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 5525-5529.	3.3	228
176	Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.. Journal of Cell Biology, 1988, 106, 87-95.	2.3	309
177	Hormonal Regulation of Tissue-Type Plasminogen Activator Messenger Ribonucleic Acid Levels in Rat Granulosa Cells: Mechanisms of Induction by Follicle-Stimulating Hormone and Gonadotropin Releasing Hormone. Molecular Endocrinology, 1988, 2, 854-861.	3.7	47
178	Transforming Growth Factors in the Regulation of Malignant Cell Growth and Invasion. Cancer Investigation, 1988, 6, 705-724.	0.6	29
179	The relationship between inhibition of plasminogen-activator activity and prostatic involution. Biochemical Journal, 1988, 252, 759-764.	1.7	18
180	Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion. Biochemical Journal, 1988, 254, 911-914.	1.7	28
181	Urokinase-Type Plasminogen Activator as a Marker for the Formation of Distant Metastases in Prostatic Carcinomas. Journal of Urology, 1988, 140, 1466-1469.	0.2	79

#	ARTICLE	IF	CITATIONS
182	Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 985-989.	3.3	72
183	Role of Enzymes Mediating Thrombosis and Thrombolysis in Lung Disease. Chest, 1988, 93, 1256-1263.	0.4	65
184	Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes.. Journal of Experimental Medicine, 1988, 168, 751-759.	4.2	112
185	Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots. Blood, 1989, 74, 999-1006.	0.6	41
186	Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562). Blood, 1989, 74, 1321-1327.	0.6	10
187	Neuronal plasminogen activators: cell surface binding sites and involvement in neurite outgrowth. Journal of Neuroscience, 1989, 9, 4269-4286.	1.7	211
188	Glucocorticoid and Cyclic Nucleotide Regulation of Plasminogen Activator and Plasminogen Activator-Inhibitor Gene Expression in Primary Cultures of Rat Hepatocytes. Molecular Endocrinology, 1989, 3, 185-192.	3.7	70
189	Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2.. EMBO Journal, 1989, 8, 3287-3294.	3.5	125
190	Characterization of 125I-tissue plasminogen activator binding to cerebellar granule neurons.. Journal of Cell Biology, 1989, 109, 265-271.	2.3	82
191	Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.. Journal of Cell Biology, 1989, 109, 915-925.	2.3	99
192	Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.. Gut, 1989, 30, 188-194.	6.1	95
193	Effect of retinoic acid on asbestos induced plasminogen activator activity of peritoneal macrophages.. Occupational and Environmental Medicine, 1989, 46, 496-497.	1.3	2
194	Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.. Journal of Cell Biology, 1989, 108, 1987-1995.	2.3	317
195	Use of Inhibitory (Anti-Catalytic) Antibodies to study extracellular Proteolysis. Immunological Investigations, 1989, 18, 211-224.	1.0	12
196	Pharmacologic Control of Wound Healing in Glaucoma Filtration Surgery. Journal of Ocular Pharmacology and Therapeutics, 1989, 5, 155-179.	0.6	95
197	Cleavage of Recombinant Murine Interferon-7 by Plasmin and Miniplasmin. Journal of Interferon Research, 1989, 9, 517-529.	1.2	10
198	Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.. Journal of Cell Biology, 1989, 108, 693-702.	2.3	143
199	Plasmin and Fibronectin Degradation in Chronic Secretory Otitis Media. JAMA Otolaryngology, 1989, 115, 48-53.	1.5	9

#	ARTICLE	IF	CITATIONS
200	Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos.. Journal of Cell Biology, 1989, 109, 2471-2479.	2.3	283
201	Tissue-Type Plasminogen Activator in Subretinal Fluid. Current Eye Research, 1989, 8, 249-252.	0.7	13
202	Epidermal Growth Factor Stimulates Tissue Plasminogen Activator Activity and Messenger Ribonucleic Acid Levels in Cultured Rat Granulosa Cells: Mediation by Pathways Independent of Protein Kinases-A and -C*. Endocrinology, 1989, 125, 126-135.	1.4	61
203	Î²-Adrenergic Agents Stimulate Tissue Plasminogen Activator Activity and Messenger Ribonucleic Acid Levels in Cultured Rat Granulosa Cells*. Endocrinology, 1989, 125, 2550-2556.	1.4	12
204	Plasminogen Activator and Plasminogen Activator Inhibitor in Human Preovulatory Follicular Fluid*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 1039-1045.	1.8	27
205	Glucocorticoid Induction of Plasminogen Activator and Plasminogen Activator-Inhibitor Messenger RNA in Rat Hepatoma Cells. Molecular Endocrinology, 1989, 3, 349-355.	3.7	53
206	Estrogen Regulation of Human Breast Cancer Cell Line MCF-7 Tissue Plasminogen Activator*. Endocrinology, 1989, 125, 492-500.	1.4	17
207	Contact lens wear is associated with the appearance of plasmin in the tear fluid " preliminary results. Graefe's Archive for Clinical and Experimental Ophthalmology, 1989, 227, 42-44.	1.0	23
208	Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochimica Et Biophysica Acta: Reviews on Cancer, 1989, 948, 305-326.	3.3	169
209	Molecular aspects of the metastatic cascade. Biochimica Et Biophysica Acta: Reviews on Cancer, 1989, 989, 65-84.	3.3	83
210	Immunohistochemical localization of tissue-type plasminogen activator in ovaries before and after induced and spontaneous ovulation in the rat. Cell and Tissue Research, 1989, 257, 1-8.	1.5	12
211	Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene. Journal of Cancer Research and Clinical Oncology, 1989, 115, 139-144.	1.2	28
212	Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis. Clinical and Experimental Metastasis, 1989, 7, 127-167.	1.7	129
213	Cytokine-mediated proteolysis in tissue remodelling. Experientia, 1989, 45, 542-549.	1.2	35
214	Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. FEBS Journal, 1989, 181, 103-107.	0.2	39
215	Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. FEBS Journal, 1989, 186, 523-533.	0.2	107
216	Plasminogen activator and its enhancement in differentiating mouse friend erythroleukemia cells. International Journal of Cancer, 1989, 43, 171-176.	2.3	7
217	Enhancement of urokinase-type plasminogen activator activity during the growth of a murine mammary adenocarcinoma. International Journal of Cancer, 1989, 43, 356-357.	2.3	3

#	ARTICLE	IF	CITATIONS
218	Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells. <i>International Journal of Cancer</i> , 1989, 43, 816-822.	2.3	24
219	Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. <i>International Journal of Cancer</i> , 1989, 44, 859-864.	2.3	52
220	The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. <i>Journal of Cellular Biochemistry</i> , 1989, 40, 215-227.	1.2	106
221	Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced k562 leukemia cell cultures: Depletion of active urokinase by excess type 1 plasminogen activator inhibitor. <i>Journal of Cellular Physiology</i> , 1989, 140, 119-130.	2.0	17
222	Heparin stimulation of plasminogen activator secretion by macrophage-like cell line raw264.7: Role of the scavenger receptor. <i>Journal of Cellular Physiology</i> , 1989, 140, 219-226.	2.0	30
223	Protease nexin I, a serpin, inhibits plasminogen-dependent degradation of muscle extracellular matrix. <i>Muscle and Nerve</i> , 1989, 12, 640-646.	1.0	28
224	Normal haemostasis and its regulation. <i>Blood Reviews</i> , 1989, 3, 237-250.	2.8	38
225	Effect of retinoic acid on human neuroblastoma: Correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 25, 25-31.	1.1	18
226	Localization of urokinase-type and tissue-type plasminogen activator mRNA during organogenesis in the mouse. <i>Roux's Archives of Developmental Biology</i> , 1989, 198, 219-226.	1.2	19
227	Transforming growth factor- $\beta$ 1/2s as modulators of pericellular proteolytic events. <i>Cytotechnology</i> , 1989, 2, 317-332.	0.7	1
228	Plasminogen activator inhibitor (type-1) in rat adrenal medulla. <i>Histochemistry</i> , 1989, 92, 377-383.	1.9	10
229	Histochemical study of alkali-burned rabbit anterior eye segment in which severe lesions were prevented by aprotinin treatment. <i>Histochemistry</i> , 1989, 92, 441-448.	1.9	23
230	Tetranectin immunoreactivity in normal human tissues. <i>Histochemistry</i> , 1989, 92, 29-35.	1.9	59
231	Inhibition of Tumor Cell Invasion by Ubenimex (Bestatin) in vitro. <i>Japanese Journal of Cancer Research</i> , 1989, 80, 873-878.	1.7	92
232	Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens. <i>British Journal of Cancer</i> , 1989, 60, 397-400.	2.9	9
233	Characterization of Keratinocyte Plasminogen Activator Inhibitors and Demonstration of the Prevention of Pemphigus IgG-induced Acantholysis by a Purified Plasminogen Activator Inhibitor. <i>Journal of Investigative Dermatology</i> , 1989, 92, 310-314.	0.3	80
234	Thrombospondin in malignant and non-malignant breast tissue. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 343-350.	0.9	49
235	Tumor necrosis factor- $\alpha$ regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines. <i>Molecular and Cellular Endocrinology</i> , 1989, 61, 87-96.	1.6	22

#	ARTICLE	IF	CITATIONS
236	Plasminogen activators in (pre)malignant conditions of the colorectum. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1989, 25, 565-569.	0.9	10
237	UIROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCER. <i>Lancet, The</i> , 1989, 334, 1049.	6.3	112
238	Considerations on the role of the plasminogen activators/plasmin system in the generation of conditions for more efficient interaction of malignant cells with large granular lymphocytes. <i>Research in Immunology</i> , 1989, 140, 281-283.	0.9	2
239	Alterations in plasminogen activator and inhibitor activity during the differentiation of a human neuroblastoma cell line, SMS-KAN. <i>Cancer Letters</i> , 1989, 44, 101-108.	3.2	13
240	The effects of intrafollicular injections of plasmin and E-aminocaproic acid on the ovulation in the ewe. <i>Fibrinolysis</i> , 1989, 3, 227-230.	0.5	11
241	Proteinases and their Inhibitors in Cells and Tissues. <i>Progress in Histochemistry and Cytochemistry</i> , 1989, 18, III-60.	5.1	8
242	Comparison of recombinant tissue-type plasminogen activator (rt-PA) expressed in mouse C127 cells and human vascular plasminogen activator (HV-PA). <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1989, 1009, 143-150.	2.4	1
243	A direct approach in fibrinolysis diagnostic: Mimicry of the leukocyte attack by oxidants. <i>Thrombosis Research</i> , 1989, 56, 213-220.	0.8	7
244	Absence of t-PA in spontaneous metastatic lesions induced by a newly established cell line. <i>Thrombosis Research</i> , 1989, 53, 395-400.	0.8	2
245	Placental and decidual u-PA, t-PA, PAI-1 and PAI-2 concentrations, as affected by cervical dilatation with laminaria tents or hegar dilators. <i>Thrombosis Research</i> , 1989, 53, 91-97.	0.8	9
246	Group A streptococci bind human plasmin but not other structurally related proteins. <i>Thrombosis Research</i> , 1989, 55, 187-193.	0.8	17
247	The effect of cervical dilatation by laminaria tent in first trimester legal abortions on blood loss related to fibrinolytic activity in the decidua and placenta. <i>International Journal of Gynecology and Obstetrics</i> , 1989, 29, 73-77.	1.0	5
248	Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these fibrinolytic components to cells. <i>Biochemistry</i> , 1989, 28, 9337-9343.	1.2	98
249	Molecular characterization of plasminogen activator in human supragingival plaque. <i>Archives of Oral Biology</i> , 1989, 34, 17-21.	0.8	8
250	Extracellular protease production by <i>Drosophila</i> imaginal discs. <i>Developmental Biology</i> , 1989, 132, 282-291.	0.9	48
251	Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA). <i>FEBS Letters</i> , 1989, 255, 83-88.	1.3	29
252	Comparison of the effects of auranofin and retinoic acid on plasminogen activator activity of peritoneal macrophages and lewis lung carcinoma cells. <i>Biochemical Pharmacology</i> , 1989, 38, 2107-2112.	2.0	7
253	Production of urokinase-type plasminogen activator by normal and transformed rat thyroid cells in culture. <i>Experimental Cell Research</i> , 1989, 182, 197-205.	1.2	8

#	ARTICLE	IF	CITATIONS
254	Evidence that plasminogen activator is not involved in basement membrane penetration at avian gastrulation. <i>Experimental Cell Research</i> , 1989, 185, 394-398.	1.2	2
255	Plasminogen activator and its inhibitor in the experimental corneal wound. <i>Experimental Eye Research</i> , 1989, 48, 445-449.	1.2	33
256	Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with propranolol. <i>Biochemical and Biophysical Research Communications</i> , 1989, 160, 977-981.	1.0	3
257	Production of proteases type plasminogen activator and their inhibitor in cornea. <i>Biochemical and Biophysical Research Communications</i> , 1989, 160, 1021-1025.	1.0	14
258	Plasminogen Activators and Gastrointestinal Neoplasms. <i>Scandinavian Journal of Gastroenterology</i> , 1989, 24, 13-18.	0.6	17
259	Decrease in plasminogen activator correlates with synapse elimination during neonatal development of mouse skeletal muscle.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 362-366.	3.3	57
260	Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 4828-4832.	3.3	167
261	Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.. <i>Molecular and Cellular Biology</i> , 1989, 9, 2133-2141.	1.1	132
262	Plasmin and plasminogen activator activities in tear fluid during corneal wound healing after anterior keratectomy. <i>Current Eye Research</i> , 1989, 8, 1293-1298.	0.7	33
263	Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 5424-5428.	3.3	88
264	Plasminogen Activators in Human Prostate Cancer Cell Lines and Tumors: Correlation with the Aggressive Phenotype. <i>Journal of Urology</i> , 1989, 142, 193-198.	0.2	94
265	Neuroendocrine regulation of oocyte tissue plasminogen activator. <i>Methods in Enzymology</i> , 1989, 168, 422-430.	0.4	3
266	Influences of Follicle-Stimulating Hormone, Proteases, and Antiproteases on Permeability of the Barrier Generated by Sertoli Cells in a Two-Chambered Assembly*. <i>Endocrinology</i> , 1989, 124, 1399-1407.	1.4	24
267	Different Mechanisms Contribute to Simultaneous Inhibition of Urokinase and Tissue-Type Plasminogen Activators by Glucocorticoids in Human Ovarian Carcinoma Cells. <i>Molecular Endocrinology</i> , 1989, 3, 1006-1013.	3.7	11
268	Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 2230-2234.	3.3	56
269	Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 3530-3533.	3.3	147
270	Tumour-associated trypsin inhibitor and tumour-associated trypsin. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1990, 50, 93-101.	0.6	19
271	Urokinase- and tissue-type plasminogen activators are suppressed by cortisol in the involuting prostate of castrated rats. <i>Biochemical Journal</i> , 1990, 269, 189-193.	1.7	34



#	ARTICLE	IF	CITATIONS
272	Inhibition of plasmin by fibrinogen. <i>Biochemical Journal</i> , 1990, 269, 299-302.	1.7	12
273	Binding of tissue plasminogen activator to human aortic endothelial cells. <i>Biochemical Journal</i> , 1990, 269, 475-482.	1.7	10
274	Inactivation of Human Tumor Cell Pro-urokinase by Granulocyte Elastase. <i>Japanese Journal of Cancer Research</i> , 1990, 81, 994-1002.	1.7	5
275	Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity.. <i>Journal of Cell Biology</i> , 1990, 110, 767-775.	2.3	532
276	Antipsoriatic Therapies Inhibit Epidermal Plasminogen Activator Activity. <i>International Journal of Dermatology</i> , 1990, 29, 528-530.	0.5	9
277	Synthesis of Urokinase-Type Plasminogen Activator and of Type- 1 Plasminogen Activator Inhibitor in Neuronal Cultures of Human Fetal Brain: Stimulation by Phorbol Ester. <i>Journal of Neurochemistry</i> , 1990, 55, 1647-1654.	2.1	31
278	Immunoelectron microscopic study of the basement membrane in oral lichen planus. <i>Journal of Cutaneous Pathology</i> , 1990, 17, 72-76.	0.7	11
279	Role of Specific Membrane Receptors in Urokinase-Dependent Migration of Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , 1990, 94, 310-316.	0.3	63
280	Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells. <i>Kidney International</i> , 1990, 37, 1466-1476.	2.6	27
281	Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay. <i>British Journal of Cancer</i> , 1990, 61, 412-414.	2.9	9
282	Tissue Plasminogen Activator in Psoriasis. <i>Journal of Investigative Dermatology</i> , 1990, 95, S13-S14.	0.3	24
283	Better reception for urokinase. <i>Nature</i> , 1990, 344, 488-489.	13.7	12
284	Human and murine urokinase cDNAs linked to the murine alphaA-crystallin promoter exhibit lens and non-lens expression in transgenic mice. <i>FEBS Journal</i> , 1990, 190, 31-38.	0.2	33
285	Binding and activation of plasminogen at the surface of <i>Staphylococcus aureus</i> . Increase in affinity after conversion to the Lys form of the ligand. <i>FEBS Journal</i> , 1990, 193, 759-765.	0.2	111
286	Protease and Plasminogen Activator Activity in Human Bladder Carcinoma. <i>British Journal of Urology</i> , 1990, 66, 170-174.	0.1	6
287	Identification of a plasminogen activator derived from nasopharyngeal carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 1990, 247, 374-8.	0.8	6
288	Reaction of thrombin and proteinases of the fibrinolytic system with a mechanism-based inhibitor, 3,4-dihydro-3-benzyl-6-chloromethylcoumarin. <i>BBA - Proteins and Proteomics</i> , 1990, 1038, 119-124.	2.1	8
289	Tumor interactions with the vasculature: angiogenesis and tumor metastasis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1990, 1032, 89-118.	3.3	276

#	ARTICLE	IF	CITATIONS
290	The urokinase receptor and regulation of cell surface plasminogen activation. <i>Cell Differentiation and Development</i> , 1990, 32, 247-253.	0.4	57
291	Plasminogen activation at the cell surface-matrix interface. <i>Cell Differentiation and Development</i> , 1990, 32, 255-262.	0.4	41
292	Serine protease and metallo protease cascade systems involved in pericellular proteolysis. <i>Cell Differentiation and Development</i> , 1990, 32, 263-275.	0.4	23
293	Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type I plasminogen activator inhibitor. <i>Cell Differentiation and Development</i> , 1990, 32, 277-285.	0.4	11
294	Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. <i>Cell Differentiation and Development</i> , 1990, 32, 287-292.	0.4	56
295	Proteolytic balance and capillary morphogenesis. <i>Cell Differentiation and Development</i> , 1990, 32, 319-327.	0.4	185
296	Antigenic modification of polioviruses by host proteolytic enzymes. <i>Archives of Virology</i> , 1990, 111, 115-125.	0.9	24
297	Plasminogen activator activities in the ventral and dorsolateral prostatic lobes of aging fischer 344 rats. <i>Prostate</i> , 1990, 16, 147-161.	1.2	22
298	Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. <i>Histochemistry</i> , 1990, 93, 559-566.	1.9	67
299	Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. <i>Cancer and Metastasis Reviews</i> , 1990, 9, 203-226.	2.7	247
300	The invasive phenotypes. <i>Cancer and Metastasis Reviews</i> , 1990, 9, 45-62.	2.7	94
301	The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. <i>Cancer and Metastasis Reviews</i> , 1990, 9, 353-367.	2.7	157
302	Mechanisms of trophoblast invasiveness and their control: the role of proteases and protease inhibitors. <i>Cancer and Metastasis Reviews</i> , 1990, 9, 369-379.	2.7	264
303	Proteases in the schistosome life cycle: a paradigm for tumour metastasis. <i>Cancer and Metastasis Reviews</i> , 1990, 9, 381-392.	2.7	20
304	Decreased tetranectin in multiple myeloma. <i>American Journal of Hematology</i> , 1990, 33, 142-144.	2.0	18
305	Developmental transition in plasticity properties of differentiating astrocytes: Age-related biochemical profile of plasminogen activators in astroglial cultures. <i>Glia</i> , 1990, 3, 413-426.	2.5	60
306	Establishment and characterization of a leukemic murine cell line derived from MCF 247 MuLV-induced T-cell lymphoma. <i>International Journal of Cancer</i> , 1990, 45, 928-934.	2.3	6
307	Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity. <i>International Journal of Cancer</i> , 1990, 46, 56-60.	2.3	45

#	ARTICLE	IF	CITATIONS
308	The presence of plasmin receptors on three mammary carcinoma MCF-7 sublines. International Journal of Cancer, 1990, 46, 745-750.	2.3	35
309	Plasminogen carbohydrate side chains in receptor binding and enzyme activation: A study of C6 glioma cells and primary cultures of rat hepatocytes. Journal of Cellular Biochemistry, 1990, 43, 213-227.	1.2	24
310	Coexpression of tumor-associated $\alpha_2$ -macroglobulin and growth factors in human melanoma cell lines. Journal of Cellular Biochemistry, 1990, 43, 315-325.	1.2	16
311	Plasminogen activators and their inhibitors in the neuromuscular system: I. Developmental regulation of plasminogen activator isoforms during in vitro myogenesis in two cell lines. Journal of Cellular Physiology, 1990, 144, 262-271.	2.0	18
312	Plasminogen activators and their inhibitors in the neuromuscular system: II. Serpins and serpin: Protease complex receptors increase during in vitro myogenesis. Journal of Cellular Physiology, 1990, 144, 272-279.	2.0	25
313	A plasminogen activator is induced during goldfish optic nerve regeneration.. EMBO Journal, 1990, 9, 2471-2477.	3.5	34
314	Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.. EMBO Journal, 1990, 9, 467-474.	3.5	546
315	Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood, 1990, 75, 1991-1998.	0.6	177
316	Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood, 1990, 75, 1673-1678.	0.6	33
317	Prolactin Inhibits Plasminogen Activator Activity in the Preovulatory Follicles. Endocrinology, 1990, 126, 631-636.	1.4	31
318	Secretion of Plasminogen Activator from Bovine Parathyroid Cells*. Endocrinology, 1990, 126, 2245-2251.	1.4	7
319	Urokinase-Type Plasminogen Activator Is Increased in the Involuting Ventral Prostate of Castrated Rats*. Endocrinology, 1990, 126, 2567-2576.	1.4	38
320	Cyclic Nucleotide Regulation of Plasminogen Activator and Plasminogen Activator-Inhibitor Messenger RNAs in Rat Hepatoma Cells. Molecular Endocrinology, 1990, 4, 171-178.	3.7	32
321	Secretion of $\alpha_2$ -macroglobulin, $\alpha_2$ -antiplasmin, and plasminogen activator inhibitor-1 by glioblastoma multiforme in primary organ culture. Journal of Neurosurgery, 1990, 73, 234-241.	0.9	24
322	Regulation of plasminogen receptor expression on human monocytes and monocytoïd cell lines.. Journal of Cell Biology, 1990, 111, 1673-1683.	2.3	72
323	Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells.. Journal of Cell Biology, 1990, 110, 511-517.	2.3	190
324	Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.. Molecular Biology of the Cell, 1990, 1, 895-905.	6.5	46
325	Angiogenic and invasive properties of neurofibroma Schwann cells.. Journal of Cell Biology, 1990, 111, 645-653.	2.3	117

#	ARTICLE	IF	CITATIONS
326	Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells.. Journal of Cell Biology, 1990, 111, 2183-2195.	2.3	77
327	8 Growth Factor-Regulated Proteases and Extracellular Matrix Remodeling during Mammalian Development. Current Topics in Developmental Biology, 1990, 24, 219-259.	1.0	190
328	Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery.. Circulation Research, 1990, 67, 61-67.	2.0	322
329	Identification of Type IV Collagenase in Rat Testicular Cell Culture: Influence of Peritubular-Sertoli Cell Interactions1. Biology of Reproduction, 1990, 43, 956-964.	1.2	46
330	Changes in and Partial Identification of the Plasminogen Activator and Plasminogen Activator Inhibitor Systems During Ovarian Follicular Maturation in the Pig1. Biology of Reproduction, 1990, 43, 636-642.	1.2	33
331	Secreted Metalloproteinases in Testicular Cell Culture1. Biology of Reproduction, 1990, 43, 946-955.	1.2	37
332	The Cellular Basis of Site-Specific Tumor Metastasis. New England Journal of Medicine, 1990, 322, 605-612.	13.9	319
333	Rapid neural regulation of muscle urokinase-like plasminogen activator as defined by nerve crush.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2926-2930.	3.3	24
334	Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor.. Journal of Cell Biology, 1990, 111, 1283-1291.	2.3	81
335	Differential Regulation of Plasminogen Activator and Plasminogen Activator Inhibitor by Osteotropic Factors in Primary Cultures of Mature Osteoblasts and Osteoblast Precursors*. Endocrinology, 1990, 126, 703-711.	1.4	81
336	Basic Fibroblast Growth Factor Induction of Granulosa Cell Tissue-Type Plasminogen Activator Expression and Oocyte Maturation: Potential Role as a Paracrine Ovarian Hormone*. Endocrinology, 1990, 127, 2357-2363.	1.4	48
337	Follicle-Stimulating Hormone and Cyclic AMP Induce Transcription from the Human Urokinase Promoter in Primary Cultures of Mouse Sertoli Cells. Molecular Endocrinology, 1990, 4, 940-946.	3.7	20
338	Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester. Nucleic Acids Research, 1990, 18, 5009-5017.	6.5	140
339	Systemic Amiloride Inhibits Experimentally Induced Neovascularization. JAMA Ophthalmology, 1990, 108, 1474.	2.6	39
340	Detection of Cathepsin B, Plasminogen Activators and Plasminogen Activator Inhibitor in Human Non-Small Lung Cancer Cell Lines. Biological Chemistry Hoppe-Seyler, 1990, 371, 617-624.	1.4	8
341	The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.. Journal of Cell Biology, 1990, 111, 783-792.	2.3	468
342	Modulation of levels of messenger RNA for tissue-type plasminogen activator in rat Sertoli cells, and levels of messenger RNA for plasminogen activator inhibitor in testis peritubular cells. Molecular and Cellular Endocrinology, 1990, 70, 73-80.	1.6	46
343	Chromosomal organization and localization of the human urokinase inhibitor gene: Perfect structural conservation with ovalbumin. Genomics, 1990, 6, 159-167.	1.3	25

#	ARTICLE	IF	CITATIONS
344	Detection of vitronectin by ligand blotting with type 1 plasminogen activator inhibitor. <i>Fibrinolysis</i> , 1990, 4, 197-202.	0.5	10
345	A recombinant pro-urokinase derived mutant missing the growth factor-like domain does not bind to its receptor. <i>Fibrinolysis</i> , 1990, 4, 53-60.	0.5	8
346	Changes in fibrinolysis in patients with localized tumors. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1990, 26, 83-87.	0.9	11
347	Fibrinolytic properties of single chain urokinase-type plasminogen activator (Pro-urokinase). <i>Fibrinolysis</i> , 1990, 4, 1-9.	0.5	44
348	Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. <i>Fibrinolysis</i> , 1990, 4, 69-78.	0.5	154
349	Occurrence of the specific plasminogen activator inhibitor of placental type, PAI-2 in ascitic fluid and tumour vessel blood from patients with ovarian carcinoma. <i>Fibrinolysis</i> , 1990, 4, 221-224.	0.5	6
350	Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells. <i>Molecular and Cellular Endocrinology</i> , 1990, 72, 103-110.	1.6	10
351	The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis. <i>Annals of the New York Academy of Sciences</i> , 1990, 598, 238-247.	1.8	29
352	Variable effect of unilateral or bilateral ovariectomy performed in young or adult animals on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition. <i>Thrombosis Research</i> , 1990, 58, 153-162.	0.8	10
353	The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. <i>Thrombosis Research</i> , 1990, 58, 355-366.	0.8	41
354	The receptor for human urokinase: a potential target for anti-invasive and anti-metastatic therapy. <i>Thrombosis Research</i> , 1990, 57, 49-60.	0.8	4
355	Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1990, 1054, 317-325.	1.9	70
356	Urokinase receptors in human monocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1990, 1052, 399-407.	1.9	60
357	Modulation of plasminogen activator production by interleukin 1. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1990, 1051, 84-93.	1.9	7
358	Relationship between tumorigenicity, in vitro invasiveness, and plasminogen activator production of human breast cell lines. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1990, 26, 793-797.	0.9	24
359	Localization of urokinase-type plasminogen activator receptor on U937 cells: Phorbol ester PMA induces heterogeneity. <i>Experimental Cell Research</i> , 1990, 187, 255-262.	1.2	21
360	Interaction of urokinase a chain with the receptor of human keratinocytes stimulates release of urokinase-like plasminogen activator. <i>Experimental Cell Research</i> , 1990, 187, 33-38.	1.2	19
361	Urokinase and tissue type plasminogen activators in human keratinocyte culture. <i>Experimental Cell Research</i> , 1990, 187, 162-169.	1.2	51

#	ARTICLE	IF	CITATIONS
362	Plasminogen activator activity of normal and retinoic acid-treated post-implantation embryos. <i>Biochemical Pharmacology</i> , 1990, 39, 1545-1548.	2.0	5
363	Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1. <i>FEBS Letters</i> , 1990, 260, 141-144.	1.3	67
364	Serine phosphorylation of biosynthetic pro-urokinase from human tumor cells. <i>FEBS Letters</i> , 1990, 266, 109-114.	1.3	14
365	Purification and characterization of human plasminogen activator inhibitor type I expressed in <i>Saccharomyces cerevisiae</i> . <i>Archives of Biochemistry and Biophysics</i> , 1990, 278, 467-474.	1.4	19
366	Tissue-plasminogen activator stimulates endothelial cell migration in wound assays. <i>Biochemical and Biophysical Research Communications</i> , 1990, 171, 1326-1332.	1.0	18
367	The effects of recombinant human interleukin-1 $\beta$ on cellular proliferation and the production of prostaglandin E <sub>2</sub> , plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. <i>Biochemical and Biophysical Research Communications</i> , 1990, 166, 208-216.	1.0	112
368	Plasminogen activator inhibitors: hormonally regulated serpins. <i>Molecular and Cellular Endocrinology</i> , 1990, 68, 1-19.	1.6	406
369	Current concepts in the pathogenesis of Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1990, 5, 44-65.	1.4	8
370	Oncostatin M stimulates urokinase-type plasminogen activator activity in human synovial fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1991, 180, 652-659.	1.0	46
371	Invasion and metastasis: Biology and clinical potential. , 1991, 52, 235-244.		27
372	Anti-interferon- $\beta$ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, 182-187.	0.9	125
373	Tissue plasminogen activator and placental plasminogen activator inhibitor in human gingival fluid. <i>Fibrinolysis</i> , 1991, 5, 239-242.	0.5	24
374	Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells. <i>Bone and Mineral</i> , 1991, 14, 189-204.	2.0	35
375	Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator. <i>Fibrinolysis</i> , 1991, 5, 207-215.	0.5	30
376	The cytokine-protease connection: Identification of a 96-kD THP-1 gelatinase and regulation by interleukin-1 and cytokine inducers. <i>Cytokine</i> , 1991, 3, 231-239.	1.4	42
377	A non-catalytic, human urokinase plasminogen activator derivative produced by mouse cells has full receptor binding activity. <i>Fibrinolysis</i> , 1991, 5, 155-164.	0.5	7
378	Modulation of synovial fibroblast plasminogen activator and plasminogen activator inhibitor production by protein kinase C. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1991, 1097, 283-288.	1.8	5
379	Enhancement of plasminogen activator activity in the gastric wall after chronic ethanol consumption. <i>Alcohol</i> , 1991, 8, 17-20.	0.8	4

#	ARTICLE	IF	CITATIONS
380	Role of Tissue Remodeling in Mammary Epithelial Cell Proliferation and Morphogenesis. <i>Journal of Dairy Science</i> , 1991, 74, 2801-2807.	1.4	32
381	Basal expression and insulin-mediated induction of PAI-1 mRNA in Hep G2 cells. <i>Fibrinolysis</i> , 1991, 5, 81-86.	0.5	16
382	Synergistic effect of intraperitoneally administered calcium channel blockade and recombinant tissue plasminogen activator to prevent adhesion formation in an animal model. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 1327-1330.	0.7	23
383	Variable response of tissue parameters of the fibrinolytic system to unilateral or bilateral adrenalectomy and unilateral or bilateral adrenal demedullation. <i>Journal of Endocrinological Investigation</i> , 1991, 14, 815-820.	1.8	5
384	Biology and Function of Tumor-Associated Trypsin Inhibitor, Tati. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1991, 51, 5-9.	0.6	47
385	Plasmin binding to the plasminogen receptor enhances catalytic efficiency and activates the receptor for subsequent ligand binding. <i>Archives of Biochemistry and Biophysics</i> , 1991, 286, 625-628.	1.4	49
386	Plasminogen activator in human periodontal health and disease. <i>Archives of Oral Biology</i> , 1991, 36, 245-250.	0.8	30
387	Recombinant human interleukin-1 inhibits plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 251-257.	1.0	32
388	The plasminogen activator inhibitor-1 binding site in the kringle-2 domain of tissue-type plasminogen activator. <i>Biochemical and Biophysical Research Communications</i> , 1991, 178, 1160-1166.	1.0	14
389	Substrate specificity of tissue-type and urokinase-type plasminogen activators. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 432-438.	1.0	21
390	Generation of interleukin-8 by plasmin from AVLPR-interleukin-8, the human fibroblast-derived neutrophil chemotactic factor. <i>FEBS Letters</i> , 1991, 282, 412-414.	1.3	50
391	Characterization of trypsinogens 1 and 2 in two human pancreatic adenocarcinoma cell lines; CFPAC-1 and CAPAN-1. <i>FEBS Letters</i> , 1991, 294, 175-178.	1.3	20
392	Natural human monocyte gelatinase and its inhibitor. <i>FEBS Letters</i> , 1991, 284, 73-78.	1.3	46
393	Plasmin cleavage of vitronectin Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. <i>FEBS Letters</i> , 1991, 285, 251-256.	1.3	47
394	Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. <i>FEBS Letters</i> , 1991, 288, 233-236.	1.3	177
395	Characterization of a tissue-type plasminogen activator from porcine urine. <i>FEBS Letters</i> , 1991, 289, 155-158.	1.3	0
396	Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. <i>Experimental Cell Research</i> , 1991, 192, 453-459.	1.2	83
397	Calcitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2. <i>Biochemical Pharmacology</i> , 1991, 41, 585-591.	2.0	9

#	ARTICLE	IF	CITATIONS
398	Plasma tetranectin and ovarian neoplasms. <i>Gynecologic Oncology</i> , 1991, 43, 103-107.	0.6	39
399	Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. <i>Cell</i> , 1991, 64, 327-336.	13.5	2,616
400	The exposure of murine macrophages to Î±2-macroglobulin â€”forms results in the rapid secretion of eicosanoids. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1991, 1093, 115-120.	1.9	19
401	Plasminogen Activators in Endometrial Physiology and Embryo Implantation: A Review. <i>Annals of the New York Academy of Sciences</i> , 1991, 622, 167-175.	1.8	24
402	Basement Membrane in Human Endometrium: Possible Role of Proteolytic Enzymes in Developing Hyperplasia and Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 1991, 622, 376-382.	1.8	16
403	Structure and Biological Role of Vitronectin. <i>Annual Review of Cell Biology</i> , 1991, 7, 275-310.	26.0	461
404	An assay system for the modulators of plasminogen activation on the cell surface. <i>Thrombosis Research</i> , 1991, 62, 519-530.	0.8	9
405	Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: Possible roles in tumor progression and metastasis. <i>Thrombosis Research</i> , 1991, 63, 59-71.	0.8	52
406	Lipoprotein (a): The link between impaired fibrinolysis and atherosclerosis. <i>Fibrinolysis</i> , 1991, 5, 135-143.	0.5	51
407	Measurement of urokinase-type plasminogen activator activity in sera of nasopharyngeal carcinoma patients by an immunocapture assay. <i>Cancer Letters</i> , 1991, 58, 233-240.	3.2	9
408	Immunological detection of conformational changes of type 1 plasminogen activator inhibitor associated with activation. <i>Fibrinolysis</i> , 1991, 5, 225-231.	0.5	4
409	Activation and proliferation signals in murine macrophages. Biochemical signals controlling the regulation of macrophage urokinase-type plasminogen activator activity by colony-stimulating factors and other agents. <i>Blood</i> , 1991, 77, 616-627.	0.6	54
410	Alterations in epidermal biochemistry as a consequence of stage-specific genetic changes in skin carcinogenesis.. <i>Environmental Health Perspectives</i> , 1991, 93, 3-10.	2.8	13
411	Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.. <i>EMBO Journal</i> , 1991, 10, 3399-3407.	3.5	103
412	Directed Plasminogen Activation at the Surface of Normal and Malignant Cells. <i>Advances in Cancer Research</i> , 1991, 57, 273-328.	1.9	254
413	A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 415-419.	3.3	504
414	Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 1928-1932.	3.3	64
415	Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: involvement of cell surface membranes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 7768-7772.	3.3	23



#	ARTICLE	IF	CITATIONS
416	Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter. <i>Nucleic Acids Research</i> , 1991, 19, 3881-3886.	6.5	56
417	Cell-shape regulation and matrix protein p52 content in phenotypic variants of ras-transformed rat kidney fibroblasts. Functional analysis and biochemical comparison of p52 with proteins implicated in cell-shape determination. <i>Biochemical Journal</i> , 1991, 273, 651-658.	1.7	27
418	Soluble fibrin preparations inhibit the reaction of plasmin with $\alpha_2$ -macroglobulin. Comparison with $\alpha_2$ -antiplasmin and leupeptin. <i>Biochemical Journal</i> , 1991, 275, 53-59.	1.7	43
419	Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation. <i>Biochemical Journal</i> , 1991, 276, 785-791.	1.7	33
420	Secretion of latent type IV procollagenase and active type IV collagenase by testicular cells in culture. <i>Biochemical Journal</i> , 1991, 279, 75-80.	1.7	27
421	Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. <i>Gastroenterology</i> , 1991, 101, 1522-1528.	0.6	72
422	Procollagen-III in serum, plasminogen activation and fibronectin in bronchoalveolar lavage fluid during and following irradiation of human lung. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 20, 973-980.	0.4	18
423	Tissue plasminogen activator (A review). <i>Indian Journal of Clinical Biochemistry</i> , 1991, 6, 1-8.	0.9	0
424	Close similarity between cultured human omental mesothelial cells and endothelial cells in cytochemical markers and plasminogen activator production. <i>In Vitro Cellular &amp; Developmental Biology</i> , 1991, 27, 542-548.	1.0	24
425	Plasminogen activator: Isolation and purification from Lymphosarcoma of ascites bearing mice. <i>Journal of Biosciences</i> , 1991, 16, 223-233.	0.5	2
426	Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin. <i>BBA - Proteins and Proteomics</i> , 1991, 1078, 23-30.	2.1	40
427	Characterization of a family of high-molecular-weight plasminogen activators secreted by a lung tumor cell line. <i>BBA - Proteins and Proteomics</i> , 1991, 1078, 360-368.	2.1	2
428	Plasminogen activators in endometrial adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 1991, 1, 223-226.	1.2	3
429	Kinin-generating Cascade in Advanced Cancer Patients and in vitro Study. <i>Japanese Journal of Cancer Research</i> , 1991, 82, 732-741.	1.7	99
430	Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. <i>Histopathology</i> , 1991, 19, 231-238.	1.6	39
431	Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. <i>British Journal of Cancer</i> , 1991, 64, 926-932.	2.9	44
432	Differential Expression of Urokinase-Type Plasminogen Activator and Its Type-1 Inhibitor During Healing of Mouse Skin Wounds. <i>Journal of Investigative Dermatology</i> , 1991, 97, 803-811.	0.3	144
433	PLASMINOGEN ACTIVATOR-DEPENDENT PERICELLULAR PROTEOLYSIS. <i>British Journal of Haematology</i> , 1991, 79, 537-543.	1.2	22

#	ARTICLE	IF	CITATIONS
434	Tissue-specific and time-coordinated hormone regulation of plasminogen-activator-inhibitor type I and tissue-type plasminogen activator in the rat ovary during gonadotropin-induced ovulation. <i>FEBS Journal</i> , 1991, 195, 549-555.	0.2	83
435	Purification and characterisation of plasminogen activator inhibitor 2 produced in <i>Saccharomyces cerevisiae</i> . <i>FEBS Journal</i> , 1991, 196, 431-438.	0.2	24
436	Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. <i>FEBS Journal</i> , 1991, 198, 391-398.	0.2	237
437	Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung. <i>Apmis</i> , 1991, 99, 981-988.	0.9	14
438	Endothelial cell regulation by transforming growth factor-beta. <i>Journal of Cellular Biochemistry</i> , 1991, 47, 224-229.	1.2	72
439	Retinoic acid priming potentiates the induction of urokinase-type plasminogen activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells. <i>Journal of Cellular Physiology</i> , 1991, 147, 46-54.	2.0	17
440	Plasminogen activators and inhibitors in the neuromuscular system: III. The serpin protease nexin I is synthesized by muscle and localized at neuromuscular synapses. <i>Journal of Cellular Physiology</i> , 1991, 147, 76-86.	2.0	66
441	Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells. <i>Journal of Cellular Physiology</i> , 1991, 149, 34-43.	2.0	59
442	Schwann cell plasminogen activator is regulated by neurons. <i>Glia</i> , 1991, 4, 514-528.	2.5	26
443	Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. <i>International Journal of Cancer</i> , 1991, 47, 592-596.	2.3	93
444	Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: Correlation with clinical outcome of anti-estrogen therapy. <i>International Journal of Cancer</i> , 1991, 47, 827-832.	2.3	19
445	Plasminogen activator inhibitor 1 in human carcinoma tissues. <i>International Journal of Cancer</i> , 1991, 48, 481-484.	2.3	35
446	Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines. <i>International Journal of Cancer</i> , 1991, 48, 557-561.	2.3	11
447	Relationships between epithelial basement membrane staining patterns in primary colorectal carcinomas and the extent of tumour spread. <i>International Journal of Cancer</i> , 1991, 48, 855-860.	2.3	24
448	Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: Correlation with CEA distribution and tumor cell kinetics. <i>Journal of Surgical Oncology</i> , 1991, 46, 246-256.	0.8	5
449	Effect of catechins and citrus flavonoids on invasion in vitro. <i>Clinical and Experimental Metastasis</i> , 1991, 9, 13-25.	1.7	51
450	Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells. <i>Clinical and Experimental Metastasis</i> , 1991, 9, 51-56.	1.7	14
451	Regulation of plasminogen activator and plasminogen activator inhibitor production by growth factors and cytokines in rat calvarial cells. <i>Calcified Tissue International</i> , 1991, 49, 321-327.	1.5	23

#	ARTICLE	IF	CITATIONS
452	Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: Increased PA activity correlates with biologically aggressive behavior. <i>Prostate</i> , 1991, 18, 201-214.	1.2	61
453	Characterization of Gelatin-Degrading Metalloproteinase Activities of the Dunning Rat Prostate Tumor Grown in Nude Mice. <i>Prostate</i> , 1991, 19, 237-250.	1.2	13
454	Differences in tetranectin immunoreactivity between benign and malignant breast tissue. <i>Histochemistry</i> , 1991, 95, 427-433.	1.9	55
455	Biological significance of tissue plasminogen activator content in brain tumors. <i>Journal of Neurosurgery</i> , 1991, 74, 480-486.	0.9	52
456	Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract.. <i>Journal of Cell Biology</i> , 1991, 115, 1763-1771.	2.3	112
457	In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.. <i>Journal of Cell Biology</i> , 1991, 115, 1107-1112.	2.3	203
458	Overexpression of the alpha-type protein kinase (PK) C in LLC-PK1 cells does not lead to a proportional increase in the induction of two 12-O-tetradecanoylphorbol-13-acetate-inducible genes.. <i>Molecular Biology of the Cell</i> , 1991, 2, 491-502.	6.5	15
459	Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.. <i>Molecular Biology of the Cell</i> , 1991, 2, 1057-1065.	6.5	20
460	Cell associated urokinase activity and colonic epithelial cells in health and disease.. <i>Gut</i> , 1991, 32, 191-195.	6.1	11
461	Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.. <i>Molecular Biology of the Cell</i> , 1991, 2, 793-803.	6.5	87
462	Regulation of Plasminogen Activator Production by Endothelial Cells: Role in Fibrinolysis and Local Proteolysis. <i>International Journal of Radiation Biology</i> , 1991, 60, 261-272.	1.0	51
463	Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization.. <i>Journal of Histochemistry and Cytochemistry</i> , 1991, 39, 341-349.	1.3	98
464	Occurrence of an Inhibitor of Tissue-Type Plasminogen Activator in Seeds and <i>in Vitro</i> Cultures of <i>Erythrina caffra</i> Thunb. <i>Plant Physiology</i> , 1991, 96, 1150-1156.	2.3	1
465	Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.. <i>Journal of Cell Biology</i> , 1991, 115, 1773-1781.	2.3	78
466	Constitutive expression of the urokinase plasminogen activator gene in murine RAW264 macrophages involves distal and 5' non-coding sequences that are conserved between mouse and pig. <i>Nucleic Acids Research</i> , 1991, 19, 6839-6847.	6.5	53
467	A cell-type specific and enhancer-dependent silencer in the regulation of the expression of the human urokinase plasminogen activator gene. <i>Nucleic Acids Research</i> , 1991, 19, 2303-2308.	6.5	23
468	Subconjunctival High Dose Plasminogen Activator in Rabbit Filtration Surgery. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 1991, 7, 9-19.	0.6	19
469	92-kD type IV collagenase mediates invasion of human cytotrophoblasts.. <i>Journal of Cell Biology</i> , 1991, 113, 437-449.	2.3	707

#	ARTICLE	IF	CITATIONS
470	The Role of Fibrin Fibrils in the Dissociation of a Cell Surface Protease-Inhibitor Complex and Evidence for the Recapture of the Inhibitor Protein. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1991, 5, 299-315.	0.5	1
471	Transforming growth factor beta stimulates urokinase-type plasminogen activator and DNA synthesis, but not prostaglandin E2 production, in human synovial fibroblasts.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 7180-7184.	3.3	41
472	Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.. <i>Journal of Cell Biology</i> , 1991, 115, 191-199.	2.3	146
473	Detection of vitronectin mRNA in tissues and cells of the mouse.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 9402-9406.	3.3	112
474	Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 3992-3996.	3.3	64
475	Regulation of Type One Plasminogen Activator Inhibitor Gene Expression in Cultured Endothelial Cells and the Vessel Wall. , 1991, , 187-208.		2
476	A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. <i>Nucleic Acids Research</i> , 1991, 19, 3389-3393.	6.5	92
477	The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.. <i>Molecular Biology of the Cell</i> , 1991, 2, 285-297.	6.5	20
478	Pathogenesis of corneal epithelial defects: Role of plasminogen activator. <i>Current Eye Research</i> , 1991, 10, 381-398.	0.7	26
479	Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 75, 1497-1502.	1.8	72
480	Plasminogen Activator Inhibitor Type 1 Production by Rat Type II Pneumocytes in Culture. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1992, 6, 133-139.	1.4	13
481	Calcium-regulated secretion of tissue plasminogen activator and parathyroid hormone from human parathyroid cells.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 74, 266-271.	1.8	7
482	Angiotensin-II induction of plasminogen activator inhibitor-1 gene expression in astroglial cells of normotensive and spontaneously hypertensive rat brain.. <i>Molecular Endocrinology</i> , 1992, 6, 2009-2017.	3.7	15
483	Wound Healing of the Ocular Surface. <i>Annals of Medicine</i> , 1992, 24, 19-27.	1.5	35
484	Phorbol ester increases plasminogen activator inhibitor accumulation in cultures of human granulosa cells.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 74, 33-38.	1.8	4
485	Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides.. <i>Molecular Endocrinology</i> , 1992, 6, 53-60.	3.7	30
486	Lung Capillary Endothelial Cells Produce and Secrete Urokinase-type Plasminogen Activator. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1992, 7, 90-94.	1.4	17
487	Heparin inhibits collagenase gene expression mediated by phorbol ester-responsive element in primate arterial smooth muscle cells.. <i>Circulation Research</i> , 1992, 70, 1062-1069.	2.0	57

#	ARTICLE	IF	CITATIONS
488	Induction of Specific Gelatinolytic Proteinases in the Lateral Prostate of Rats by Ectopic Pituitary Grafts1. <i>Biology of Reproduction</i> , 1992, 46, 671-679.	1.2	9
489	Heparin inhibits the expression of tissue-type plasminogen activator by smooth muscle cells in injured rat carotid artery.. <i>Circulation Research</i> , 1992, 70, 1128-1136.	2.0	81
490	Metalloproteinase Activities Expressed during Development and Maturation of the Rat Prostatic Complex and Seminal Vesicles1. <i>Biology of Reproduction</i> , 1992, 47, 683-691.	1.2	31
491	Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 7427-7431.	3.3	330
492	Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 7422-7426.	3.3	264
493	Stimulation of plasmin activity by oleic acid. <i>Biochemical Journal</i> , 1992, 282, 863-866.	1.7	29
494	Separation, purification and N-terminal sequence analysis of a novel leupeptin-sensitive serine endopeptidase present in chemically induced rat mammary tumour. <i>Biochemical Journal</i> , 1992, 283, 209-216.	1.7	4
495	Lipoprotein (a) promotes plasmin inhibition by Î±2-antiplasmin. <i>Biochemical Journal</i> , 1992, 286, 79-84.	1.7	16
496	Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-Î³ and tumor necrosis factor-Î±. <i>Journal of Leukocyte Biology</i> , 1992, 51, 256-263.	1.5	56
497	Prostate and Bone Fibroblasts Induce Human Prostate Cancer Growth in Vivo: Implications for Bidirectional Tumor-Stromal Cell Interaction in Prostate Carcinoma Growth and Metastasis. <i>Journal of Urology</i> , 1992, 147, 1151-1159.	0.2	183
498	In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 10686-10690.	3.3	166
499	Regulation of tumor-host interactions in breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 41, 389-400.	1.2	15
500	Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase. <i>British Journal of Cancer</i> , 1992, 65, 51-57.	2.9	9
501	Invasion of brain tissue by primary glioma: Evidence for the involvement of urokinase-type plasminogen activator as an activator of type iv collagenase. <i>Biochemical and Biophysical Research Communications</i> , 1992, 186, 348-354.	1.0	60
502	Treatment of Postcataract Fibrinous Membranes with Tissue Plasminogen Activator. <i>Ophthalmology</i> , 1992, 99, 1256-1259.	2.5	46
503	Occupancy of the cancer urokinase receptor (uPAR): Effects of acid elution and exogenous uPA on cell surface urokinase (uPA). <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1992, 1117, 143-152.	1.1	8
504	Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus. <i>Gynecologic Oncology</i> , 1992, 46, 330-336.	0.6	17
505	Effect of chromosomal anomalies on the plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition in spermatozoa and seminal plasma 1. Chromosomal chimaerism XX/XY in the ram. <i>Animal Reproduction Science</i> , 1992, 29, 241-254.	0.5	8

#	ARTICLE	IF	CITATIONS
506	Cytokines and proteases in invasive processes: Molecular similarities between inflammation and cancer. <i>Cytokine</i> , 1992, 4, 251-258.	1.4	156
507	The effect of tissue type plasminogen activator (tPA) on osteoclastic resorption in embryonic mouse long bone explants: a possible role for the growth factor domain of tPA. <i>Bone and Mineral</i> , 1992, 17, 1-13.	2.0	21
508	Thrombospondin, a platelet $\alpha$ -granule and matrix glycoprotein, is increased in muscle basement membrane of patients with amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 1992, 113, 99-107.	0.3	13
509	Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues. <i>Thrombosis Research</i> , 1992, 65, 709-719.	0.8	55
510	Urokinase-type plasminogen activator and its specific receptor in high metastatic and non-metastatic cell lines derived from human lung adenocarcinoma. <i>Thrombosis Research</i> , 1992, 65, 449-456.	0.8	15
511	The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion. <i>Annals of the New York Academy of Sciences</i> , 1992, 667, 13-31.	1.8	154
512	Plasminogen Activators and Plasminogen Activator Inhibitors in Neural Development. <i>Annals of the New York Academy of Sciences</i> , 1992, 667, 32-40.	1.8	47
513	Plasminogen Activators and Their Inhibitors in Arthritic Disease. <i>Annals of the New York Academy of Sciences</i> , 1992, 667, 87-100.	1.8	28
514	Impact of Endothelial Activation on Fibrinolysis and Local Proteolysis in Tissue Repair. <i>Annals of the New York Academy of Sciences</i> , 1992, 667, 151-162.	1.8	22
515	Polarized secretion of plasminogen activators by epithelial cell monolayers. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992, 1175, 1-6.	1.9	17
516	Cell-specific regulation of plasminogen activator inhibitor 1 and tissue type plasminogen activator release by human kidney mesangial cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992, 1134, 189-196.	1.9	18
517	The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. <i>Gynecologic Oncology</i> , 1992, 47, 58-61.	0.6	18
518	Characterization and regulation of the urokinase receptor of human endothelial cells. <i>Fibrinolysis</i> , 1992, 6, 1-9.	0.5	49
519	The role of urokinase and urokinase inhibitor in tumour cell metastasis. <i>Fibrinolysis</i> , 1992, 6, 23-29.	0.5	13
520	Secretion of plasminogen activators by normal bone marrow cells and leukaemic myeloid cells. <i>Fibrinolysis</i> , 1992, 6, 77-79.	0.5	8
521	A practical method for uniform isotopic labeling of recombinant proteins in mammalian cells. <i>Biochemistry</i> , 1992, 31, 12713-12718.	1.2	80
522	Ionic modulation of the effects of heparin on plasminogen activation by tissue plasminogen activator: The effects of ionic strength, divalent cations, and chloride. <i>Archives of Biochemistry and Biophysics</i> , 1992, 296, 530-538.	1.4	9
523	Plasminogen activators in normal and malignant oral epithelium in vivo and in vitro. <i>Archives of Oral Biology</i> , 1992, 37, 749-756.	0.8	6

#	ARTICLE	IF	CITATIONS
524	Microglia isolated from rat brain secrete a urokinase-type plasminogen activator. <i>Brain Research</i> , 1992, 577, 285-292.	1.1	126
525	Mechanisms of C6 glioma cell and fetal astrocyte migration into hydrated collagen I gels. <i>Brain Research</i> , 1992, 581, 81-90.	1.1	31
526	Plasminogen activators in the neuromuscular system of the wobbler mutant mouse. <i>Brain Research</i> , 1992, 580, 303-310.	1.1	24
527	Polarized secretion of urokinase-type plasminogen activator by epithelial cells. <i>Experimental Cell Research</i> , 1992, 203, 236-243.	1.2	24
528	Modulation of plasminogen activator and plasminogen activator inhibitor expression in the human U373 glioblastoma/astrocytoma cell line by inflammatory mediators. <i>Experimental Cell Research</i> , 1992, 198, 93-100.	1.2	22
529	Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: A key event in melanoma cell invasiveness in vitro. <i>Experimental Cell Research</i> , 1992, 199, 179-190.	1.2	52
530	Okadaic acid strongly increases gene transcription, mRNA and protein level for the urokinase receptor in human A549 cells. <i>FEBS Letters</i> , 1992, 298, 177-181.	1.3	10
531	Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. <i>FEBS Letters</i> , 1992, 297, 112-118.	1.3	128
532	The receptor for the plasminogen activator of urokinase type is up-regulated in transformed rat thyroid cells. <i>FEBS Letters</i> , 1992, 306, 193-198.	1.3	11
533	TATA box-independent transcription of the human tissue plasminogen activator gene initiates within a sequence conserved in related genes. <i>FEBS Letters</i> , 1992, 309, 130-134.	1.3	27
534	Production and secretion of plasminogen in cultured rat brain microglia. <i>FEBS Letters</i> , 1992, 308, 179-182.	1.3	91
535	Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. <i>FEBS Letters</i> , 1992, 311, 17-21.	1.3	78
536	Human urokinase contains Ga1NAc <sup>2</sup> (1-4)[Fuc <sup>1</sup> (1-3)]G1cNAc <sup>2</sup> (1-2) as a novel terminal element in N-linked carbohydrate chains. <i>FEBS Letters</i> , 1992, 314, 389-394.	1.3	51
537	Modulation of activities and RNA level of the components of the plasminogen activation system during fusion of human myogenic satellite cells in vitro. <i>Developmental Biology</i> , 1992, 151, 166-175.	0.9	41
538	Differential effects of platelet-derived growth factor isoforms on plasminogen activator activity in fetal rat osteoblasts due to isoform-specific receptor functions. <i>Endocrinology</i> , 1992, 130, 2059-2066.	1.4	20
539	A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. <i>EMBO Journal</i> , 1992, 11, 4573-4582.	3.5	115
540	Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. <i>EMBO Journal</i> , 1992, 11, 4825-4833.	3.5	502
541	Structural and Biologic Properties of Integrin-Mediated Cell Adhesion. <i>Clinics in Laboratory Medicine</i> , 1992, 12, 217-236.	0.7	44

#	ARTICLE	IF	CITATIONS
542	The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 1992, 79, 1447-1455.	0.6	142
543	Endocytosis and lysosomal delivery of tissue plasminogen activator-inhibitor 1 complexes in Hep G2 cells. <i>Blood</i> , 1992, 80, 2746-2754.	0.6	13
544	Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells. <i>Blood</i> , 1992, 80, 1486-1495.	0.6	4
545	Effects of interleukin-1, tumor necrosis factor- $\alpha$ , and forskolin on tissue plasminogen activator activity in human osteoblastic osteosarcoma cells. <i>Calcified Tissue International</i> , 1992, 50, 129-133.	1.5	4
546	Active cell death in hormone-dependent tissues. <i>Cancer and Metastasis Reviews</i> , 1992, 11, 197-220.	2.7	258
547	Expression of gelatinase/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion. <i>Clinical and Experimental Metastasis</i> , 1992, 10, 211-220.	1.7	19
548	Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities. <i>Clinical and Experimental Metastasis</i> , 1992, 10, 395-401.	1.7	7
549	Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin). <i>Clinical and Experimental Metastasis</i> , 1992, 10, 49-59.	1.7	62
550	Density dependent polarized secretion of a prostatic epithelial cell line. <i>Prostate</i> , 1992, 20, 15-27.	1.2	6
551	Biology of metastasis: Clinical implications. <i>Journal of Surgical Oncology</i> , 1992, 8, 267-273.	1.4	4
552	Urokinase Plasminogen Activator Is Immunocytochemically Detectable in Squamous Cell but Not Basal Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 1992, 98, 351-358.	0.3	18
553	Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid. <i>British Journal of Dermatology</i> , 1992, 127, 272-277.	1.4	25
554	Plasminogen binding sites in normal human skin. <i>British Journal of Dermatology</i> , 1992, 126, 35-41.	1.4	36
555	Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 24, 949-957.	0.4	20
556	Bovine embryos produce a urokinase-type plasminogen activator. <i>Molecular Reproduction and Development</i> , 1992, 31, 14-19.	1.0	17
557	Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1. <i>BBA - Proteins and Proteomics</i> , 1992, 1160, 325-334.	2.1	17
558	Demonstration of a possible link between high grade malignancy in dimethylbenz[a]anthracene-induced rat mammary carcinoma and increased urokinase plasminogen activator content. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 22, 165-168.	1.0	5
559	The plasminogen-plasmin system in malignancy. <i>Cancer and Metastasis Reviews</i> , 1992, 11, 291-311.	2.7	187



#	ARTICLE	IF	CITATIONS
560	Inhibiting tissue invasion and metastasis as targets for cancer therapy. <i>Biotherapy (Dordrecht)</i> , 1992, 4, 107-115.	0.7	15
561	LOCALIZATION OF COMPONENTS FROM THE PLASMINOGEN ACTIVATION SYSTEM IN MAMMALIAN TISSUES. <i>Apmis</i> , 1992, 100, 5-27.	0.9	10
562	Disruption of the cytoskeleton-extracellular matrix linkage promotes the accumulation of plasminogen activators in F9 derived parietal endoderm. <i>Differentiation</i> , 1992, 50, 153-162.	1.0	4
563	Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. <i>FEBS Journal</i> , 1992, 205, 451-458.	0.2	57
564	A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor. <i>FEBS Journal</i> , 1992, 207, 177-183.	0.2	9
565	Urokinase binding to laminin-nidogen. Structural requirements and interactions with heparin. <i>FEBS Journal</i> , 1992, 207, 937-942.	0.2	21
566	A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. <i>FEBS Journal</i> , 1992, 208, 397-404.	0.2	66
567	Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator. <i>FEBS Journal</i> , 1992, 208, 493-500.	0.2	53
568	A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. <i>FEBS Journal</i> , 1992, 209, 985-992.	0.2	87
569	Presence of Urokinase-Type Plasminogen Activator (u-PA) in Tissue Extracts of Antrochoanal Polyp. <i>Laryngoscope</i> , 1992, 102, 1049-1052.	1.1	11
570	Regulation of plasminogen activators and type-1 plasminogen activator inhibitor by cyclic AMP and phorbol ester in rat astrocytes. <i>Glia</i> , 1992, 6, 163-171.	2.5	34
571	Teratocarcinoma F9 cells induced to differentiate with sodium butyrate produce both tissue-type and urokinase-type plasminogen activators. <i>Journal of Cellular Biochemistry</i> , 1992, 49, 284-289.	1.2	3
572	Localization of the cleavage sites on fibronectin following digestion by urokinase. <i>Journal of Cellular Biochemistry</i> , 1992, 50, 441-452.	1.2	29
573	Type-1 plasminogen activator inhibitor in human breast carcinomas. <i>International Journal of Cancer</i> , 1992, 50, 208-214.	2.3	102
574	Growth-factor-independence and invasive properties of colorectal carcinoma cells. <i>International Journal of Cancer</i> , 1992, 50, 274-280.	2.3	13
575	Plasminogen activator system in human breast cancer. <i>International Journal of Cancer</i> , 1992, 50, 345-348.	2.3	81
576	The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. <i>International Journal of Cancer</i> , 1992, 50, 871-873.	2.3	91
577	Post-transcriptional regulation of urokinase plasminogen activator gene expression occurs in the nucleus of BC1 rat mammary tumor cells. <i>International Journal of Cancer</i> , 1992, 50, 918-923.	2.3	11

#	ARTICLE	IF	CITATIONS
578	Study of fibronectin mRNA in human laryngeal and ectocervical carcinomas by IN SITU hybridization and image analysis. <i>International Journal of Cancer</i> , 1992, 51, 692-697.	2.3	22
579	Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells. <i>International Journal of Cancer</i> , 1992, 52, 298-304.	2.3	18
580	Okadaic acid induces the expression of both early and secondary response genes in mouse keratinocytes. <i>Molecular Carcinogenesis</i> , 1992, 5, 16-24.	1.3	35
581	Urokinase activity in the developing avian heart: A spatial and temporal analysis. <i>Developmental Dynamics</i> , 1992, 193, 24-33.	0.8	36
582	D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy prognostic significance for the success of anti-cancer treatment. <i>Cancer</i> , 1992, 69, 2289-2292.	2.0	35
583	Coagulation-fibrinolysis system and markers of collagen metabolism in lung cancer. <i>Cancer</i> , 1992, 70, 2631-2636.	2.0	28
584	Molecular aspects of tumor cell invasion and metastasis. <i>Cancer</i> , 1993, 71, 1368-1383.	2.0	441
585	The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. <i>Cancer</i> , 1993, 72, 2415-2422.	2.0	60
586	Characterization of immunotrap assays for urokinase plasminogen activator and its inhibitors and measurements of these molecules in human plasma and mouse macrophage in culture. <i>International Journal of Biochemistry &amp; Cell Biology</i> , 1993, 25, 781-788.	0.8	3
587	Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. <i>BioEssays</i> , 1993, 15, 105-111.	1.2	381
588	Differential regulation of gelatinase b and tissue-type plasminogen activator expression in human bowes melanoma cells. <i>International Journal of Cancer</i> , 1993, 53, 395-400.	2.3	29
589	Persistence of plasmin-mediated pro-urokinase activation on the surface of human monocytoid leukemia cells In Vitro. <i>International Journal of Cancer</i> , 1993, 53, 499-505.	2.3	10
590	The plasminogen-activation system in ovarian tumors. <i>International Journal of Cancer</i> , 1993, 55, 27-31.	2.3	52
591	Binding of tissue-type plasminogen activator to human melanoma cells. <i>Journal of Cellular Biochemistry</i> , 1993, 51, 326-335.	1.2	28
592	Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. <i>Journal of Cellular Biochemistry</i> , 1993, 53, 135-144.	1.2	87
593	Autocrine/paracrine regulation of keratinocyte urokinase plasminogen activator through the TGF- $\beta$ /EGF receptor. <i>Journal of Cellular Physiology</i> , 1993, 155, 333-339.	2.0	30
594	Molecular mechanisms of protease-mediated tumor invasiveness. <i>Journal of Surgical Oncology</i> , 1993, 53, 21-23.	0.8	21
595	Cell adhesion and metastasis: is the site specificity of cancer metastasis determined by leukocyte-endothelial cell recognition and adhesion?. <i>Critical Reviews in Oncology/Hematology</i> , 1993, 14, 229-278.	2.0	35

#	ARTICLE	IF	CITATIONS
596	Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann. Archives of Dermatological Research, 1993, 284, 432-439.	1.1	20
597	Role of matrix metalloproteinases in invasion, and metastasis: biology, diagnosis and inhibitors. Cytotechnology, 1993, 12, 367-384.	0.7	16
598	Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer and Metastasis Reviews, 1993, 12, 303-324.	2.7	791
599	Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Research and Treatment, 1993, 28, 223-229.	1.1	27
600	Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors. Journal of Neuro-Oncology, 1993, 17, 215-221.	1.4	32
601	Evidence for an extra-cellular function for protein kinase A. Molecular and Cellular Biochemistry, 1993, 127-128, 283-291.	1.4	21
602	Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. British Journal of Cancer, 1993, 67, 721-727.	2.9	75
603	Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells. British Journal of Cancer, 1993, 67, 99-101.	2.9	19
604	Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. British Journal of Cancer, 1993, 67, 537-544.	2.9	43
605	Role of cytokines and inflammatory mediators in tissue destruction. Journal of Periodontal Research, 1993, 28, 500-510.	1.4	508
606	The synthesis of three 4-substitutedbenzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase. Bioorganic and Medicinal Chemistry, 1993, 1, 403-410.	1.4	30
607	An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. Clinical and Experimental Dermatology, 1993, 18, 119-123.	0.6	10
608	Urokinase-type plasminogen activator in human eccrine sweat. British Journal of Dermatology, 1993, 128, 178-183.	1.4	6
609	Lysosome Labilizers Potentiate the Antitumor Effects of Tumor Necrosis Factor- $\alpha$ . Japanese Journal of Cancer Research, 1993, 84, 451-454.	1.7	0
610	Increased Cell-surface Urokinase in Advanced Ovarian Cancer. Japanese Journal of Cancer Research, 1993, 84, 633-640.	1.7	31
611	Tetranectin: a Novel Secretory Protein from Human Monocytes. Scandinavian Journal of Immunology, 1993, 37, 39-42.	1.3	34
612	MESOGLYCAN TREATMENT RESTORES DEFECTIVE FIBRINOLYTIC POTENTIAL IN CUTANEOUS NECROTIZING VENUKITIS. International Journal of Dermatology, 1993, 32, 368-371.	0.5	15
613	Microglia-Derived Elastase Produces a Low-Molecular-Weight Plasminogen that Enhances Neurite Outgrowth in Rat Neocortical Explant Cultures. Journal of Neurochemistry, 1993, 61, 2155-2163.	2.1	39

#	ARTICLE	IF	CITATIONS
614	Immobilization of plasminogen on Escherichia coli flagella. FEMS Microbiology Letters, 1993, 106, 309-314.	0.7	31
615	Proteolytic activity in leg ulcer exudate. Experimental Dermatology, 1993, 2, 29-37.	1.4	95
616	Primary structure of N-linked carbohydrate chains of a human chimeric plasminogen activator K2tu-PA expressed in Chinese hamster ovary cells. FEBS Journal, 1993, 212, 639-656.	0.2	36
617	Transient and cell-specific expression of tissue-type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during gonadotropin-induced ovulation. FEBS Journal, 1993, 214, 147-156.	0.2	56
618	Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. FEBS Journal, 1993, 218, 1071-1082.	0.2	68
619	Plasminogen activator activity and fertilizing ability of human spermatozoa. Journal of Developmental and Physical Disabilities, 1993, 16, 201-206.	3.6	15
620	Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. Apmis, 1993, 101, 235-241.	0.9	38
621	10 The importance of blood cell-vessel wall interactions in tumour metastasis. Best Practice and Research: Clinical Haematology, 1993, 6, 731-752.	1.1	23
622	Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell. Teratogenesis, Carcinogenesis, and Mutagenesis, 1993, 13, 75-88.	0.8	15
623	Adhesion molecules and their role in cancer metastasis. Cell Biophysics, 1993, 23, 3-89.	0.4	43
624	Secreted proteins of normal and myc-ras oncogene transformed rat embryo fibroblasts. Journal of Biosciences, 1993, 18, 47-57.	0.5	0
625	Fibrin binding, fibrinolytic and fibrinogenolytic activity of plasminogen activator derived from the paranasal mucous membrane of humans. Laryngoscope, 1993, 103, 197-202.	1.1	1
626	Matrix Metalloproteinases: A Review. Critical Reviews in Oral Biology and Medicine, 1993, 4, 197-250.	4.4	2,600
627	Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Research and Treatment, 1993, 24, 195-208.	1.1	338
628	The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Research and Treatment, 1993, 24, 257-264.	1.1	29
629	Impaired fibrinolysis in patients with blackfoot disease. Thrombosis Research, 1993, 72, 211-218.	0.8	14
630	The potential role of platelet PAI-1 in t-PA mediated clot lysis of platelet rich plasma. Thrombosis Research, 1993, 71, 289-300.	0.8	21
631	Hormonal regulation of the fibrinolytic components in the ovary. Thrombosis Research, 1993, 71, 1-45.	0.8	37

#	ARTICLE	IF	CITATIONS
632	Production and characterization of domain-specific monoclonal antibodies against tissue-type plasminogen activator. <i>Animal Reproduction Science</i> , 1993, 34, 69-81.	0.5	1
633	A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking. <i>FEBS Letters</i> , 1993, 336, 394-396.	1.3	26
634	Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. <i>FEBS Letters</i> , 1993, 322, 37-40.	1.3	98
635	Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. <i>FEBS Letters</i> , 1993, 315, 293-297.	1.3	39
636	Processing of complex between urokinase and its type-2 inhibitor on the cell surface. <i>FEBS Letters</i> , 1993, 323, 279-284.	1.3	19
637	An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. <i>FEBS Letters</i> , 1993, 326, 69-74.	1.3	74
638	Localization of epitopes recognized by monoclonal antibodies on tissue-type and urokinase-type plasminogen activators using recombinant hybrid enzymes. <i>Fibrinolysis</i> , 1993, 7, 1-14.	0.5	7
639	Immunohistochemical characterization of the plasminogen activator system in psoriatic epidermis. <i>British Journal of Dermatology</i> , 1993, 128, 612-618.	1.4	32
640	Southwestern blot mapping of potential regulatory proteins binding to the DNA encoding plasminogen activator inhibitor type 2. <i>Gene</i> , 1993, 134, 201-208.	1.0	17
641	Functional roles of microglia in the brain. <i>Neuroscience Research</i> , 1993, 17, 187-203.	1.0	196
642	Prognostic Value of Serum Tetranectin in Patients with Metastatic Breast Cancer. <i>Acta OncolÃ³gica</i> , 1993, 32, 631-636.	0.8	36
643	Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin. <i>Biochemistry</i> , 1993, 32, 2314-2320.	1.2	24
644	Acute ischaemia of the lower limb: An unusual presenting feature of acute lymphoblastic leukaemia. <i>European Journal of Vascular Surgery</i> , 1993, 7, 750-752.	0.9	7
645	Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells. <i>European Journal of Cancer</i> , 1993, 29, 1184-1189.	1.3	21
646	Sex-related differences of plasminogen activator activity and plasminogen activator inhibition in the gastric wall after chronic ethanol consumption: Effect of orchidectomy or ovariectomy. <i>Alcohol</i> , 1993, 10, 375-379.	0.8	1
647	Treatment of anterior chamber fibrin following cataract surgery with tissue plasminogen activator. <i>Journal of Cataract and Refractive Surgery</i> , 1993, 19, 301-305.	0.7	28
648	Biochemical and histochemical studies of plasminogen activator of urokinase type (u-PA) activity. I. A simple rapid semiquantitative fluorescent method for its detection in the tear fluid. <i>Acta Histochemica</i> , 1993, 95, 232-237.	0.9	6
649	Effects of retinoic acid, auranofin and mercuric chloride on plasminogen activator activity in post-implantation cultured mouse embryos. <i>Toxicology in Vitro</i> , 1993, 7, 751-755.	1.1	0

#	ARTICLE	IF	CITATIONS
650	Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: Relative prognostic value versus total cathepsin D. <i>European Journal of Cancer</i> , 1993, 29, 1248-1251.	1.3	31
651	Expression of plasminogen activator and plasminogen activator inhibitor by rat mesothelioma induced by asbestos. <i>Cancer Letters</i> , 1993, 68, 119-127.	3.2	1
652	Plasmatic parameters of fibrin formation and degradation in cancer patients: correlation between fibrinopeptide A and D-dimer. <i>Biomedicine and Pharmacotherapy</i> , 1993, 47, 235-239.	2.5	12
653	Different induction pathways for urokinase (u-PA) in A431 cells by EGF and by the phorbol ester, TPA. <i>Fibrinolysis</i> , 1993, 7, 31-40.	0.5	4
654	Characterization of plasmin digested peptide maps for recombinant high molecular weight urokinase and pro-Urokinase . Its use for the estimation of low molecular weight urokinase in pro-UK/HMW-UK. <i>Fibrinolysis</i> , 1993, 7, 219-224.	0.5	1
655	Urokinase-type plasminogen activator and malignancy. <i>Fibrinolysis</i> , 1993, 7, 295-302.	0.5	54
656	Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1993, 1178, 55-62.	1.9	88
657	Modulation of the plasminogen activation system in murine macrophages. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1993, 1176, 113-122.	1.9	14
658	Enzyme-linked immunosorbent assays for plasminogen activators. <i>Journal of Immunological Methods</i> , 1993, 162, 193-200.	0.6	16
659	Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer. <i>Thrombosis Research</i> , 1993, 69, 209-220.	0.8	27
660	[16] Probing structureâ€”function relationships of tissue-type plasminogen activator by oligonucleotide-mediated site-specific mutagenesis. <i>Methods in Enzymology</i> , 1993, 223, 249-271.	0.4	12
661	High levels of human chorionic gonadotropin retard first trimester trophoblast invasion in vitro by decreasing urokinase plasminogen activator and collagenase activities.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 77, 1506-1511.	1.8	46
662	Integrins: Structure, Function, and Biological Properties. <i>Advances in Molecular and Cell Biology</i> , 1993, , 225-252.	0.1	51
663	Regulation of the endothelial cell urokinase-type plasminogen activator receptor. Evidence for cyclic AMP-dependent and protein kinase C-dependent pathways.. <i>Circulation Research</i> , 1993, 72, 330-340.	2.0	41
664	Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1993, 53, 741-746.	0.6	39
665	Partial Characterization of the Plasminogen Activator Produced by Ovine Embryos in Vitro1. <i>Biology of Reproduction</i> , 1993, 49, 381-386.	1.2	9
666	Purification and cDNA cloning of a transcription factor which functionally cooperates within a cAMP regulatory unit in the porcine uPA gene. <i>Nucleic Acids Research</i> , 1993, 21, 1845-1852.	6.5	19
667	Converting tissue plasminogen activator to a zymogen: a regulatory triad of Asp-His-Ser. <i>Science</i> , 1993, 262, 419-421.	6.0	87

#	ARTICLE	IF	CITATIONS
668	U937 Cells Can Utilize Plasminogen Activator to Regulate Human Interferon- $\hat{1}$ <sup>3</sup> . Journal of Interferon Research, 1993, 13, 397-406.	1.2	6
669	Factors contributing to increased vascular fibrinolytic activity in mongrel dogs.. Circulation, 1993, 87, 1990-2000.	1.6	46
670	The Role of the Host Response in Periodontal Disease Progression: Implications for Future Treatment Strategies. Journal of Periodontology, 1993, 64, 792-806.	1.7	142
671	Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy.. Gut, 1993, 34, 1120-1122.	6.1	18
672	Pharmacologic Induction of Posterior Vitreous Detachment in the Rabbit. JAMA Ophthalmology, 1993, 111, 849.	2.6	162
673	Fibrinogenolytic and fibrinolytic activity of cell-associated plasmin.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 48-55.	3.8	12
674	New Insights into the Pathogenesis of Coagulation Dysfunction in Acute Promyelocytic Leukemia. Leukemia and Lymphoma, 1993, 11, 27-36.	0.6	59
675	Plasminogen Activator Activity in Preovulatory Follicles during the Ovulatory Cycle of the Chicken <sup>1</sup> . Biology of Reproduction, 1993, 49, 1141-1146.	1.2	20
676	Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.. Gut, 1993, 34, 80-85.	6.1	59
677	Cytoskeletal reorganization and TPA differently modify AP-1 to induce the urokinase-type plasminogen activator gene in LLC-PK1 cells. Nucleic Acids Research, 1993, 21, 3365-3372.	6.5	54
678	Thrombin adhesive properties: induction by plasmin and heparan sulfate.. Journal of Cell Biology, 1993, 123, 1279-1287.	2.3	28
679	[13] Cellular receptor for urokinase-type plasminogen activator: Protein structure. Methods in Enzymology, 1993, 223, 207-222.	0.4	33
680	Enzymes and Morphogenesis: Alkaline Phosphatase and Control of Cell Migration. Advances in Developmental Biology (1992), 1993, , 153-183.	1.1	1
681	Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. British Journal of Cancer, 1993, 68, 524-529.	2.9	33
682	Breast cancer prognosis is poor when total plasminogen activator activity is low. British Journal of Cancer, 1993, 67, 374-378.	2.9	17
683	Receptor-recognized $\hat{1}$ $\pm$ 2-macroglobulin-methylamine elevates intracellular calcium, inositol phosphates and cyclic AMP in murine peritoneal macrophages. Biochemical Journal, 1993, 290, 885-891.	1.7	75
684	Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochemical Journal, 1993, 296, 505-510.	1.7	22
685	Effects of macrophage-colony stimulating factor on human monocytes: Induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E <sub>2</sub> , interleukin-6, interleukin-1, or tumor necrosis factor- $\alpha$ . Journal of Leukocyte Biology, 1993, 53, 707-714.	1.5	27

#	ARTICLE	IF	CITATIONS
686	Monocyte urokinase expression: modulation by interleukins. <i>Journal of Leukocyte Biology</i> , 1993, 53, 598-601.	1.5	36
687	Immunohistochemical Study of Tumor Cell-associated Plasminogen Activators and Plasminogen Activator Inhibitors in Lung Carcinomas. <i>Chest</i> , 1993, 104, 8-13.	0.4	23
688	Transcriptional regulation of the rat tissue type plasminogen activator gene: localization of DNA elements and nuclear factors mediating constitutive and cyclic AMP-induced expression.. <i>Molecular and Cellular Biology</i> , 1993, 13, 266-275.	1.1	30
689	Evaluating Prethrombotic State In Lung Cancer Using Molecular Markers. <i>Chest</i> , 1993, 103, 196-200.	0.4	67
690	The N-terminal domain of human urokinase receptor contains two distinct regions critical for ligand recognition. <i>Blood</i> , 1993, 82, 2719-2729.	0.6	21
691	Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases.. <i>Molecular and Cellular Biology</i> , 1993, 13, 5888-5897.	1.1	29
693	Plasma D-Dimer Measurement as a Marker of Gynecologic Tumors: Comparison with CA 125. <i>Tumori</i> , 1993, 79, 347-351.	0.6	20
694	Overview of the Biologic Markers of Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1994, 8, 73-100.	0.9	56
695	Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells. <i>Blood</i> , 1994, 83, 3206-3217.	0.6	19
696	Effect of thrombin, the thrombin receptor activation peptide, and other mitogens on vascular smooth muscle cell urokinase receptor mRNA levels. <i>Blood</i> , 1994, 84, 3700-3708.	0.6	35
697	Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.. <i>Journal of Clinical Oncology</i> , 1994, 12, 1648-1658.	0.8	209
698	The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.. <i>EMBO Journal</i> , 1994, 13, 3983-3991.	3.5	156
699	Inactivation of Receptor-Bound Pro-Urokinase-Type Plasminogen Activator (pro-uPA) by Thrombin and Thrombin/Thrombomodulin Complex. <i>Biological Chemistry Hoppe-Seyler</i> , 1994, 375, 603-608.	1.4	10
700	Tissue-type plasminogen activator and its inhibitor in rat aorta. Effect of endotoxin.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1994, 14, 1459-1465.	3.8	27
701	Synergistic induction of tissue-type plasminogen activator gene expression by glucocorticoids and cyclic nucleotides in rat HTC hepatoma cells.. <i>Endocrinology</i> , 1994, 135, 1195-1204.	1.4	14
702	Prolactin Inhibits Ovulation by Reducing Ovarian Plasmin Generation. <i>Biology of Reproduction</i> , 1994, 50, 1223-1230.	1.2	15
703	Regulation of the Urokinase Gene by the Retinoblastoma Protein. <i>DNA and Cell Biology</i> , 1994, 13, 1063-1069.	0.9	1
704	MConfocal Fluorescence Microscopy of Urokinase Plasminogen Activator Receptor and Cathepsin D in Human MDA-MB-231 Breast Cancer Cells Migrating in Reconstituted Basement Membrane. <i>Biotechnic and Histochemistry</i> , 1994, 69, 61-67.	0.7	18



#	ARTICLE	IF	CITATIONS
705	Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.. Journal of Cell Biology, 1994, 126, 259-270.	2.3	260
706	Activation of cAMP-dependent protein kinase alters the chromatin structure of the urokinase-type plasminogen activator gene promoter. Nucleic Acids Research, 1994, 22, 569-575.	6.5	11
707	In Vitro Urokinase Type Plasminogen Activator Levels and Total Plasminogen Activator Activity in Squamous Cell Carcinomas of the Head and Neck. JAMA Otolaryngology, 1994, 120, 989-992.	1.5	19
708	Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation.. Circulation Research, 1994, 75, 41-54.	2.0	278
709	Integrating with integrins.. Molecular Biology of the Cell, 1994, 5, 389-393.	0.9	181
710	Overexpression of urokinase-type plasminogen activator in transgenic mice is correlated with impaired learning.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3196-3200.	3.3	74
711	Expression of Plasminogen Activator Enzymes in Psoriatic Epidermis. Journal of Investigative Dermatology, 1994, 102, 333-338.	0.3	34
712	Heterogeneities of attachment, chemotaxis, and protease production among clones with different metastatic potentials from a human pancreatic cancer cell line. Clinical and Experimental Metastasis, 1994, 12, 238-244.	1.7	17
713	Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clinical and Experimental Metastasis, 1994, 12, 117-128.	1.7	39
714	Acute promyelocytic leukemia: Aparadigm for differentiation therapy with retinoic acid. Blood Reviews, 1994, 8, 70-78.	2.8	9
715	Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry, 1994, 101, 105-112.	1.9	47
716	Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate, 1994, 24, 46-53.	1.2	90
717	Novel thrombolytic agents. Cardiovascular Drugs and Therapy, 1994, 8, 801-811.	1.3	9
718	Preface: Tumor invasion and brain cancer. Journal of Neuro-Oncology, 1994, 18, v-viii.	1.4	0
719	Tumor invasion, proteolysis, and angiogenesis. Journal of Neuro-Oncology, 1994, 18, 89-103.	1.4	63
720	Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro Matrigel model. Journal of Neuro-Oncology, 1994, 18, 129-138.	1.4	67
721	Hemostatic changes in patients with brain tumors. Journal of Neuro-Oncology, 1994, 22, 87-100.	1.4	28
722	Prognostic significance of proteolytic enzymes in human brain tumors. Journal of Neuro-Oncology, 1994, 22, 101-110.	1.4	75

#	ARTICLE	IF	CITATIONS
723	Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. <i>Journal of Neuro-Oncology</i> , 1994, 22, 139-151.	1.4	34
724	Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor. <i>Journal of Neuro-Oncology</i> , 1994, 22, 153-160.	1.4	40
725	Modulation of fibrinolysis by ionizing radiation. <i>Journal of Neuro-Oncology</i> , 1994, 22, 161-171.	1.4	12
726	Plasminogen activator and hemorrhage in brain tumors. <i>Journal of Neuro-Oncology</i> , 1994, 22, 183-187.	1.4	15
727	The borderline: Basement membranes and the transition from premalignant to malignant neoplasia. <i>Microscopy Research and Technique</i> , 1994, 28, 216-225.	1.2	29
728	Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma. <i>Journal of Surgical Oncology</i> , 1994, 56, 168-171.	0.8	8
729	Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. <i>Cancer</i> , 1994, 73, 1398-1405.	2.0	64
730	Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes. <i>International Journal of Cancer</i> , 1994, 56, 214-218.	2.3	40
731	Angiostatic activities of medroxyprogesterone acetate and its analogues. <i>International Journal of Cancer</i> , 1994, 56, 393-399.	2.3	60
732	Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. <i>International Journal of Cancer</i> , 1994, 56, 552-559.	2.3	114
733	Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. <i>International Journal of Cancer</i> , 1994, 57, 378-384.	2.3	41
734	Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. <i>International Journal of Cancer</i> , 1994, 57, 553-560.	2.3	56
735	Inhibition of metastasis of lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. <i>International Journal of Cancer</i> , 1994, 57, 727-733.	2.3	91
736	The state of differentiation of HT-29 colon carcinoma cells alters the secretion of cathepsin D and of plasminogen activator. <i>International Journal of Cancer</i> , 1994, 57, 875-882.	2.3	17
737	A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. <i>International Journal of Cancer</i> , 1994, 58, 877-881.	2.3	82
738	Binding and activation of plasminogen on the surface of osteosarcoma cells. <i>Journal of Cellular Physiology</i> , 1994, 159, 1-10.	2.0	20
739	Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator. <i>Journal of Cellular Physiology</i> , 1994, 161, 285-292.	2.0	7
740	Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: Modulation by inflammatory agents. <i>Hepatology</i> , 1994, 20, 186-190.	3.6	34

#	ARTICLE	IF	CITATIONS
741	Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. <i>Annals of Neurology</i> , 1994, 35, 89-97.	2.8	173
742	Engineering Plasminogen Activator Inhibitor 1 Mutants with Increased Functional Stability. <i>Biochemistry</i> , 1994, 33, 3643-3648.	1.2	105
743	Calcium modulates the expression of urokinase plasminogen activator and plasminogen activator inhibitor 2 by human keratinocytes. <i>Experimental Dermatology</i> , 1994, 3, 85-88.	1.4	8
744	Binding of vitronectin and plasminogen to <i>Helicobacter pylori</i> . <i>FEMS Immunology and Medical Microbiology</i> , 1994, 9, 29-34.	2.7	35
745	Physiological consequences of loss of plasminogen activator gene function in mice. <i>Nature</i> , 1994, 368, 419-424.	13.7	1,030
746	Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. <i>British Journal of Cancer</i> , 1994, 69, 398-405.	2.9	145
747	Extracellular matrix accumulation in immune-mediated tubulointerstitial injury. <i>Kidney International</i> , 1994, 45, 1077-1084.	2.6	42
748	LPS induces major changes in the extracellular proteolytic balance in the murine kidney. <i>Kidney International</i> , 1994, 45, 500-508.	2.6	24
749	Tetranectin expression in human colonic neoplasia. <i>Histopathology</i> , 1994, 25, 463-467.	1.6	18
750	Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. <i>Histopathology</i> , 1994, 24, 131-138.	1.6	120
751	Antigen expression associated with lymph node metastasis in gastric adenocarcinomas. <i>Pathology International</i> , 1994, 44, 844-849.	0.6	28
752	A common response element mediates differential effects of phorbol esters and forskolin on type-1 plasminogen activator inhibitor gene expression in human breast carcinoma cells. <i>FEBS Journal</i> , 1994, 220, 63-74.	0.2	40
753	Purification and Characterization of Active and Stable Recombinant Plasminogen-Activator Inhibitor Accumulated at High Levels in <i>Escherichia coli</i> . <i>FEBS Journal</i> , 1994, 224, 125-134.	0.2	65
754	Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA-MB-231. <i>Apmis</i> , 1994, 102, 279-286.	0.9	11
755	Aminated fucoidan promotes the invasion of 3 LL cells through reconstituted basement membrane: its possible mechanism of action. <i>Cancer Letters</i> , 1994, 85, 133-138.	3.2	12
756	Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. <i>European Journal of Cancer</i> , 1994, 30, 1302-1309.	1.3	62
757	Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. <i>Journal of Immunological Methods</i> , 1994, 167, 91-101.	0.6	55
758	Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1994, 57, 175-178.	0.5	15

#	ARTICLE	IF	CITATIONS
759	Tissue plasminogen activator expression in the embryonic nervous system. <i>Developmental Brain Research</i> , 1994, 81, 41-49.	2.1	66
760	Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. <i>Urology</i> , 1994, 43, 782-786.	0.5	129
761	The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. <i>Fibrinolysis</i> , 1994, 8, 189-203.	0.5	192
762	The plasminogen activation system in bovine milk: Differential localization of tissue-type plasminogen activator and urokinase in milk fractions is caused by binding to casein and urokinase receptor. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1994, 1222, 45-55.	1.9	54
763	Regulation of plasminogen activation by interleukin-6 in human lung fibroblasts. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1994, 1221, 307-314.	1.9	25
764	Protease and Protease Inhibitor Expression during in Vitro Decidualization of Human Endometrial Stromal Cells. <i>Annals of the New York Academy of Sciences</i> , 1994, 734, 33-42.	1.8	12
765	The Role of Progesteronally Regulated Stromal Cell Tissue Factor and Type-1 Plasminogen Activator Inhibitor (PAI-1) in Endometrial Hemostasis and Menstruation. <i>Annals of the New York Academy of Sciences</i> , 1994, 734, 57-79.	1.8	80
766	Matrix Metalloproteinase-9 in Tumor Cell Invasion. <i>Annals of the New York Academy of Sciences</i> , 1994, 732, 324-334.	1.8	14
767	?2-Macroglobulin in the Regulation of Pericellular Plasminogen Activation of Human Tumor Cells. <i>Annals of the New York Academy of Sciences</i> , 1994, 737, 409-418.	1.8	3
768	Tissue-type plasminogen activator (tPA) is the main plasminogen activator associated with isolated rat nerve growth cones. <i>Neuroscience Letters</i> , 1994, 180, 123-126.	1.0	26
769	Growth hormone induction of rat granulosa cell tissue-plasminogen activator expression and progesterone synthesis. <i>Molecular and Cellular Endocrinology</i> , 1994, 99, 153-159.	1.6	33
770	Localization of urokinase- and tissue-type plasminogen activator mRNAs in rat testes. <i>Molecular and Cellular Endocrinology</i> , 1994, 105, 55-64.	1.6	24
771	RNA synthesis inhibition stabilises urokinase mRNA in macrophages. <i>FEBS Letters</i> , 1994, 356, 311-313.	1.3	20
772	Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. <i>FEBS Letters</i> , 1994, 338, 69-74.	1.3	36
773	Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). <i>FEBS Letters</i> , 1994, 337, 131-134.	1.3	96
774	Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. <i>FEBS Letters</i> , 1994, 338, 239-245.	1.3	136
775	Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. <i>FEBS Letters</i> , 1994, 343, 103-106.	1.3	60
776	Plasminogen activators in bovine milk during mastitis, an inflammatory disease. <i>Fibrinolysis</i> , 1994, 8, 22-30.	0.5	48

#	ARTICLE	IF	CITATIONS
777	Transgenic mice carrying a human t-pa promoter $\hat{\epsilon}$ lacZ reporter gene: A model for the study of pharmacological modulation of fibrinolytic potential. <i>Fibrinolysis</i> , 1994, 8, 16-18.	0.5	11
778	Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis. <i>Fibrinolysis</i> , 1994, 8, 221-236.	0.5	77
779	Inhibition of plasminogen activation by polymerized ampicillin. <i>Thrombosis Research</i> , 1994, 75, 643-651.	0.8	1
780	The concomitant augmentation of urokinase-type plasminogen activator and collagenase-like proteinase activities in X-ray irradiated cells of a human metastatic carcinomatous line. <i>Thrombosis Research</i> , 1994, 74, 565-576.	0.8	3
781	Fibrinolytic changes in malignant ascites. <i>Fibrinolysis</i> , 1994, 8, 156-161.	0.5	1
782	Activation of pro-urokinase by cathepsin G in the presence of glucosaminoglycans. <i>Fibrinolysis</i> , 1994, 8, 192-199.	0.5	13
783	Stability of tetranectin concentration in blood samples. <i>Fibrinolysis</i> , 1994, 8, 101-103.	0.5	8
784	Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: Possible markers of placental function. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 171, 60-64.	0.7	33
786	Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1994, 1201, 223-228.	1.1	23
787	Production of Various Forms of Plasminogen Activator and Plasminogen Activator Inhibitor by Cultured Mammary Epithelial Cells. <i>Journal of Dairy Science</i> , 1994, 77, 2949-2958.	1.4	19
788	Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema?. <i>Clinical Neurology and Neurosurgery</i> , 1994, 96, 305-309.	0.6	4
789	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 170, 1285-1296.	0.7	32
790	Cytokine modulation of plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down-regulation by tumor necrosis factor $\hat{\pm}$ and up-regulation by transforming growth factor- $\hat{1}^2$ and basic fibroblast growth factor. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1994, 1226, 277-285.	1.8	27
791	Effects of sulfur mustard on selected biochemical parameters of murine peritoneal macrophages in culture. <i>Toxicology in Vitro</i> , 1994, 8, 125-130.	1.1	3
792	Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. <i>Gastroenterology</i> , 1994, 107, 1449-1456.	0.6	69
793	Conformational Studies of Human Plasminogen and Plasminogen Fragments: Evidence for a Novel Third Conformation of Plasminogen. <i>Biochemistry</i> , 1994, 33, 3599-3606.	1.2	104
794	Unfolding Studies of the Protease Domain of Urokinase-Type Plasminogen Activator: The Existence of Partly Folded States and Stable Subdomains. <i>Biochemistry</i> , 1994, 33, 2951-2960.	1.2	19
795	Elevated Levels of Plasminogen Activators in the Pathogenesis of Delayed Radiation Damage in Rat Cervical Spinal Cord In Vivo. <i>Radiation Research</i> , 1994, 138, 386.	0.7	8

#	ARTICLE	IF	CITATIONS
796	Immediate X-Ray-Inducible Responses from Mammalian Cells. Radiation Research, 1994, 138, S44.	0.7	24
797	Differential regulation of astrocyte plasminogen activators by insulin-like growth factor-I and epidermal growth factor.. Endocrinology, 1994, 134, 2606-2613.	1.4	29
798	Increased fibronectin-receptor expression in colon carcinoma-derived HT 29 cells decreases tumorigenicity in nude mice. Gastroenterology, 1994, 106, 19-27.	0.6	40
799	The gelatin-binding site of human 72 kDa type IV collagenase (gelatinase A). Biochemical Journal, 1994, 298, 403-407.	1.7	85
800	Regulation of fibrinolysis by non-esterified fatty acids. Biochemical Journal, 1994, 300, 251-255.	1.7	24
801	Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. American Journal of Obstetrics and Gynecology, 1994, 170, 1285-1296.	0.7	31
802	Receptor-Mediated Endocytosis of Plasminogen Activators. Advances in Molecular and Cell Biology, 1994, 8, 87-131.	0.1	1
804	Diversity and Modulation of Plasminogen Activator Activity in Human Transitional Carcinoma Cell Lines. Journal of Urology, 1994, 151, 1691-1696.	0.2	8
805	The Content of Urokinase-Type Plasminogen Activator and Tumor Recurrence in Superficial Bladder Cancer. Journal of Urology, 1994, 151, 16-19.	0.2	41
806	In vitro production of plasminogen activator by human granulosa cells.. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 174-179.	1.8	5
807	Gene regulation of interleukin-1 <sup>β</sup> , interleukin-1 receptor type I, and plasminogen activator inhibitor-1 and -2 in human granulosa-luteal cells**Supported by the Johnson and Johnson Focused Giving Program, New Brunswick, New Jersey.. Fertility and Sterility, 1994, 62, 760-770.	0.5	48
808	The outer surface protein A of the spirochete Borrelia burgdorferi is a plasmin(ogen) receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 12594-12598.	3.3	201
809	Urokinase-type plasminogen activator enhances invasion of human T cells (Jurkat) into a fibrin matrix. Journal of Leukocyte Biology, 1994, 56, 110-116.	1.5	10
810	The plasminogen-activating system in gingival fluid from adults.. European Journal of Oral Sciences, 1994, 102, 334-341.	0.7	3
811	Characterization of interstitial collagenases in jaw cyst wall. European Journal of Oral Sciences, 1995, 103, 141-147.	0.7	42
812	The Activation of Type 1 and Type 2 Plasminogen by Type I and Type II Tissue Plasminogen Activator. Journal of Biological Chemistry, 1995, 270, 3261-3267.	1.6	31
813	Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochemical Journal, 1995, 307, 867-873.	1.7	45
814	Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase. Biochemical Journal, 1995, 309, 977-982.	1.7	13

#	ARTICLE	IF	CITATIONS
815	Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. <i>Biochemical Journal</i> , 1995, 310, 345-352.	1.7	113
816	Plasminogen activators in ectopic and uterine endometrium. <i>Fertility and Sterility</i> , 1995, 63, 45-51.	0.5	36
817	Function of the urokinase receptor (CD87) in neutrophil Chemotaxis. <i>Journal of Leukocyte Biology</i> , 1995, 58, 533-538.	1.5	90
818	Plasminogen Activator Inhibitor-1 in Brain Tumors. <i>Neurosurgery</i> , 1995, 36, 375-381.	0.6	31
819	Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent. <i>British Journal of Cancer</i> , 1995, 72, 1131-1137.	2.9	45
820	Inhibitory Effect of a Conjugate between Human Urokinase and Urinary Trypsin Inhibitor on Tumor Cell Invasion in Vitro. <i>Journal of Biological Chemistry</i> , 1995, 270, 8361-8366.	1.6	82
821	Regulation of Urokinase-Type Plasminogen Activator Gene Transcription by Macrophage Colony-Stimulating Factor. <i>Molecular and Cellular Biology</i> , 1995, 15, 3430-3441.	1.1	125
822	Regulation of Mesothelial Cell Mitogenesis by Antisense Oligonucleotides for the Urokinase Receptor. <i>Antisense Research and Development</i> , 1995, 5, 307-314.	3.3	33
823	Fibrinolytic agents. <i>Fibrinolysis</i> , 1995, 9, 9-15.	0.5	11
824	Purification of human plasminogen activator inhibitor (PAI-1) from <i>Escherichia coli</i> and separation of its active and latent forms by hydrophobic interaction chromatography. <i>Fibrinolysis</i> , 1995, 9, 215-221.	0.5	54
825	Reduction of PAI-2 production in cultured human peripheral blood monocytes by estradiol and progesterone-no effect on t-PA, u-PA and PAI-1. <i>Fibrinolysis</i> , 1995, 9, 152-156.	0.5	7
826	The induction of the plasminogen activator system during phorbol ester (PMA)-induced differentiation in HL-60 leukemic cells. <i>Fibrinolysis</i> , 1995, 9, 71-78.	0.5	4
827	Avian urokinase-type plasminogen activator (u-PA) lacks the putative binding site for plasminogen activator inhibitor (PAI) and is resistant to inhibition by human PAI-1 and PAI-2. <i>Fibrinolysis</i> , 1995, 9, 93-99.	0.5	7
828	One-phase reverse zymography after denaturing gel electrophoresis: High sensitivity detection of activity of plasminogen activator inhibitor 2 and other protease inhibitors. <i>Fibrinolysis</i> , 1995, 9, 331-342.	0.5	9
829	Comparison of the inhibition of urokinase-type plasminogen activator (u-PA) activity by monoclonal antibodies specific for u-PA as assessed by different assays. <i>Fibrinolysis</i> , 1995, 9, 343-349.	0.5	6
830	The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. <i>Structure</i> , 1995, 3, 681-691.	1.6	155
831	Neutrophil proteinases and matrix degradation. The cellbiology of pericellular proteolysis. <i>Seminars in Cell Biology</i> , 1995, 6, 367-376.	3.5	71
832	2 Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 291-312.	1.1	65

#	ARTICLE	IF	CITATIONS
833	6 The urokinase/urokinase-receptor system and cancer invasion. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 365-389.	1.1	62
834	Effects of Serum to Cushion Mesenchymal Cell Migration of the Developing Chick Heart in Vitro. <i>Congenital Anomalies (discontinued)</i> , 1995, 35, 207-213.	0.3	2
835	Plasminogen activators in tissue extract of aural cholesteatoma. <i>Laryngoscope</i> , 1995, 105, 305-310.	1.1	7
836	Comparative Studies of Ovarian Steroids in Blood, and Specific Proteolytic Enzymes in the Cervical Mucus, in Four Sheep Breeds after Oestrus Synchronization (Progesterone and PMSG). 2. Breed Variation of PAA, PAI and PI in the Cervical Mucus during Natural Oestrus, Synchronized Oestrus, and the First Oestrus after Synchronized Oestrus. <i>Reproduction in Domestic Animals</i> , 1995, 30, 14-20.	0.6	2
837	The Major N-Linked Carbohydrate Chains from Human Urokinase. The Occurrence of 4-O-sulfated, (alpha2-6)-sialylated or (alpha1-3)-fucosylated N-acetylgalactosamine(beta1-4)-N-acetylglucosamine Elements. <i>FEBS Journal</i> , 1995, 228, 1009-1019.	0.2	5
838	Urokinase-Type Plasminogen Activator/Type-2 Plasminogen-Activator Inhibitor Complexes are not Internalized Upon Binding to the Urokinase-Type-Plasminogen-Activator Receptor in THP-1 Cells. Interaction of Urokinase-Type Plasminogen Activator/Type-2 Plasminogen-Activator Inhibitor Complexes with the Cell Surface. <i>FEBS Journal</i> , 1995, 233, 514-519.	0.2	9
839	Distribution of vitronectin mRNA during murine development. <i>Developmental Dynamics</i> , 1995, 203, 71-79.	0.8	59
840	Cysteine and serine proteases in gastric cancer. <i>Cancer</i> , 1995, 76, 367-375.	2.0	53
841	Effects of stimulators of protein kinases A and C and modulators of phosphorylation on plasminogen activator activity in porcine oocyte-cumulus cell complexes during in vitro maturation. <i>Molecular Reproduction and Development</i> , 1995, 40, 364-370.	1.0	27
842	Expression of urokinase receptor in various stromal-cell populations in human colon cancer: Immunoelectron microscopical analysis. <i>International Journal of Cancer</i> , 1995, 62, 691-696.	2.3	36
843	Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: Lack of association with in vitro invasion. <i>International Journal of Cancer</i> , 1995, 63, 92-99.	2.3	13
844	Inhibition of metastasis of lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. <i>International Journal of Cancer</i> , 1995, 63, 455-462.	2.3	47
845	Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. <i>International Journal of Cancer</i> , 1995, 63, 863-865.	2.3	55
846	Increased expression of a high molecular weight (130 KD) protein kinase C isoform in a differentiation-defective ras-transfected keratinocyte line. <i>Journal of Cellular Physiology</i> , 1995, 164, 509-521.	2.0	6
847	Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts. <i>Journal of Cellular Physiology</i> , 1995, 165, 521-529.	2.0	25
848	Current triton X-100 treatments do not allow a complete plasminogen activator extraction from developing nervous tissue. <i>Neurochemical Research</i> , 1995, 20, 137-142.	1.6	9
849	Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. <i>Breast Cancer Research and Treatment</i> , 1995, 33, 199-207.	1.1	78
850	The urokinase plasminogen activator (u-PA) and its inhibitor (PAI-1) in embryo-fetal bone formation in the human: an immunohistochemical study. <i>Anatomy and Embryology</i> , 1995, 192, 363-368.	1.5	14



#	ARTICLE	IF	CITATIONS
851	Expression of 72 kDa and 92 kDa type IV collagenases from human giant-cell tumor of bone. <i>Clinical and Experimental Metastasis</i> , 1995, 13, 420-426.	1.7	25
852	Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines. <i>Clinical and Experimental Metastasis</i> , 1995, 13, 439-452.	1.7	2
853	Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas. <i>Clinical and Experimental Metastasis</i> , 1995, 13, 492-498.	1.7	3
854	Urokinase plasminogen activator expression by primary and HPV 16-transformed keratinocytes. <i>Clinical and Experimental Metastasis</i> , 1995, 13, 260-268.	1.7	12
855	Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. <i>Clinical and Experimental Metastasis</i> , 1995, 13, 296-302.	1.7	82
856	Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6. <i>Clinical and Experimental Metastasis</i> , 1995, 13, 116-122.	1.7	11
857	Overexpression and localization of cathepsin B during the progression of human gliomas. <i>Clinical and Experimental Metastasis</i> , 1995, 13, 49-56.	1.7	108
858	Synaptic transmission blockade increases plasminogen activator activity in mouse skeletal muscle poisoned with botulinum toxin type A. <i>Synapse</i> , 1995, 20, 24-32.	0.6	15
859	Components of the plasminogen activation system in uveal melanoma—a clinico-pathological study. <i>Journal of Pathology</i> , 1995, 175, 59-67.	2.1	35
860	Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft. <i>Prostate</i> , 1995, 26, 94-104.	1.2	27
861	Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. <i>Prostate</i> , 1995, 27, 179-186.	1.2	30
862	Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. <i>Prostate</i> , 1995, 27, 269-276.	1.2	18
863	Localization of Urokinase-type Plasminogen Activator, Plasminogen Activator Inhibitor-1, 2 and Plasminogen in Colon Cancer. <i>Japanese Journal of Cancer Research</i> , 1995, 86, 48-56.	1.7	22
864	Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: Evidence for cytokine dependence and detection of a novel sulfatase. <i>Immunology and Cell Biology</i> , 1995, 73, 113-124.	1.0	69
865	Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis. <i>Kidney International</i> , 1995, 48, 1459-1468.	2.6	55
866	Urokinase and macrophages in tumour angiogenesis. <i>British Journal of Cancer</i> , 1995, 72, 818-823.	2.9	114
867	In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. <i>British Journal of Cancer</i> , 1995, 71, 271-277.	2.9	50
868	Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. <i>British Journal of Cancer</i> , 1995, 71, 393-396.	2.9	20

#	ARTICLE	IF	CITATIONS
869	Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. <i>Nature Structural Biology</i> , 1995, 2, 891-897.	9.7	104
870	Proteolytic enzymes in salivary extravasation mucoceles. <i>Journal of Oral Pathology and Medicine</i> , 1995, 24, 299-302.	1.4	15
871	Keratinocyte Growth Factor Stimulation of Gelatinase (Matrix Metalloproteinase-9) and Plasminogen Activator in Histiotypic Epithelial Cell Culture. <i>Journal of Investigative Dermatology</i> , 1995, 104, 989-994.	0.3	37
872	FIBRINOLYTIC ACTIVITY IN LIVER TISSUES OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1995, 22, S275-S276.	0.9	3
873	Characterization of a plasminogen activator produced by <i>Acanthamoeba castellanii</i> . <i>Molecular and Biochemical Parasitology</i> , 1995, 73, 157-164.	0.5	61
874	Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in paediatric tumour cells. Effects of tumour cell proliferation modulators on gelatinolytic activity. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995, 121, 275-278.	1.2	17
875	Interleukin-1 $\beta$ inhibits luteinizing hormone-induced plasminogen activator activity in rat preovulatory follicles in vitro. <i>Endocrine</i> , 1995, 3, 49-54.	2.2	22
876	Urokinase receptor mediates mechanical force transfer across the cell surface. <i>American Journal of Physiology - Cell Physiology</i> , 1995, 268, C1062-C1066.	2.1	62
877	The Urokinase Receptor. Protein Structure and Role in Plasminogen Activation and Cancer Invasion. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 1995, 6, 212-236.	0.1	135
878	Mechanism by Which U937 Promonocytic Cells Inactivate Human Interferon- $\beta$ . <i>Journal of Interferon and Cytokine Research</i> , 1995, 15, 557-565.	0.5	4
879	Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. <i>Current Eye Research</i> , 1995, 14, 449-458.	0.7	35
880	Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. <i>Nucleic Acids Research</i> , 1995, 23, 3710-3717.	6.5	137
881	Differential Cytokine Regulation of PAI-1 Gene Expression Between Human Umbilical and Subcutaneous Fat-Derived Microvascular Endothelial Cells. <i>Endothelium: Journal of Endothelial Cell Research</i> , 1995, 3, 243-252.	1.7	1
882	Differential Regulation of Plasminogen Activation in Normal Keratinocytes and SCC-4 Cells by Fibroblasts. <i>Journal of Investigative Dermatology</i> , 1995, 104, 374-378.	0.3	10
883	A Novel Plasminogen Activator from Snake Venom. <i>Journal of Biological Chemistry</i> , 1995, 270, 10246-10255.	1.6	155
884	Hormonal Regulation of Urokinase- and Tissue-Type Plasminogen Activator in Rat Sertoli Cells. <i>Biology of Reproduction</i> , 1995, 53, 193-200.	1.2	24
885	Studies on the Role of Plasminogen Activators and Plasminogen Activator Inhibitor Type-1 in Rat Corpus Luteum of Pregnancy. <i>Biology of Reproduction</i> , 1995, 53, 1131-1138.	1.2	19
886	A Plasma Membrane-associated Component of Ovarian Adenocarcinoma Cells Enhances the Catalytic Efficiency of Matrix Metalloproteinase-2. <i>Journal of Biological Chemistry</i> , 1995, 270, 999-1002.	1.6	35

#	ARTICLE	IF	CITATIONS
887	Role of LFB3 in Cell-specific cAMP Induction of the Urokinase-type Plasminogen Activator Gene. <i>Journal of Biological Chemistry</i> , 1995, 270, 21833-21838.	1.6	16
888	Review. <i>Biological Chemistry Hoppe-Seyler</i> , 1995, 376, 131-156.	1.4	13
889	Isolation of a High Affinity Inhibitor of Urokinase-type Plasminogen Activator by Phage Display of Ecotin. <i>Journal of Biological Chemistry</i> , 1995, 270, 12250-12256.	1.6	67
890	Review. <i>Biological Chemistry Hoppe-Seyler</i> , 1995, 376, 259-280.	1.4	26
891	Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.. <i>Genes and Development</i> , 1995, 9, 794-807.	2.7	404
892	Plasminogen Activator Inhibitor Type 2 Inhibits Tumor Necrosis Factor $\alpha$ -induced Apoptosis. <i>Journal of Biological Chemistry</i> , 1995, 270, 27894-27904.	1.6	195
893	The Receptor for Urokinase-type Plasminogen Activator Is Not Essential for Mouse Development or Fertility. <i>Journal of Biological Chemistry</i> , 1995, 270, 16886-16894.	1.6	200
894	Very Low Density Lipoprotein Receptor Binds and Mediates Endocytosis of Urokinase-type Plasminogen Activator-Type-1 Plasminogen Activator Inhibitor Complex. <i>Journal of Biological Chemistry</i> , 1995, 270, 20855-20861.	1.6	105
895	Plasma tetranectin and colorectal cancer. <i>European Journal of Cancer</i> , 1995, 31, 888-894.	1.3	21
896	Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. <i>European Journal of Cancer</i> , 1995, 31, 1105-1109.	1.3	44
897	Metastatic tumours to the oral region. An overview. <i>European Journal of Cancer Part B, Oral Oncology</i> , 1995, 31, 355-360.	0.9	201
898	Effect of cyclic AMP on urokinase-type plasminogen activator receptor and fibrinolytic factors in a human osteoblast-like cell line. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1995, 1266, 50-56.	1.9	8
899	Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1995, 1268, 143-151.	1.9	16
900	Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. <i>Human Pathology</i> , 1995, 26, 1133-1138.	1.1	64
901	Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells. <i>Thrombosis Research</i> , 1995, 79, 353-361.	0.8	6
902	The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and without ketorolac infusion. <i>Thrombosis Research</i> , 1995, 79, 501-514.	0.8	17
903	Retinoic acid enhances plasminogen activation on the cell surface. <i>Thrombosis Research</i> , 1995, 80, 47-56.	0.8	6
904	Evidence that conformational changes upon the transition of the native to the modified form of vitronectin are not limited to the heparin binding domain. <i>FEBS Letters</i> , 1995, 368, 155-159.	1.3	27

#	ARTICLE	IF	CITATIONS
905	Ovarian carcinoma serum markers and ovarian steroid activity " is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotropin levels. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1995, 59, 53-56.	0.5	14
906	Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (CD87): A New Target in Tumor Invasion and Metastasis. <i>Journal of Obstetrics and Gynaecology (Tokyo, Japan)</i> , 1995, 21, 151-165.	0.1	51
907	Tissue Plasminogen Activator Induction in Purkinje Neurons After Cerebellar Motor Learning. <i>Science</i> , 1995, 270, 1992-1994.	6.0	307
908	Complex intracellular signal transduction regulates tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1) synthesis in cultured human umbilical vein endothelium. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1995, 55, 323-330.	0.6	35
909	The damaging effect of UV rays below 320 nm on the rabbit anterior eye segment. II. Enzyme histochemical changes and plasmin activity after prolonged irradiation. <i>Acta Histochemica</i> , 1995, 97, 183-188.	0.9	25
910	Urokinase plasminogen activator activity is increased in the myocardium during coronary artery occlusion. <i>Journal of Molecular and Cellular Cardiology</i> , 1995, 27, 1317-1324.	0.9	26
911	Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen. <i>Microbial Pathogenesis</i> , 1995, 18, 153-166.	1.3	52
912	Cell Surface-Bound Urokinase-Type Plasminogen Activator Facilitates Infiltration of Freshly Isolated Granulocytes into a Fibrin Matrix. <i>Immunobiology</i> , 1995, 194, 363-375.	0.8	8
913	Urokinase Plasminogen Activator Induces Angiogenesis and Tumor Vessel Invasion in Breast Cancer. <i>Pathology Research and Practice</i> , 1995, 191, 403-409.	1.0	37
914	Differential regulation of urokinase-type-1 inhibitor complex endocytosis by phorbol esters in different cell lines is associated with differential regulation of $\alpha$ 2-macroglobulin receptor and urokinase receptor expression. <i>Molecular and Cellular Endocrinology</i> , 1995, 109, 209-217.	1.6	18
915	Regulation of the secretion of urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in T98C human glioblastoma cells by cytokines and dexamethasone. <i>Fibrinolysis</i> , 1996, 10, 303-307.	0.5	0
916	Prognostic Value of Urokinase Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Renal Cell Cancer. <i>Journal of Urology</i> , 1996, 155, 858-862.	0.2	37
917	Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. <i>Urology</i> , 1996, 47, 34-37.	0.5	47
918	Plasminogen Activators in Abdominal Aortic Aneurysmal Disease. <i>Annals of the New York Academy of Sciences</i> , 1996, 800, 151-156.	1.8	23
919	Unesterified Long Chain Fatty Acids Inhibit the Binding of Single Chain Urokinase to the Urokinase Receptor. <i>Biochemistry</i> , 1996, 35, 6884-6890.	1.2	10
920	FIBRINOLYTIC SYSTEM IN PLASMA AND PLEURAL FLUID IN MALIGNANT PLEURAL MESOTHELIOMA. <i>Thrombosis Research</i> , 1996, 84, 121-128.	0.8	11
921	Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. <i>European Journal of Cancer</i> , 1996, 32, 793-801.	1.3	56
922	In Vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells. <i>European Journal of Cancer</i> , 1996, 32, 702-707.	1.3	21

#	ARTICLE	IF	CITATIONS
923	Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop. <i>European Journal of Cancer</i> , 1996, 32, 1371-1381.	1.3	71
924	Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase. <i>International Journal of Biochemistry and Cell Biology</i> , 1996, 28, 1141-1150.	1.2	31
925	Localization of urokinase-type plasminogen activator mRNA in the adult mouse brain. <i>Molecular Brain Research</i> , 1996, 35, 139-148.	2.5	51
926	Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER. <i>Cancer Letters</i> , 1996, 99, 209-215.	3.2	22
927	Stabilization of plasmin by lysine derivatives. <i>Clinica Chimica Acta</i> , 1996, 245, 7-18.	0.5	267
928	High plasma level of plasmin- $\alpha$ 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. <i>Clinica Chimica Acta</i> , 1996, 244, 69-81.	0.5	21
929	Expression of urokinase-type plasminogen activator, its receptor and type-1 plasminogen activator inhibitor is differently regulated by inhibitors of protein synthesis in human cancer cell lines. <i>FEBS Letters</i> , 1996, 383, 139-144.	1.3	12
930	Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization. <i>FEBS Letters</i> , 1996, 385, 72-76.	1.3	27
931	Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system. <i>FEBS Letters</i> , 1996, 393, 31-36.	1.3	17
932	Human glioma U-251 cells contain type 1 plasminogen activator inhibitor in a rapidly releasable form. <i>FEBS Letters</i> , 1996, 393, 216-220.	1.3	4
933	Post-transcriptional Regulation of Extracellular Matrix Metalloproteinase in Human Heart End-stage Failure Secondary to Ischemic Cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 1996, 28, 1415-1428.	0.9	133
934	REGULATION OF SINGLE CHAIN UROKINASE BY SMALL PEPTIDES. <i>Thrombosis Research</i> , 1996, 84, 243-252.	0.8	14
935	Loss of Fibrinogen Rescues Mice from the Pleiotropic Effects of Plasminogen Deficiency. <i>Cell</i> , 1996, 87, 709-719.	13.5	413
936	The effects of reformulated 2-rod Norplant <sup>®</sup> implant on hemostasis after three years. <i>Contraception</i> , 1996, 54, 219-228.	0.8	9
937	Prognostic parameters in uveal melanoma: a review. <i>Survey of Ophthalmology</i> , 1996, 41, 215-228.	1.7	188
938	Vascular endothelial cell monolayer formed on membrane filter potentiates the defense against tumor cell invasion by treatment with brefeldin A. <i>Cancer Letters</i> , 1996, 108, 49-54.	3.2	2
939	The Plasminogen Activation System in Tumour Invasion and Metastasis. <i>Pathology Research and Practice</i> , 1996, 192, 718-733.	1.0	38
940	Injury-Specific Cytotoxic Response of Tumor Cells and Endothelial Cells. <i>Pathology Research and Practice</i> , 1996, 192, 1-9.	1.0	12

#	ARTICLE	IF	CITATIONS
941	Plasminogen Activator System: Implications for Mammary Cell Growth and Involution. <i>Journal of Dairy Science</i> , 1996, 79, 1097-1107.	1.4	88
943	Plasminogen Activators and Plasminogen Activator Inhibitor in Portal Blood from Patients with and without Gastric Malignancy. <i>Scandinavian Journal of Gastroenterology</i> , 1996, 31, 170-174.	0.6	1
944	Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin. <i>Biochemistry and Cell Biology</i> , 1996, 74, 899-910.	0.9	14
945	Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells. <i>Current Eye Research</i> , 1996, 15, 755-763.	0.7	7
946	Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. <i>Blood</i> , 1996, 87, 3545-3549.	0.6	61
947	Regulation of the plasminogen activator inhibitor type-2 gene in monocytes: localization of an upstream transcriptional silencer. <i>Blood</i> , 1996, 88, 3686-3697.	0.6	31
948	Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins. <i>Blood</i> , 1996, 88, 542-551.	0.6	49
949	Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 5899-5904.	3.3	262
950	From legumes to leukocytes: biological roles for sulfated carbohydrates. <i>FASEB Journal</i> , 1996, 10, 1137-1146.	0.2	92
951	Identification of Plasminogen in Matrigel™ and Its Activation by Reconstitution of This Basement Membrane Extract. <i>BioTechniques</i> , 1996, 21, 904-909.	0.8	33
952	Interaction of Tissue Plasminogen Activator Inhibitor with Cell Surface Guanidinobenzoatase and Urokinase Plasminogen Activator. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1996, 10, 281-288.	0.5	2
953	Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. <i>British Journal of Cancer</i> , 1996, 74, 1168-1174.	2.9	18
954	Transforming Growth Factor- $\beta$ System and Its Regulation by Members of the Steroid-Thyroid Hormone Superfamily. <i>Advances in Cancer Research</i> , 1996, 70, 63-94.	1.9	29
955	Complex regulation of plasminogen activator inhibitor type-1 (PAI-1) gene expression by serum and substrate adhesion. <i>Biochemical Journal</i> , 1996, 314, 1041-1046.	1.7	48
956	Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions. <i>Biochemical Journal</i> , 1996, 313, 775-780.	1.7	29
957	Use of Tetranectin, CA-125 and Casa to Predict Residual Tumor and Survival at Second- and Third-Look Operations for Ovarian Cancer. <i>Acta Oncologica</i> , 1996, 35, 63-69.	0.8	16
958	Altered expression of plasminogen activator and plasminogen activator inhibitor during cellular senescence. <i>Experimental Gerontology</i> , 1996, 31, 175-193.	1.2	87
959	Gastric mucosal plasminogen activators in <i>Helicobacter pylori</i> infection. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1577-1582.	1.1	13

#	ARTICLE	IF	CITATIONS
960	A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 151-159.	1.1	51
961	Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 209-223.	1.1	58
962	Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 257-263.	1.1	15
963	The outer surface protein A (OspA) of <i>Borrelia burgdorferi</i> : A vaccine candidate and bioactive mediator. <i>Infection</i> , 1996, 24, 190-194.	2.3	23
964	Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. <i>Histochemistry and Cell Biology</i> , 1996, 105, 53-60.	0.8	53
965	Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. <i>Inflammation</i> , 1996, 20, 319-326.	1.7	39
966	Cytokines may influence tumor growth and spread. <i>International Journal of Clinical and Laboratory Research</i> , 1996, 26, 240-244.	1.0	5
967	Role of C-Jun and Proximal Phorbol 12-Myristate-13-Acetate-(PMA)-Responsive Elements in the Regulation of Basal and PMA-Stimulated Plasminogen-Activator Inhibitor-1 Gene Expression in HepG2. <i>FEBS Journal</i> , 1996, 241, 393-402.	0.2	37
968	Systematic Mutational Analysis of the Receptor-Binding Region of the Human Urokinase-Type Plasminogen Activator. <i>FEBS Journal</i> , 1996, 237, 743-751.	0.2	64
969	Plasminogen activators in human corneal fibroblasts: secretion, cellular localization, and regulation. <i>Fibrinolysis</i> , 1996, 10, 255-262.	0.5	6
970	Role of urokinase plasminogen activator in human breast cancer: Active involvement of stromal fibroblasts. <i>Fibrinolysis</i> , 1996, 10, 79-83.	0.5	4
971	The effect of treatment of <i>Helicobacter pylori</i> infection on gastric mucosal plasminogen activators. <i>Fibrinolysis</i> , 1996, 10, 85-89.	0.5	5
972	Localization of the components of the plasminogen activation system in cutaneous melanocytic lesions – a minireview. <i>Fibrinolysis</i> , 1996, 10, 91-94.	0.5	3
973	Decreased serum tetranectin in multiple myeloma – relation to disease stage. <i>Fibrinolysis</i> , 1996, 10, 105-107.	0.5	1
974	Quality control in quantitation of components of the plasminogen activator system in tumour extracts. <i>Fibrinolysis</i> , 1996, 10, 149-151.	0.5	3
975	Extracellular proteolysis and the migrating vascular smooth muscle cell. <i>Fibrinolysis</i> , 1996, 10, 59-74.	0.5	33
977	Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. , 1996, 62, 288-297.		47
978	EXPRESSION OF PLASMINOGEN ACTIVATORS IN BASAL CELL CARCINOMA. <i>Journal of Pathology</i> , 1996, 178, 290-296.	2.1	15

#	ARTICLE	IF	CITATIONS
979	TETRANECTIN AND PLASMIN/PLASMINOGEN ARE SIMILARLY DISTRIBUTED AT THE INVASIVE FRONT OF CUTANEOUS MELANOMA LESIONS. , 1996, 179, 260-265.		49
980	Prognostic value of the plasminogen activation system in patients with gastric carcinoma. <i>Cancer</i> , 1996, 77, 1035-1043.	2.0	53
981	Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues. , 1996, 77, 1079-1088.		104
982	Urokinase-type plasminogen activator regulates cranial neural crest cell migration in vitro. , 1996, 207, 281-290.		16
983	Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines. , 1996, 65, 178-185.		1
984	Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and I±2-macroglobulin receptor in human breast carcinomas. , 1996, 66, 441-452.		86
985	Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. , 1996, 69, 268-272.		51
986	Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. , 1996, 69, 475-479.		53
987	Protein kinase C mediates up-regulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro. , 1996, 167, 500-511.		38
988	Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. <i>Clinical and Experimental Metastasis</i> , 1996, 14, 27-34.	1.7	66
989	Different effects of lipopolysaccharide on plasminogen activator inhibitor-1 production in aortic media in vivo and in culture. <i>Journal of Thrombosis and Thrombolysis</i> , 1996, 3, 215-223.	1.0	1
990	Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1996, 427, 487-96.	1.4	41
991	Aggravation of gingival inflammatory symptoms during pregnancy associated with the concentration of plasminogen activator inhibitor type 2 (PAI-2) in gingival fluid. <i>Journal of Periodontal Research</i> , 1996, 31, 271-277.	1.4	45
992	Inverse Correlation between mRNA Expression of Plasminogen Activator Inhibitor-2 and Lymph Node Metastasis in Human Breast Cancer. <i>Japanese Journal of Cancer Research</i> , 1996, 87, 480-487.	1.7	24
993	Effects of Sex Steroids and Growth Factors on Migration and Invasion of Endometrial Adenocarcinoma SNG-M Cells in vitro. <i>Japanese Journal of Cancer Research</i> , 1996, 87, 524-533.	1.7	27
994	CUTANEOUS NECROTIZING VASCULITIS. <i>International Journal of Dermatology</i> , 1996, 35, 457-474.	0.5	39
995	Plasminogen activator system in pemphigus vulgaris. <i>British Journal of Dermatology</i> , 1996, 135, 726-732.	1.4	23
996	Impaired wound healing in mice with a disrupted plasminogen gene. <i>Nature Medicine</i> , 1996, 2, 287-292.	15.2	553



#	ARTICLE	IF	CITATIONS
997	Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. <i>Kidney International</i> , 1996, 50, 2011-2019.	2.6	64
998	Elevated Levels of Plasminogen Activator Inhibitor-1 May Account for the Altered Fibrinolysis by Keloid Fibroblasts. <i>Journal of Investigative Dermatology</i> , 1996, 106, 1007-1011.	0.3	80
999	Differential Expression of Urokinase-Type Plasminogen Activator, Its Receptor, and Inhibitors in Mouse Skin After Exposure to a Tumor-Promoting Phorbol Ester. <i>Journal of Investigative Dermatology</i> , 1996, 106, 622-630.	0.3	15
1000	SIGNIFICANCE OF SERINE PROTEINASE AND MATRIX METALLOPROTEINASE SYSTEMS IN THE DESTRUCTION OF HUMAN ARTICULAR CARTILAGE. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 885-889.	0.9	18
1001	Plasminogen Activation on Tumor Cell Surface and its Involvement in Human Leukemia. <i>Advances in Cancer Research</i> , 1996, 69, 101-133.	1.9	18
1002	Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. <i>Carcinogenesis</i> , 1996, 17, 2581-2587.	1.3	37
1003	Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 230-236.	0.5	51
1004	Presence of Urokinase Plasminogen Activator and Plasminogen Activator Inhibitor-1 Messenger Ribonucleic Acids in Rat Endometrium during Decidualization in Vivo1. <i>Biology of Reproduction</i> , 1996, 55, 493-497.	1.2	23
1005	Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation. <i>Journal of Biological Chemistry</i> , 1996, 271, 17124-17131.	1.6	644
1006	Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. <i>Journal of Cell Biology</i> , 1996, 134, 1563-1571.	2.3	433
1007	Interaction of <i>Haemophilus influenzae</i> with the Mammalian Extracellular Matrix. <i>Journal of Infectious Diseases</i> , 1996, 173, 1137-1147.	1.9	62
1008	Human Colon Carcinoma Cells Synthesize and Secrete $\pm 1$ -Proteinase Inhibitor. <i>Biological Chemistry Hoppe-Seyler</i> , 1996, 377, 301-312.	1.4	23
1009	Epigenetic Modification of Transgenes under the Control of the Mouse Mammary Tumor Virus LTR: Tissue-Dependent Influence on Transcription of the Transgenes. <i>Biological Chemistry Hoppe-Seyler</i> , 1996, 377, 711-720.	1.4	6
1010	Structural and Functional Analysis of the Plasminogen Activator Inhibitor-1 Binding Motif in the Somatomedin B Domain of Vitronectin. <i>Journal of Biological Chemistry</i> , 1996, 271, 12716-12723.	1.6	91
1011	Domain Interplay in the Urokinase Receptor. <i>Journal of Biological Chemistry</i> , 1996, 271, 22885-22894.	1.6	92
1012	Molecular aspects of implantation. <i>Molecular Human Reproduction</i> , 1996, 2, 405-424.	1.3	81
1013	Premplantation embryology. <i>Molecular Human Reproduction</i> , 1996, 2, 273-276.	1.3	36
1014	Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.. <i>Journal of Clinical Pathology</i> , 1996, 49, 577-580.	1.0	47

#	ARTICLE	IF	CITATIONS
1015	Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs.. American Journal of Respiratory Cell and Molecular Biology, 1996, 15, 78-87.	1.4	60
1016	Localization of plasminogen activator and inhibitor, LH and androgen receptors and inhibin subunits in monkey epididymis. Molecular Human Reproduction, 1997, 3, 945-952.	1.3	39
1017	Expression of Urokinase-Type Plasminogen Activator and Its Receptor during Ovarian Follicular Development<sup>1</sup>. Endocrinology, 1997, 138, 2790-2799.	1.4	21
1018	Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease.. Journal of Clinical Pathology, 1997, 50, 157-160.	1.0	39
1019	Growth factors and cytokines in tumor invasion and metastasis. Growth Factors and Cytokines in Health and Disease, 1997, , 381-437.	0.2	1
1020	Role of Insulin-Like Growth Factor Binding Protein-2 and Its Limited Proteolysis in Neuroblastoma Cell Proliferation: Modulation by Transforming Growth Factor- $\beta$ and Retinoic Acid*. Endocrinology, 1997, 138, 683-690.	1.4	45
1021	Characterization of the Growth Center of the Avian Preovulatory Follicle1. Biology of Reproduction, 1997, 56, 469-474.	1.2	23
1022	Tissue-specific Expression of the Relaxed Conformation of Plasminogen Activator Inhibitor-2 and Low-density Lipoprotein Receptor-related Protein in Human Term Gestational Tissues. Journal of Histochemistry and Cytochemistry, 1997, 45, 1593-1602.	1.3	17
1023	Molecular and Functional Characterization of the Urokinase Receptor on Human Mast Cells. Journal of Biological Chemistry, 1997, 272, 7824-7832.	1.6	61
1024	Urokinase in rheumatoid arthritis: causal or coincidental?. Annals of the Rheumatic Diseases, 1997, 56, 705-706.	0.5	6
1025	Reduction in Surface Urokinase Receptor Forces Malignant Cells into a Protracted State of Dormancy. Journal of Cell Biology, 1997, 137, 767-777.	2.3	154
1026	Transgenic Mice Overexpressing Urokinase-Type Plasminogen Activator in the Brain Exhibit Reduced Food Consumption, Body Weight and Size, and Increased Longevity. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1997, 52A, B118-B124.	1.7	108
1027	Tamoxifen-Induced Changes in the Plasma Fibrinolytic Factors in Menopausal Women with Breast Cancer. Clinical and Applied Thrombosis/Hemostasis, 1997, 3, 234-238.	0.7	2
1028	Characterization of the Binding of Different Conformational Forms of Plasminogen Activator Inhibitor-1 to Vitronectin. Journal of Biological Chemistry, 1997, 272, 7676-7680.	1.6	105
1029	Phosphorylation of Human Pro-Urokinase on Ser138/303 Impairs Its Receptor-dependent Ability to Promote Myelomonocytic Adherence and Motility. Journal of Cell Biology, 1997, 137, 779-791.	2.3	52
1030	Embryonic Fibroblasts That Are Genetically Deficient in Low Density Lipoprotein Receptor-related Protein Demonstrate Increased Activity of the Urokinase Receptor System and Accelerated Migration on Vitronectin. Journal of Biological Chemistry, 1997, 272, 14372-14379.	1.6	86
1031	Arterial expression of the plasminogen activator system early after cardiac transplantation. Cardiovascular Research, 1997, 35, 241-249.	1.8	20
1032	Optimal Subsite Occupancy and Design of a Selective Inhibitor of Urokinase. Journal of Biological Chemistry, 1997, 272, 20456-20462.	1.6	85

#	ARTICLE	IF	CITATIONS
1033	Up-Regulation of Urokinase Plasminogen Activator Messenger Ribonucleic Acid and Protein in Hen Granulosa Cells by Transforming Growth Factor $\beta$ in Vitro during Follicular Development. <i>Biology of Reproduction</i> , 1997, 56, 1317-1322.	1.2	5
1034	Distinguishing the Specificities of Closely Related Proteases. <i>Journal of Biological Chemistry</i> , 1997, 272, 16603-16609.	1.6	50
1035	Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells. <i>Molecular Human Reproduction</i> , 1997, 3, 1019-1027.	1.3	18
1036	Detection of the Receptor for the Human Urokinase-type Plasminogen Activator Using Fluoresceinated uPA. <i>Journal of Histochemistry and Cytochemistry</i> , 1997, 45, 1307-1313.	1.3	4
1037	Expression of Avian Urokinase and Tissue-Type Plasminogen Activator Messenger Ribonucleic Acid during Follicle Development and Atresia. <i>Biology of Reproduction</i> , 1997, 56, 581-588.	1.2	15
1038	Characterization of the Precursor of Prostate-specific Antigen. <i>Journal of Biological Chemistry</i> , 1997, 272, 21582-21588.	1.6	173
1039	Role of fibrin and plasminogen activators in repair-associated angiogenesis: In Vitro studies with human endothelial cells. <i>Exs</i> , 1997, 79, 391-411.	1.4	63
1040	Cytoskeleton Reorganization Induces the Urokinase-type Plasminogen Activator Gene via the Ras/Extracellular Signal-regulated Kinase (ERK) Signaling Pathway. <i>Journal of Biological Chemistry</i> , 1997, 272, 1904-1909.	1.6	71
1041	Co-ordinated expression of MMP-2 and its putative activator, MT1-MMP, in human placentation. <i>Molecular Human Reproduction</i> , 1997, 3, 713-723.	1.3	40
1042	A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols. <i>International Journal of Biological Markers</i> , 1997, 12, 6-14.	0.7	83
1043	Posttranscriptional Regulation of Urokinase Receptor mRNA: Identification of a Novel Urokinase Receptor mRNA Binding Protein in Human Mesothelioma Cells. <i>Molecular and Cellular Biology</i> , 1997, 17, 1075-1083.	1.1	103
1044	Renaturation, Purification, and Characterization of Human Plasminogen Activator Inhibitor Type 2 (PAI-2) Accumulated at High Level in <i>Escherichia coli</i> . <i>Journal of Biochemistry</i> , 1997, 121, 930-934.	0.9	7
1045	p52PAI-1 gene expression in butyrate-induced flat revertants of v-ras-transformed rat kidney cells: mechanism of induction and involvement in the morphological response. <i>Biochemical Journal</i> , 1997, 321, 431-437.	1.7	13
1046	The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies. <i>Biochemical Journal</i> , 1997, 325, 339-349.	1.7	36
1047	Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. <i>British Journal of Cancer</i> , 1997, 75, 1793-1801.	2.9	41
1048	The Biochemistry of Cancer Dissemination. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 1997, 32, 175-252.	2.3	146
1049	Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis. <i>Human Pathology</i> , 1997, 28, 1283-1290.	1.1	9
1050	Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 1997, 33, 867-872.	1.3	79

#	ARTICLE	IF	CITATIONS
1051	Temporal pattern of plasminogen activator activity in the developing chick cerebellum. <i>International Journal of Developmental Neuroscience</i> , 1997, 15, 875-882.	0.7	1
1052	An in vivo <sup>2</sup> In vitro study of the use of a human skin equivalent for irritancy screening of fatty acids. <i>Toxicology in Vitro</i> , 1997, 11, 365-376.	1.1	16
1053	Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma. <i>Human Pathology</i> , 1997, 28, 206-213.	1.1	24
1054	MONOCYTES MODULATE THE FIBRINOLYTIC BALANCE OF ENDOTHELIAL CELLS. <i>Thrombosis Research</i> , 1997, 85, 377-385.	0.8	18
1055	Plasminogen Is Required for Efficient Dissemination of <i>B. burgdorferi</i> in Ticks and for Enhancement of Spirochetemia in Mice. <i>Cell</i> , 1997, 89, 1111-1119.	13.5	339
1056	Glycosylation at Asn-289 facilitates the ligand-induced conformational changes of human Glu-plasminogen. <i>FEBS Letters</i> , 1997, 405, 363-368.	1.3	18
1057	Stimulation of cell-surface urokinase-type plasminogen activator activity and cell migration in vascular endothelial cells by a novel hexapeptide analogue of neurotensin. <i>FEBS Letters</i> , 1997, 418, 341-345.	1.3	9
1058	The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. <i>FEBS Letters</i> , 1997, 420, 79-85.	1.3	131
1059	Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation. <i>FEBS Letters</i> , 1997, 411, 322-326.	1.3	11
1060	Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. <i>Gastroenterology</i> , 1997, 113, 904-913.	0.6	57
1061	The role of thrombin-like (serine) proteases in the development, plasticity and pathology of the nervous system. <i>Brain Research Reviews</i> , 1997, 25, 85-95.	9.1	123
1062	Calcium spirulan as an inducer of tissue-type plasminogen activator in human fetal lung fibroblasts. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1997, 1355, 241-247.	1.9	32
1063	Quantitative assessment of interaction of urokinase-type plasminogen activator and its receptor (CD87) by use of a solid-phase uPA-ligand binding assay. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 11-19.	1.1	8
1064	Binding of plasminogen and tissue-type plasminogen activator to dimeric $\hat{1}\pm 2$ -casein accelerates plasmin generation. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 29-36.	1.1	12
1065	Decrease in urokinase-type plasminogen activator (u-PA) levels in patients with non-insulin dependent diabetes mellitus. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 215-219.	1.1	2
1066	Signal transduction via urokinase receptor: is a transmembrane adapter molecule really necessary?. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 165-169.	1.1	13
1067	Plasma and cerebrospinal fluid activities of tissue plasminogen activator, urokinase and plasminogen activator inhibitor-1 in multiple sclerosis. <i>Fibrinolysis and Proteolysis</i> , 1997, 11, 109-113.	1.1	10
1068	Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression. <i>Molecular and Cellular Endocrinology</i> , 1997, 133, 109-116.	1.6	25

#	ARTICLE	IF	CITATIONS
1069	Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2. <i>Gene</i> , 1997, 201, 179-187.	1.0	66
1070	Evidence for a role of the ovarian surface epithelium in the ovulatory mechanism of the sheep: secretion of urokinase-type plasminogen activator. <i>Animal Reproduction Science</i> , 1997, 47, 197-204.	0.5	51
1071	Regulation of Plasminogen Gene Expression by Interleukin-6. <i>Blood</i> , 1997, 89, 2394-2403.	0.6	50
1072	Inhibition of Metastasis of Intraocular Melanomas by Adenovirus-Mediated Gene Transfer of Plasminogen Activator Inhibitor Type 1 (PAI-1) in an Athymic Mouse Model. <i>Blood</i> , 1997, 90, 2738-2746.	0.6	77
1074	Stromal Expression of MMP-9 and Urokinase Receptor Is Inversely Associated with Liver Metastasis and with Infiltrating Growth in Human Colorectal Cancer: A Novel Approach from Immune/Inflammatory Aspect. <i>Japanese Journal of Cancer Research</i> , 1997, 88, 72-81.	1.7	63
1075	Two Transcription Factors, E1AF and N-myc, Correlate with the Invasiveness of Neuroblastoma Cell Lines. <i>Japanese Journal of Cancer Research</i> , 1997, 88, 394-400.	1.7	17
1076	The pituitary-gonadal function in postmenopausal women with epithelial ovarian tumors. <i>Apmis</i> , 1997, 105, 5-27.	0.9	1
1077	Pemphigus IgG Induces Expression of Urokinase Plasminogen Activator Receptor on the Cell Surface of Cultured Keratinocytes. <i>Journal of Investigative Dermatology</i> , 1997, 109, 650-655.	0.3	43
1078	Healing hormones. <i>Nature Medicine</i> , 1997, 3, 1195-1196.	15.2	2
1079	Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. <i>British Journal of Cancer</i> , 1997, 75, 388-395.	2.9	198
1080	Cell-Surface Acceleration of Urokinase-Catalyzed Receptor Cleavage. <i>FEBS Journal</i> , 1997, 243, 21-26.	0.2	99
1081	Plasminogen Activation by Pro-Urokinase in Complex with its Receptor - Dependence on a Tripeptide (Spectrozyme Plasmin). <i>FEBS Journal</i> , 1997, 247, 256-261.	0.2	18
1082	Kinetics of Reciprocal Pro-Urokinase/Plasminogen Activation. Stimulation by a Template Formed by the Urokinase Receptor Bound to Poly(D-lysine). <i>FEBS Journal</i> , 1997, 245, 316-323.	0.2	36
1083	Breast Carcinoma Epithelial Cells Express a Very Low-Density Lipoprotein Receptor Variant Lacking the O-Linked Glycosylation Domain Encoded by Exon 16, But with Full Binding Activity for Serine Proteinase/Serpin Complexes and Mr-40000 Receptor-Associated Protein. <i>FEBS Journal</i> , 1997, 248, 583-591.	0.2	31
1084	Characterisation of the Rat Tissue-Type Plasminogen Activator Gene Promoter. Identification of a TAAT-Containing Promoter Element. <i>FEBS Journal</i> , 1997, 248, 676-683.	0.2	12
1085	Detection of fibronectin expression by human endothelial cells using a enzyme-linked immunosorbent assay (ELISA): enzymatic degradation by activated plasminogen. <i>Journal of Immunological Methods</i> , 1997, 202, 67-75.	0.6	10
1086	The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. <i>Journal of Immunological Methods</i> , 1997, 203, 55-65.	0.6	18
1087	Fibronectinase activity in cultured human trophoblasts is mediated by urokinase-type plasminogen activator. <i>American Journal of Obstetrics and Gynecology</i> , 1997, 176, 58-65.	0.7	11

#	ARTICLE	IF	CITATIONS
1088	Stimulation of plasminogen activator/plasmin system in gingival fibroblast cells by oxygen radicals. Archives of Oral Biology, 1997, 42, 263-270.	0.8	18
1089	Expression of stromelysin-3 in the human placenta and placental bed. Placenta, 1997, 18, 277-285.	0.7	41
1090	Tumor-Associated Proteolytic Factors uPA and PAI-1 in Endometrial Carcinoma. Gynecologic Oncology, 1997, 66, 268-274.	0.6	22
1091	Biochemical Characterization of Primary Peritoneal Carcinoma Cell Adhesion, Migration, and Proteinase Activity. Gynecologic Oncology, 1997, 67, 193-199.	0.6	11
1092	Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Research and Treatment, 1997, 43, 153-163.	1.1	48
1093	Hepatocyte growth factor stimulates the invasion of gallbladder carcinoma cell lines in vitro. Clinical and Experimental Metastasis, 1997, 16, 74-82.	1.7	32
1094	Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride. Clinical and Experimental Metastasis, 1997, 16, 353-357.	1.7	37
1095	Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clinical and Experimental Metastasis, 1997, 15, 440-446.	1.7	70
1096	Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clinical and Experimental Metastasis, 1997, 15, 418-426.	1.7	43
1097	Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro. Clinical and Experimental Metastasis, 1997, 15, 447-452.	1.7	1
1098	The concentration of u-PA and PAI-1 antigen in tissue extracts of nasopharyngeal carcinoma. European Archives of Oto-Rhino-Laryngology, 1997, 254, 277-280.	0.8	4
1099	Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochemistry and Cell Biology, 1997, 107, 313-320.	0.8	42
1100	A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue. Journal of Cancer Research and Clinical Oncology, 1997, 123, 555-559.	1.2	12
1101	Glucocorticosteroids inhibit degradation in bovine cartilage explants stimulated with concomitant plasminogen and interleukin-1<math>\alpha</math>. Inflammation Research, 1997, 46, 60-64.	1.6	20
1102	Effect of sulphur mustard on the expression of urokinase in cultured 3T3 fibroblasts. Archives of Toxicology, 1997, 71, 243-249.	1.9	10
1103	Molecular biology of colorectal cancer. Current Problems in Cancer, 1997, 21, 233-299.	1.0	173
1104	Prognostic factors in gastric cancer. British Journal of Surgery, 1997, 84, 1651-1664.	0.1	9
1105	Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology, 1997, 25, 856-861.	3.6	42

#	ARTICLE	IF	CITATIONS
1106	Low-energy diode laser irradiation reduced plasminogen activator activity in human periodontal ligament cells. , 1997, 21, 456-463.		45
1107	Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. Journal of Pathology, 1997, 183, 388-397.	2.1	50
1108	Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo. , 1997, 32, 196-204.		45
1109	Induced PAI-1 mRNA expression and targeted protein accumulation are early G1 events in serum-stimulated rat kidney cells. , 1997, 170, 8-18.		15
1110	Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase. , 1997, 172, 137-145.		49
1111	Altered in vitro spreading and cytoskeletal organization in human glioma cells by downregulation of urokinase receptor. Molecular Carcinogenesis, 1997, 20, 355-365.	1.3	26
1112	Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. , 1997, 80, 1457-1463.		86
1113	Proteinase inhibition in invasive cancer therapy: Four control levels of matrix degradation. International Journal of Cancer, 1997, 70, 628-630.	2.3	5
1114	Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system. International Journal of Cancer, 1997, 71, 116-122.	2.3	79
1115	The urokinase-type plasminogen activator system in cancer metastasis: A review. International Journal of Cancer, 1997, 72, 1-22.	2.3	1,493
1116	ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts. , 1997, 72, 416-423.		15
1117	Ethanol-exposed central neurons fail to migrate and undergo apoptosis. , 1997, 48, 439-448.		95
1118	Alterations of glycosidases in human colonic adenocarcinoma. Clinical Biochemistry, 1997, 30, 17-25.	0.8	14
1119	Urokinase induces receptor mediated brain tumor cell migration and invasion. Journal of Neuro-Oncology, 1998, 40, 215-226.	1.4	32
1120	Expression and localization of urokinase-type plasminogen activator in human spinal column tumors. Clinical and Experimental Metastasis, 1998, 16, 713-719.	1.7	4
1121	G-CSF increases secretion of urokinase-type plasminogen activator by human lung cancer cells. Clinical and Experimental Metastasis, 1998, 16, 551-558.	1.7	11
1122	Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clinical and Experimental Metastasis, 1998, 16, 513-528.	1.7	82
1123	The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells. Clinical and Experimental Metastasis, 1998, 16, 235-241.	1.7	7

#	ARTICLE	IF	CITATIONS
1124	Identification of a BamHI Polymorphism for the Urokinase Gene Associated with Symptomatic Coronary Artery Disease. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 113-118.	1.0	3
1125	Developmental pattern of plasminogen activator activity in chick brain hemispheres. <i>Neurochemical Research</i> , 1998, 23, 1185-1190.	1.6	0
1126	Ultrastructural localization and biochemical characterization of vitronectin in developing rat bone. <i>The Histochemical Journal</i> , 1998, 30, 111-119.	0.6	10
1127	Recent Advances in Assisted Reproductive Technologies. <i>Endocrine</i> , 1998, 9, 15-26.	2.2	11
1128	Secretion of plasminogen activator by cultured rat endometrial stromal cells from uteri differentially sensitized for the decidual cell reaction. <i>Molecular Reproduction and Development</i> , 1998, 49, 268-276.	1.0	5
1129	Regulation of plasminogen activator in rat endometrial stromal cells: The role of epidermal growth factor. <i>Molecular Reproduction and Development</i> , 1998, 50, 63-69.	1.0	3
1130	Changes in the bovine zona pellucida induced by plasmin or embryonic plasminogen activator. <i>Molecular Reproduction and Development</i> , 1998, 51, 330-338.	1.0	12
1131	Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 936-944.	1.4	13
1132	Effects of Sex Steroids and Growth Factors on Invasive Activity and 5-Deoxy-5-fluorouridine Sensitivity in Ovarian Adenocarcinoma OMC-3 Cells. <i>Japanese Journal of Cancer Research</i> , 1998, 89, 1334-1342.	1.7	6
1133	Expression of human PAI-2 in the baculovirus expression system. <i>Journal of Industrial Microbiology and Biotechnology</i> , 1998, 21, 175-177.	1.4	1
1134	Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. <i>British Journal of Cancer</i> , 1998, 77, 932-940.	2.9	97
1135	Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods. <i>British Journal of Cancer</i> , 1998, 77, 1495-1501.	2.9	18
1136	Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. <i>British Journal of Cancer</i> , 1998, 78, 88-95.	2.9	34
1137	Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. <i>British Journal of Cancer</i> , 1998, 78, 833-839.	2.9	40
1138	In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies. <i>British Journal of Cancer</i> , 1998, 78, 1578-1585.	2.9	3
1139	Human tetranectin: Methodological and clinical studies. <i>Apmis</i> , 1998, 106, 7-31.	0.9	14
1140	Localization and distribution of tissue type and urokinase type plasminogen activators and their inhibitors type 1 and 2 in human and rhesus monkey fetal membranes. <i>Placenta</i> , 1998, 19, 171-180.	0.7	26
1141	Immunohistochemical identification of the receptor for urokinase plasminogen activator associated with fibrin deposition in normal and ectopic human placenta. <i>Placenta</i> , 1998, 19, 501-508.	0.7	33



#	ARTICLE	IF	CITATIONS
1142	Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. <i>Oral Oncology</i> , 1998, 34, 58-62.	0.8	74
1143	Molecular determinants of colon cancer metastasis. <i>Surgical Oncology</i> , 1998, 7, 183-195.	0.8	31
1144	The interaction of <i>Streptococcus dysgalactiae</i> with plasmin and plasminogen. <i>Veterinary Microbiology</i> , 1998, 61, 121-135.	0.8	30
1145	Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. , 1998, 82, 724-732.		25
1146	Transforming growth factor- $\beta$ 1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. , 1998, 75, 721-730.		106
1147	Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. , 1998, 79, 179-186.		50
1148	HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. , 1998, 76, 749-756.		71
1149	Urokinase-type-plasminogen-activator(UPA) production by human breast (myo)fibroblasts in vitro: Influence of transforming growth factor- $\beta$ 1 (TGF $\beta$ 1) compared with factor(s) released by human epithelial-carcinoma cells. , 1998, 76, 829-835.		33
1150	The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. , 1998, 77, 128-137.		187
1151	Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer. , 1998, 78, 320-325.		13
1152	Fibrinolytic components in nasal mucosa and nasal secretion. <i>Histochemistry and Cell Biology</i> , 1998, 110, 449-455.	0.8	3
1153	Differentiating cells of murine stratified squamous epithelia constitutively express plasminogen activator inhibitor type 2 (PAI-2). <i>Histochemistry and Cell Biology</i> , 1998, 110, 559-569.	0.8	25
1154	Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 55-68.	1.0	85
1155	Urokinase-type plasminogen activator, its receptor and inhibitor expression in hepatocellular carcinoma relation to cancer invasiveness and prognosis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 1998, 10, 268-271.	0.7	1
1156	In vitro angiogenic activity of Aloe vera gel on calf pulmonary artery endothelial (CPAE) cells. <i>Archives of Pharmacal Research</i> , 1998, 21, 260-265.	2.7	35
1157	Structural/functional properties of the Glu1â€Ser57 Nâ€terminal fragment of human plasminogen: Conformational characterization and interaction with kringle domains. <i>Protein Science</i> , 1998, 7, 1947-1959.	3.1	16
1158	Plasminogen activator in acute myeloid leukaemic marrows: uâ€PA in contrast to tâ€PA in normal marrow. <i>British Journal of Haematology</i> , 1998, 101, 626-631.	1.2	11
1159	The urokinase receptor. <i>Fibrinolysis and Proteolysis</i> , 1998, 12, 191-204.	1.1	65

#	ARTICLE	IF	CITATIONS
1160	Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor. <i>Fibrinolysis and Proteolysis</i> , 1998, 12, 219-240.	1.1	42
1161	Plasma clearance of urokinase-type plasminogen activator. <i>Fibrinolysis and Proteolysis</i> , 1998, 12, 251-258.	1.1	7
1162	Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control and tumour xenograft-bearing mice. <i>Fibrinolysis and Proteolysis</i> , 1998, 12, 145-154.	1.1	14
1163	Thrombolytic agents – an updated overview. <i>Fibrinolysis and Proteolysis</i> , 1998, 12, 39-58.	1.1	19
1164	The field bean protease inhibitor has the potential to suppress B16F10 melanoma cell lung metastasis in mice. <i>Cancer Letters</i> , 1998, 129, 15-20.	3.2	22
1165	Prostaglandin I2 analog enhances the expression of urokinase-type plasminogen activator and wound healing in cultured human fibroblast. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1998, 1403, 189-198.	1.9	23
1166	Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation. <i>International Journal of Cardiology</i> , 1998, 66, S57-S64.	0.8	13
1167	Cutaneous small-vessel vasculitis. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 667-690.	0.6	199
1168	Differential Regulation of Protease Activated Receptor-1 and Tissue Plasminogen Activator Expression by Shear Stress in Vascular Smooth Muscle Cells. <i>Circulation Research</i> , 1998, 83, 1027-1034.	2.0	70
1169	Dipeptidyl peptidase III in malignant and non-malignant gynaecological tissue. <i>European Journal of Cancer</i> , 1998, 34, 399-405.	1.3	40
1170	Co-Localization of Fibrinolytic Activators and Inhibitors with Macrophages in Atherosclerotic Vessels. <i>Cardiovascular Pathology</i> , 1998, 7, 223-231.	0.7	5
1171	Bacterial O6-methylguanine-DNA methyltransferase reduces N-methyl-N <sup>ε</sup> -nitro-N-nitrosoguanidine induction of plasminogen activator in Mer <sup>+</sup> human glioblastoma A1235 cell line. <i>Mutation Research DNA Repair</i> , 1998, 408, 47-54.	3.8	3
1172	Activation of single-chain urokinase-type plasminogen activator by a hemorrhagic metalloproteinase, jararafibrinase I, in Bothrops jararaca venom. <i>Toxicon</i> , 1998, 36, 993-1000.	0.8	7
1173	Fibrinolytic factors, matrix metalloproteinase-1, and tissue inhibitor of metalloproteinase-1 in gastric carcinoma. <i>Pathophysiology</i> , 1998, 5, 99-104.	1.0	1
1174	Proteases in cutaneous melanoma. <i>Annals of Medicine</i> , 1998, 30, 431-442.	1.5	25
1175	Sulfated Glycosaminoglycans Enhance Tumor Cell Invasion in Vitro by Stimulating Plasminogen Activation. <i>Experimental Cell Research</i> , 1998, 239, 301-310.	1.2	26
1176	Irsogladine Maleate Inhibits Angiogenesis in Wild-Type and Plasminogen Activator-Deficient Mice. <i>Journal of Surgical Research</i> , 1998, 77, 126-131.	0.8	6
1177	Activation of the Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor System and Redistribution of E-Cadherin Are Associated with Hepatocyte Growth Factor-Induced Motility of Pancreas Tumor Cells Overexpressing Met. <i>American Journal of Pathology</i> , 1998, 153, 201-212.	1.9	63

#	ARTICLE	IF	CITATIONS
1178	Potential Functions of the Clotting System in Wound Repair. , 1998, , 57-85.		2
1179	Plasminogen Activator Inhibitor-1 Is Expressed in Cultured Rat Sertoli Cells1. <i>Biology of Reproduction</i> , 1998, 59, 591-598.	1.2	34
1180	Effects of Epidermal Growth Factor and Interleukin-1 $\beta$ on Plasminogen Activator Secretion and Decidualization in Rat Endometrial Stromal Cells1. <i>Biology of Reproduction</i> , 1998, 59, 131-135.	1.2	12
1181	The Jak/Stat Pathway and Urokinase Receptor Signaling in Human Aortic Vascular Smooth Muscle Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 315-321.	1.6	165
1182	Urokinase type plasminogen activator receptor expression in colorectal neoplasms. <i>Gut</i> , 1998, 43, 798-805.	6.1	48
1183	Biologic Functions. , 1998, , 233-341.		0
1184	Glycosylation Profile of a Recombinant Urokinase-type Plasminogen Activator Receptor Expressed in Chinese Hamster Ovary Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 13933-13943.	1.6	62
1185	Inhibition of Urokinase Activity by the Antiangiogenic Factor 16K Prolactin: Activation of Plasminogen Activator Inhibitor 1 Expression. <i>Endocrinology</i> , 1998, 139, 3696-3703.	1.4	61
1186	Elevated Expression of Urokinase-like Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 During the Vascular Remodeling Associated With Pulmonary Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 808-815.	1.1	41
1187	Tetranectin Levels in Patients with Acute Myocardial Infarction and Their Alterations during Thrombolytic Treatment. <i>Annals of Clinical Biochemistry</i> , 1998, 35, 400-407.	0.8	23
1188	A Characterization of the Coagulant and Fibrinolytic Profile of Human Pancreatic Carcinoma Cells. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1998, 28, 1-6.	0.5	7
1189	Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. <i>BMJ: British Medical Journal</i> , 1998, 316, 829-830.	2.4	68
1190	Plasminogen Activator Expression in Rat Arterial Smooth Muscle Cells Depends on Their Phenotype and Is Modulated by Cytokines. <i>Circulation Research</i> , 1998, 82, 1086-1093.	2.0	42
1191	UV Irradiation Induces the Murine Urokinase-Type Plasminogen Activator Gene via the c-Jun N-Terminal Kinase Signaling Pathway: Requirement of an AP1 Enhancer Element. <i>Molecular and Cellular Biology</i> , 1998, 18, 4537-4547.	1.1	58
1192	Binding of urokinase-type plasminogen activatorâ€™plasminogen activator inhibitor-1 complex to the endocytosis receptors $\alpha$ 2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor. <i>Biochemical Journal</i> , 1998, 329, 55-63.	1.7	87
1193	Inhibitory Effect of Amiloride on the Urokinase Plasminogen Activators in Prostatic Cancer. <i>Tumor Biology</i> , 1998, 19, 60-64.	0.8	16
1194	Apposition-Dependent Induction of Plasminogen Activator Inhibitor Type 1 Expression: A Mechanism for Balancing Pericellular Proteolysis During Angiogenesis. <i>Blood</i> , 1998, 92, 939-945.	0.6	24
1195	Tissue Factor Regulates Plasminogen Binding and Activation. <i>Blood</i> , 1998, 91, 1987-1998.	0.6	47

#	ARTICLE	IF	CITATIONS
1196	Plasminogen Deficiency Differentially Affects Recruitment of Inflammatory Cell Populations in Mice. <i>Blood</i> , 1998, 91, 2005-2009.	0.6	216
1197	A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 274, L871-L882.	1.3	28
1198	Thromboxane A <sub>2</sub> modulates the fibrinolytic system in glomerular mesangial cells. <i>American Journal of Physiology - Renal Physiology</i> , 1998, 275, F262-F269.	1.3	8
1199	Structure and Function of the Urokinase Receptor. <i>Thrombosis and Haemostasis</i> , 1999, 82, 19-22.	1.8	31
1200	Fibrinolytic Activity of Subretinal Fluid after Cryopexy. <i>European Journal of Ophthalmology</i> , 1999, 9, 291-296.	0.7	5
1201	Transcriptional Regulation of the Murine Urokinase-type Plasminogen Activator Gene in Skeletal Myoblasts. <i>Thrombosis and Haemostasis</i> , 1999, 81, 767-774.	1.8	10
1202	Determination of the Complex between Urokinase and Its Type-1 Inhibitor in Plasma from Healthy Donors and Breast Cancer Patients. <i>Clinical Chemistry</i> , 1999, 45, 1206-1213.	1.5	16
1203	Difference in mRNA expression and occurrence of plasminogen activator inhibitors in intrauterine decidua of normal and ectopic human pregnancies. <i>Human Fertility</i> , 1999, 2, 127-132.	0.7	0
1204	Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis. <i>Journal of the National Cancer Institute</i> , 1999, 91, 869-874.	3.0	251
1205	Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo <sup>1</sup> . <i>Endocrinology</i> , 1999, 140, 4056-4064.	1.4	31
1206	Angiostatin Binds to Smooth Muscle Cells in the Coronary Artery and Inhibits Smooth Muscle Cell Proliferation and Migration In Vitro. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2041-2048.	1.1	40
1207	Plasmin Cleaves Tumor Necrosis Factor $\alpha$ Exodomain from Sheep Follicular Endothelium: Implication in the Ovulatory Process <sup>1</sup> . <i>Biology of Reproduction</i> , 1999, 60, 1166-1171.	1.2	15
1208	Immunohistochemical Analysis of PAI-2 (Plasminogen Activator Inhibitor Type 2) and p53 Protein in Early Gastric Cancer Patients with Recurrence: A Preliminary Report. <i>Japanese Journal of Clinical Oncology</i> , 1999, 29, 187-191.	0.6	4
1209	Hormonal Control of Urokinase Plasminogen Activator Secretion by Sheep Ovarian Surface Epithelial Cells <sup>1</sup> . <i>Biology of Reproduction</i> , 1999, 61, 1487-1491.	1.2	24
1210	Production of Plasminogen Activators (PAs) in Bovine Cumulus-Oocyte Complexes during Maturation In Vitro: Effects of Epidermal Growth Factor on Production of PAs in Oocytes and Cumulus Cells <sup>1</sup> . <i>Biology of Reproduction</i> , 1999, 61, 298-304.	1.2	23
1211	Different Tyrosine Autophosphorylation Requirements in Fibroblast Growth Factor Receptor-1 Mediate Urokinase-Type Plasminogen Activator Induction and Mitogenesis. <i>Molecular Biology of the Cell</i> , 1999, 10, 23-33.	0.9	27
1212	Interaction between Group A Streptococci and the Plasmin(ogen) System Promotes Virulence in a Mouse Skin Infection Model. <i>Journal of Infectious Diseases</i> , 1999, 179, 907-914.	1.9	64
1213	The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. <i>Thorax</i> , 1999, 54, 169-179.	2.7	53

#	ARTICLE	IF	CITATIONS
1214	Tumor Necrosis Factor $\alpha$ Regulates Collagenolytic Activity in Preovulatory Ovine Follicles: Relationship to Cytokine Secretion by the Oocyte-Cumulus Cell Complex. <i>Biology of Reproduction</i> , 1999, 61, 1581-1585.	1.2	31
1215	Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor. <i>Journal of Biological Chemistry</i> , 1999, 274, 16377-16386.	1.6	80
1216	Tissue Plasminogen Activator Binds to Human Vascular Smooth Muscle Cells by a Novel Mechanism. <i>Journal of Biological Chemistry</i> , 1999, 274, 21555-21561.	1.6	27
1217	The Transcription Factor EGR-1 Suppresses Transformation of Human Fibrosarcoma HT1080 Cells by Coordinated Induction of Transforming Growth Factor- $\beta$ 1, Fibronectin, and Plasminogen Activator Inhibitor-1. <i>Journal of Biological Chemistry</i> , 1999, 274, 4400-4411.	1.6	105
1218	Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 11054-11061.	3.3	240
1219	Emerging therapeutic targets in oncology: urokinase-type plasminogen activator system. <i>Expert Opinion on Therapeutic Targets</i> , 1999, 3, 109-133.	1.0	15
1220	Nonenzymatic Interactions between Proteinases and the Cell Surface: Novel Roles in Normal and Malignant Cell Physiology. <i>Advances in Cancer Research</i> , 1999, 78, 103-157.	1.9	65
1221	BDNF stimulates expression, activity and release of tissue-type plasminogen activator in mouse cortical neurons. <i>European Journal of Neuroscience</i> , 1999, 11, 1639-1646.	1.2	46
1222	Gossypol-induced inhibition of plasminogen activator activity in human and ovine acrosomal extract. <i>Andrologia</i> , 1999, 31, 355-359.	1.0	8
1223	Suppression of Keratinocyte Proliferation by Plasminogen Activator Inhibitor-2. <i>Journal of Investigative Dermatology</i> , 1999, 112, 85-90.	0.3	33
1224	Urokinase is a Positive Regulator of Epidermal Proliferation In Vivo. <i>Journal of Investigative Dermatology</i> , 1999, 112, 240-244.	0.3	26
1225	Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing. <i>Wound Repair and Regeneration</i> , 1999, 7, 154-165.	1.5	96
1226	A Prospective Study on the Effects of Reformulated 2-rod Norplant Implant on Haemostasis after Five Years of Use. <i>Journal of Obstetrics and Gynaecology Research</i> , 1999, 25, 177-183.	0.6	2
1227	The plasminogen activation system in lung cancer " with special reference to the prognostic role in "non-small cell lung cancer". <i>Apmis</i> , 1999, 107, 5-29.	0.9	1
1228	Regulation of cell adhesion by PAI-1. <i>Apmis</i> , 1999, 107, 54-61.	0.9	151
1229	The urokinase receptor. A cell surface, regulated chemokine. <i>Apmis</i> , 1999, 107, 96-101.	0.9	86
1230	Cancer invasion and tissue remodeling " cooperation of protease systems and cell types. <i>Apmis</i> , 1999, 107, 120-127.	0.9	273
1231	The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. <i>Apmis</i> , 1999, 107, 160-167.	0.9	48

#	ARTICLE	IF	CITATIONS
1232	Inhibitory Role of Plasminogen Activator Inhibitor-1 in Invasion and Proliferation of HLE Hepatocellular Carcinoma Cells. Japanese Journal of Cancer Research, 1999, 90, 747-752.	1.7	24
1233	Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene, 1999, 18, 4554-4563.	2.6	144
1234	Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. British Journal of Cancer, 1999, 79, 888-894.	2.9	40
1235	Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. British Journal of Cancer, 1999, 79, 1190-1198.	2.9	38
1236	Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. British Journal of Cancer, 1999, 79, 1746-1751.	2.9	120
1237	A comparative study of the effects of genistein and 2-methoxyestradiol on the proteolytic balance and tumour cell proliferation. British Journal of Cancer, 1999, 80, 17-24.	2.9	28
1238	Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. British Journal of Cancer, 1999, 80, 167-174.	2.9	32
1239	Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. British Journal of Cancer, 1999, 80, 286-294.	2.9	39
1240	Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. British Journal of Cancer, 1999, 80, 419-426.	2.9	83
1241	Soluble urokinase receptor released from human carcinoma cells: A plasma parameter for xenograft tumour studies. British Journal of Cancer, 1999, 81, 203-211.	2.9	34
1242	Inhibition of Protein Synthesis by Chromium(VI) Differentially Affects Expression of Urokinase and Its Receptor in Human Type II Pneumocytes. Toxicology and Applied Pharmacology, 1999, 158, 288-295.	1.3	13
1243	Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Research and Treatment, 1999, 54, 147-157.	1.1	73
1244	Cytokine-regulated urokinase-type plasminogen activator (uPA) production by human breast fibroblasts in vitro. Breast Cancer Research and Treatment, 1999, 55, 9-20.	1.1	35
1245	Posttranscriptional regulation of urokinase receptor gene expression in human lung carcinoma and mesothelioma cells in vitro. , 1999, 199, 189-200.		33
1246	Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms. Molecular and Cellular Biochemistry, 1999, 195, 199-206.	1.4	42
1247	Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO Journal, 1999, 18, 4645-4656.	3.5	225
1248	Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. Clinical and Experimental Metastasis, 1999, 17, 87-95.	1.7	14
1249	Effect of recombinant forms of urokinase plasminogen activator on platelet aggregation and intracellular calcium accumulation. Bulletin of Experimental Biology and Medicine, 1999, 128, 952-955.	0.3	0

#	ARTICLE	IF	CITATIONS
1250	Urokinase-type plasminogen activator and plasminogen activator inhibitor antigen in tissue extracts of paranasal sinus mucous membranes affected by chronic sinusitis and antrochoanal polyps. <i>European Archives of Oto-Rhino-Laryngology</i> , 1999, 256, 237-241.	0.8	17
1251	Expression and significance of urokinase-type plasminogen activator in breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 1999, 11, 295-298.	0.7	1
1252	Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. <i>Journal of Immunological Methods</i> , 1999, 222, 125-133.	0.6	39
1253	Use of the plasminogen activation system by microorganisms. <i>Translational Research</i> , 1999, 134, 567-576.	2.4	83
1254	Localization of plasminogen activators and plasminogen-activator inhibitors in human gingival tissues demonstrated by immunohistochemistry and in situ hybridization. <i>Archives of Oral Biology</i> , 1999, 44, 1027-1034.	0.8	44
1255	The effect of dexamethasone on fibrinolytic parameters of ram lymphocytes. <i>Small Ruminant Research</i> , 1999, 32, 279-284.	0.6	0
1256	Zonal regulation of gene expression during liver regeneration of urokinase transgenic mice. <i>Hepatology</i> , 1999, 29, 1106-1113.	3.6	21
1257	Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. <i>Hepatology</i> , 1999, 29, 1768-1778.	3.6	264
1258	Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. , 1999, 180, 225-235.		125
1259	Growth state-dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor- $\beta$ 1. , 1999, 181, 96-106.		31
1260	The role of cysteine and serine proteases in colorectal carcinoma. <i>Cancer</i> , 1999, 86, 1135-1142.	2.0	97
1261	Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. , 1999, 86, 2602-2611.		53
1262	Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. , 1999, 84, 74-79.		56
1263	Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells. , 1999, 82, 748-753.		17
1264	Brain tumour invasion: Many cooks can spoil the broth. <i>Journal of Clinical Neuroscience</i> , 1999, 6, 455-463.	0.8	3
1265	Cerebrospinal fluid plasminogen, plasmin and protease inhibitors in multiple sclerosis. <i>Fibrinolysis and Proteolysis</i> , 1999, 13, 99-103.	1.1	3
1266	Anti-angiogenic activity of a novel synthetic agent, 9 $\beta$ -fluoromedroxyprogesterone acetate. <i>Cancer Letters</i> , 1999, 145, 107-114.	3.2	11
1267	Effects of sodium hyaluronic acid on fibrinolytic factors in the synovial fluid (in vivo). <i>Pathophysiology</i> , 1999, 6, 41-44.	1.0	6

#	ARTICLE	IF	CITATIONS
1268	Tissue plasminogen activator gene expression in multiple sclerosis brain tissue. <i>Journal of the Neurological Sciences</i> , 1999, 165, 71-76.	0.3	24
1269	Transmembrane Signaling for Adhesive Regulation of Desmosomes and Hemidesmosomes, and for Cell-Cell Detachment Induced by Pemphigus IgG in Cultured Keratinocytes: Involvement of Protein Kinase C. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 1999, 4, 137-144.	0.8	102
1270	Demonstration of Urokinase Expression in Cancer Cells of Colon Adenocarcinomas by Immunohistochemistry and in Situ Hybridization. <i>American Journal of Pathology</i> , 1999, 155, 1115-1120.	1.9	40
1271	Regulation of Motility and Protease Expression in PKC-Mediated Induction of MCF-7 Breast Cancer Cell Invasiveness. <i>Experimental Cell Research</i> , 1999, 247, 105-113.	1.2	59
1272	Regulation of Tissue-Type Plasminogen Activator and Its Inhibitor (PAI-1) by Lipopolysaccharide-Induced Phagocytosis in a Sertoli Cell Line. <i>Experimental Cell Research</i> , 1999, 247, 367-372.	1.2	14
1273	Structure of the complex of the antistatin-type inhibitor bdellastatin with trypsin and modelling of the bdellastatin-microplasmin system. <i>Journal of Molecular Biology</i> , 1999, 293, 93-106.	2.0	21
1274	Retinoic Acid Synergizes with Cyclic AMP to Enhance MMP-2 Basal Promoter Activity. <i>Biochemical and Biophysical Research Communications</i> , 1999, 258, 663-667.	1.0	11
1275	The cell biology of leukocyte-mediated proteolysis. <i>Journal of Leukocyte Biology</i> , 1999, 65, 137-150.	1.5	360
1276	Chapter 9 biology of prostate cancer bone marrow metastasis. <i>Advances in Oncobiology</i> , 1999, 3, 189-200.	0.0	0
1277	c-erbB-2 Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems. <i>Journal of Clinical Oncology</i> , 2000, 18, 2201-2209.	0.8	257
1278	Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells. <i>Biochemical Journal</i> , 2000, 345, 595-601.	1.7	42
1279	Proteolytic and Cellular Death Mechanisms in Ovulatory Ovarian Rupture. <i>NeuroSignals</i> , 2000, 9, 102-114.	0.5	35
1280	Osteoblast-derived TGF- $\beta$ 1 modulates matrix degrading protease expression and activity in prostate cancer cells. <i>International Journal of Cancer</i> , 2000, 85, 407-415.	2.3	59
1281	Osteoblast-derived TGF- $\beta$ 1 modulates matrix degrading protease expression and activity in prostate cancer cells. , 2000, 86, 888-888.		16
1282	Topological localization of plasminogen activator inhibitor type 2. , 2000, 40, 32-41.		2
1283	PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. <i>Journal of Cellular Physiology</i> , 2000, 182, 269-280.	2.0	48
1284	Proteases with plasminogen activator activity in hamster oviduct. , 2000, 55, 47-54.		11
1285	Identification and characterization of a Kunitz-type protease inhibitor in ascites fluid from patients with ovarian carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 44-54.	2.3	8



#	ARTICLE	IF	CITATIONS
1286	Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. <i>International Journal of Cancer</i> , 2000, 89, 519-523.	2.3	22
1287	Ceramide-enhanced urokinase-type plasminogen activator (uPA) release is mediated by protein kinase C in cultured microglia. <i>Glia</i> , 2000, 32, 226-233.	2.5	11
1288	Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer. <i>Breast Journal</i> , 2000, 6, 130-136.	0.4	18
1289	Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. <i>British Journal of Haematology</i> , 2000, 109, 815-822.	1.2	34
1290	Do plasminogen activators play a role in lichen sclerosus?. <i>Clinical and Experimental Dermatology</i> , 2000, 25, 432-435.	0.6	2
1291	Oct-1 specifically binds the UEF4 Site of the human AP1-regulated urokinase enhancer. <i>FEBS Journal</i> , 2000, 267, 5427-5437.	0.2	10
1292	Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 422-430.	1.4	55
1293	Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. <i>Chemistry and Biology</i> , 2000, 7, 299-312.	6.2	79
1294	Myeloid leukaemic cells can lyse fibrin directly. <i>British Journal of Haematology</i> , 2000, 111, 524-529.	1.2	0
1295	Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. <i>Pathology International</i> , 2000, 50, 392-397.	0.6	35
1296	Interaction of <i>Leishmania mexicana</i> promastigotes with the plasminogen-plasmin system. <i>Molecular and Biochemical Parasitology</i> , 2000, 110, 183-193.	0.5	33
1297	Size distribution of the urokinase mRNA decay intermediates in different tissues and cell lines. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2000, 1517, 33-45.	2.4	4
1298	Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization. <i>Journal of Immunological Methods</i> , 2000, 234, 107-116.	0.6	24
1299	Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. <i>Digestive Diseases and Sciences</i> , 2000, 45, 114-121.	1.1	45
1300	Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. <i>Journal of Neuro-Oncology</i> , 2000, 46, 115-123.	1.4	52
1301	In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 239-244.	1.7	36
1302	Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 163-170.	1.7	74
1303	Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 303-308.	1.7	37

#	ARTICLE	IF	CITATIONS
1304	The Prognostic Value of Pretherapeutic Tetranectin and CA-125 in Patients with Relapse of Ovarian Cancer. <i>Gynecologic Oncology</i> , 2000, 79, 416-419.	0.6	15
1305	True. <i>British Journal of Cancer</i> , 2000, 82, 1702-1708.	2.9	126
1306	Isolation and characterization of cell lines with reduced urokinase binding. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 29-36.	1.7	0
1307	Reduction of Plasminogen Activator Activity Stimulated by Lipopolysaccharide from Periodontal Pathogen in Human Gingival Fibroblasts by Low-energy Laser Irradiation. <i>Lasers in Medical Science</i> , 2000, 15, 35-42.	1.0	17
1308	The cJun N-terminal kinase (JNK) signaling pathway mediates induction of urokinase-type plasminogen activator (uPA) by the alkylating agent MNNG. <i>Blood</i> , 2000, 96, 1415-1424.	0.6	26
1309	Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. <i>Blood</i> , 2000, 96, 4091-4095.	0.6	185
1310	Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. <i>Journal of Clinical Pathology</i> , 2000, 53, 307-312.	2.1	45
1311	TGF $\beta$ <sup>2</sup> autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells. <i>FASEB Journal</i> , 2000, 14, 1147-1158.	0.2	46
1312	A study of the interaction between <i>Helicobacter pylori</i> and components of the human fibrinolytic system. <i>Brazilian Journal of Medical and Biological Research</i> , 2000, 33, 1015-1021.	0.7	6
1313	Tissue-Type Plasminogen Activator (tPA) Content in Colorectal Cancer and in Surrounding Mucosa: Relationship with Clinicopathologic Parameters and Prognostic Significance. <i>International Journal of Biological Markers</i> , 2000, 15, 44-50.	0.7	10
1314	Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 278, L148-L156.	1.3	27
1315	Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 279, L707-L715.	1.3	63
1316	Vasoactive intestinal peptide influences hatching of ovine blastocysts. <i>Reproduction, Fertility and Development</i> , 2000, 12, 7.	0.1	2
1317	Urokinase Receptor-Deficient Mice Have Impaired Neutrophil Recruitment in Response to <i>Pseudomonas aeruginosa</i> Infection. <i>Journal of Immunology</i> , 2000, 165, 1513-1519.	0.4	207
1318	Lysophosphatidylcholine Induces Urokinase-Type Plasminogen Activator and Its Receptor in Human Macrophages Partly Through Redox-Sensitive Pathway. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 244-250.	1.1	40
1319	RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. , 2001, 39, 299-306.		1
1320	Cellular Localization of Membrane-type Serine Protease 1 and Identification of Protease-activated Receptor-2 and Single-chain Urokinase-type Plasminogen Activator as Substrates. <i>Journal of Biological Chemistry</i> , 2000, 275, 26333-26342.	1.6	377
1321	Retinoid Modulation of Plasminogen Activator Production in Rat Sertoli Cells1. <i>Biology of Reproduction</i> , 2000, 63, 544-550.	1.2	13

#	ARTICLE	IF	CITATIONS
1322	A Urokinase Receptor-associated Protein with Specific Collagen Binding Properties. Journal of Biological Chemistry, 2000, 275, 1993-2002.	1.6	134
1323	Identity of Urinary Trypsin Inhibitor-binding Protein to Link Protein. Journal of Biological Chemistry, 2000, 275, 21185-21191.	1.6	41
1324	Activation of Hepatocyte Growth Factor and Urokinase/Plasminogen Activator by Matriptase, an Epithelial Membrane Serine Protease. Journal of Biological Chemistry, 2000, 275, 36720-36725.	1.6	339
1325	Urokinase Redistribution from the Secreted to the Cell-Bound Fraction in Granulosa Cells of Rat Preovulatory Follicles <sup>1</sup> . Biology of Reproduction, 2000, 62, 895-903.	1.2	14
1326	IGF-I stimulates chemotaxis of human neuroblasts. Involvement of type 1 IGF receptor, IGF binding proteins, phosphatidylinositol-3 kinase pathway and plasmin system. Journal of Endocrinology, 2000, 165, 123-131.	1.2	42
1327	Binding of the NG2 Proteoglycan to Kringle Domains Modulates the Functional Properties of Angiostatin and Plasmin(ogen). Journal of Biological Chemistry, 2000, 275, 28625-28633.	1.6	63
1328	Nonfibrinolytic Functions of Plasminogen. Methods, 2000, 21, 103-110.	1.9	33
1329	The Generation of Enzymatically Active Plasmin on the Surface of Spirochetes. Methods, 2000, 21, 133-141.	1.9	24
1330	Stimulation of Plasminogen Activator and Inhibitor in the Lymphatic Endothelium. Microvascular Research, 2000, 60, 201-211.	1.1	11
1331	Immunohistochemical Expression of uPA, uPAR, and PAI-1 in Breast Carcinoma. American Journal of Pathology, 2000, 157, 1219-1227.	1.9	83
1332	Cellular Distribution and Clinical Value of Urokinase-Type Plasminogen Activator, Its Receptor, and Plasminogen Activator Inhibitor-2 in Esophageal Squamous Cell Carcinoma. American Journal of Pathology, 2000, 156, 567-575.	1.9	36
1333	Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: An immunohistochemical study. Pathology Research and Practice, 2000, 196, 15-21.	1.0	50
1334	Plasminogen activation in multiple sclerosis and other neurological disorders. Fibrinolysis and Proteolysis, 2000, 14, 1-14.	1.1	5
1335	Effect of thrombomodulin on plasminogen activation. Fibrinolysis and Proteolysis, 2000, 14, 221-228.	1.1	10
1336	Resistance of cancer cells to immune recognition and killing. Medical Hypotheses, 2000, 54, 456-460.	0.8	14
1337	Expression of membrane-type 1 matrix metalloproteinase in coronary vessels of allotransplanted primate hearts. Journal of Heart and Lung Transplantation, 2000, 19, 1193-1198.	0.3	15
1338	Induction of tissue plasminogen activator in differentiated NG108â€¢15 cells. International Journal of Developmental Neuroscience, 2000, 18, 145-150.	0.7	3
1339	Unraveling the role of proteases in cancer. Clinica Chimica Acta, 2000, 291, 113-135.	0.5	521

#	ARTICLE	IF	CITATIONS
1340	Proteases in gastrointestinal neoplastic diseases. <i>Clinica Chimica Acta</i> , 2000, 291, 171-187.	0.5	54
1341	Induction of Urokinase-Type Plasminogen Activator by Lipopolysaccharide in PC-3 Human Prostatic Cancer Cells. <i>Thrombosis Research</i> , 2000, 97, 343-347.	0.8	15
1342	Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor. <i>FEBS Letters</i> , 2000, 476, 166-170.	1.3	23
1343	The Blood-Brain Barrier and Its Role in Inflammation. <i>Journal of Veterinary Internal Medicine</i> , 2000, 14, 399-411.	0.6	66
1344	Tumor cell-mediated proteolysis: regulatory mechanisms and functional consequences. <i>Fibrinolysis and Proteolysis</i> , 2000, 14, 87-97.	1.1	7
1345	IL-1 $\beta$ Down-Regulates Tissue-Type Plasminogen Activator by Up-Regulating Low-Density Lipoprotein Receptor-Related Protein in AML 12 Cells. <i>Biochemical and Biophysical Research Communications</i> , 2001, 288, 42-48.	1.0	15
1346	Stimulation of Plasminogen Activator Activity and Matrix Metalloproteinases of Human Dental Pulp-Derived Cells by Tumor Necrosis Factor- $\alpha$ . <i>Journal of Endodontics</i> , 2001, 27, 175-179.	1.4	24
1347	Overexpression of Plasminogen Activator in Male Breast Cancer. <i>Clinical Breast Cancer</i> , 2001, 2, 156-157.	1.1	2
1348	High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 78, 185-191.	1.2	29
1349	Cellular strategies for proteolytic targeting during migration and invasion. <i>FEBS Letters</i> , 2001, 506, 1-5.	1.3	45
1350	Induction of Hepatic Tissue-Type Plasminogen Activator and Type 1 Plasminogen Activator-Inhibitor Gene Expressions and Appearance of Their Translation Products in the Bile Following Acute Liver Injury in Rats. <i>Thrombosis Research</i> , 2001, 104, 283-291.	0.8	11
1352	Is Cadmium Chloride-Induced Inter-Sertoli Tight Junction Permeability Barrier Disruption a Suitable <i>In Vitro</i> Model to Study the Events of Junction Disassembly during Spermatogenesis in the Rat Testis?*. <i>Endocrinology</i> , 2001, 142, 1878-1888.	1.4	188
1353	Gene targeting in hemostasis. plasminogen. <i>Frontiers in Bioscience - Landmark</i> , 2001, 6, d555.	3.0	6
1354	S-Phase Fraction and Urokinase Plasminogen Activator Are Better Markers for Distant Recurrences Than Nottingham Prognostic Index and Histologic Grade in a Prospective Study of Premenopausal Lymph Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2010-2019.	0.8	63
1355	Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling. <i>International Journal of Biological Markers</i> , 2001, 16, 233-239.	0.7	71
1356	DRL performance in mice with deletion of tPA, uPA or PAI-1 genes. <i>Behavioural Pharmacology</i> , 2001, 12, 487-496.	0.8	11
1357	Development of Quality Control Preparations for Immunocytochemical Assessment of Urokinase-type Plasminogen Activator. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2001, 9, 281-287.	0.6	0
1358	Identification of the Substrates for Plasma Hyaluronan Binding Protein.. <i>Biological and Pharmaceutical Bulletin</i> , 2001, 24, 140-143.	0.6	33

#	ARTICLE	IF	CITATIONS
1359	Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. <i>Blood</i> , 2001, 98, 257-265.	0.6	116
1360	Effects of Aging on Luteinizing Hormone Secretion, Ovulation, and Ovarian Tissue-Type Plasminogen Activator Expression. <i>Experimental Biology and Medicine</i> , 2001, 226, 127-132.	1.1	12
1361	Ras Regulation of urokinase-type plasminogen activator. <i>Methods in Enzymology</i> , 2001, 333, 105-116.	0.4	7
1364	Expression of urokinase-type plasminogen activator in an experimental model of hepatocarcinoma. <i>Toxicology</i> , 2001, 161, 13-23.	2.0	7
1365	Ectopic expression of the cAMP-responsive element binding protein inhibits phorbol ester-mediated induction of tissue-type plasminogen activator gene expression. <i>FEBS Journal</i> , 2001, 268, 987-996.	0.2	3
1366	Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator. <i>FEBS Journal</i> , 2001, 268, 4430-4439.	0.2	50
1367	Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. <i>Journal of Pathology</i> , 2001, 195, 236-243.	2.1	45
1368	Patterns of angiogenesis in nonsmall-cell lung carcinoma. <i>Cancer</i> , 2001, 91, 1500-1509.	2.0	72
1369	Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer. <i>Cytometry</i> , 2001, 46, 184-189.	1.8	15
1370	The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. <i>Medicinal Research Reviews</i> , 2001, 21, 146-170.	5.0	125
1371	Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 225-237.	1.1	10
1372	Plasmin-independent gelatinase B (matrix metalloproteinase-9) release by monocytes under the influence of urokinase. <i>Biochemistry (Moscow)</i> , 2001, 66, 954-959.	0.7	12
1373	Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. <i>British Journal of Cancer</i> , 2001, 85, 85-92.	2.9	40
1374	Bacterial plasminogen activators and receptors. <i>FEMS Microbiology Reviews</i> , 2001, 25, 531-552.	3.9	262
1375	Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. <i>Chemistry and Biology</i> , 2001, 8, 1107-1121.	6.2	55
1376	The Urokinase Plasminogen Activator Receptor-associated Protein/Endo180 Is Coexpressed with Its Interaction Partners Urokinase Plasminogen Activator Receptor and Matrix Metalloprotease-13 during Osteogenesis. <i>Laboratory Investigation</i> , 2001, 81, 1403-1414.	1.7	62
1377	Urokinase Plasminogen Activator Is Localized in Stromal Cells in Ductal Breast Cancer. <i>Laboratory Investigation</i> , 2001, 81, 1485-1501.	1.7	72
1378	Differential expression of angiogenic cytokines by cell lines and primary cultures of human prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2001, 4, 106-111.	2.0	7

#	ARTICLE	IF	CITATIONS
1379	A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. <i>Nature Cell Biology</i> , 2001, 3, 267-275.	4.6	150
1380	Urokinase Receptor and Vascular Endothelial Growth Factor Are Synergistically Associated with the Liver Metastasis of Colorectal Cancer. <i>Japanese Journal of Cancer Research</i> , 2001, 92, 516-523.	1.7	26
1381	The Urokinase Receptor Associated Protein (uPARAP/Endo180) A Novel Internalization Receptor Connected to the Plasminogen Activation System. <i>Trends in Cardiovascular Medicine</i> , 2001, 11, 7-13.	2.3	43
1382	Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate. <i>Differentiation</i> , 2001, 69, 108-120.	1.0	9
1383	Direct Binding of Occupied Urokinase Receptor (uPAR) to LDL Receptor-related Protein Is Required for Endocytosis of uPAR and Regulation of Cell Surface Urokinase Activity. <i>Molecular Biology of the Cell</i> , 2001, 12, 1467-1479.	0.9	171
1384	Plasminogen expression in the neonatal and adult mouse brain. <i>Journal of Neurochemistry</i> , 2001, 77, 318-325.	2.1	61
1385	Tissue-Type Plasminogen Activator Deficiency Exacerbates Arthritis. <i>Journal of Immunology</i> , 2001, 167, 1047-1052.	0.4	57
1386	Plasminogen Activator Production in a Rat Model of <i>Pneumocystis carinii</i> Pneumonia. <i>Microbiology and Immunology</i> , 2001, 45, 605-611.	0.7	4
1387	Urokinase Plasminogen Activator and Plasmin Efficiently Convert Hemofiltrate CC Chemokine 1 into Its Active [9â€“74] Processed Variant. <i>Journal of Immunology</i> , 2001, 167, 3406-3413.	0.4	54
1388	Urokinase Induces Expression of Its Own Receptor in Beas2B Lung Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 24549-24556.	1.6	43
1389	Regulation of extravascular coagulation and fibrinolysis by heparinâ€“dependent mast cell chymase. <i>FASEB Journal</i> , 2001, 15, 1-25.	0.2	37
1390	Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling Pathways. <i>Journal of Biological Chemistry</i> , 2001, 276, 2015-2022.	1.6	65
1391	Cutting Edge: Antigen-Driven Lymphocyte Recruitment to the Lung Is Diminished in the Absence of Urokinase-type Plasminogen Activator (uPA) Receptor, but Is Independent of uPA. <i>Journal of Immunology</i> , 2001, 167, 5539-5542.	0.4	41
1392	Identification of a Target Site in Plasminogen Activator Inhibitor-1 That Allows Neutralization of Its Inhibitory Properties Concomitant with an Allosteric Up-regulation of Its Antiadhesive Properties. <i>Journal of Biological Chemistry</i> , 2001, 276, 26243-26248.	1.6	23
1393	Fibrin Turnover in Lung Inflammation and Neoplasia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 578-584.	2.5	57
1394	Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. <i>British Journal of Ophthalmology</i> , 2001, 85, 6-10.	2.1	116
1395	Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8862-8867.	3.3	61
1396	Anti-plasmin Activity of a Peptide That Binds to the Receptor-binding Site of Angiogenin. <i>Journal of Biological Chemistry</i> , 2002, 277, 9690-9694.	1.6	15

#	ARTICLE	IF	CITATIONS
1397	Collagen Dissolution by Keratinocytes Requires Cell Surface Plasminogen Activation and Matrix Metalloproteinase Activity. <i>Journal of Biological Chemistry</i> , 2002, 277, 45154-45161.	1.6	70
1398	Urokinase-Type Plasminogen Activator Is Required for the Generation of a Type 1 Immune Response to Pulmonary <i>Cryptococcus neoformans</i> Infection. <i>Journal of Immunology</i> , 2002, 168, 801-809.	0.4	60
1399	Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow. <i>Journal of Clinical Oncology</i> , 2002, 20, 2005-2016.	0.8	73
1400	Post-Transcriptional Regulation of Gene Expression in the Plasminogen Activation System. <i>Biological Chemistry</i> , 2002, 383, 47-53.	1.2	16
1401	Comparison of the inhibitory effects of two types (90 kDa and 190 kDa) of hyaluronic acid on the expression of fibrinolytic factors in human synovial fibroblasts. <i>Modern Rheumatology</i> , 2002, 12, 160-166.	0.9	5
1402	The Urokinase Plasminogen Activator Receptor in the Regulation of the Actin Cytoskeleton and Cell Motility. <i>Biological Chemistry</i> , 2002, 383, 5-19.	1.2	94
1403	Pituitary Adenylate Cyclase-Activating Polypeptide Modulates Plasminogen Activator Expression in Rat Granulosa Cell1. <i>Biology of Reproduction</i> , 2002, 66, 830-835.	1.2	22
1404	Phosphatidylinositol 3-Kinase and NF- $\kappa$ B Regulate Motility of Invasive MDA-MB-231 Human Breast Cancer Cells by the Secretion of Urokinase-type Plasminogen Activator. <i>Journal of Biological Chemistry</i> , 2002, 277, 3150-3157.	1.6	122
1405	Identification of the Disulfide Bonds in the Recombinant Somatomedin B Domain of Human Vitronectin. <i>Journal of Biological Chemistry</i> , 2002, 277, 27109-27119.	1.6	25
1406	Prometastatic Effect of N-Acetylglucosaminyltransferase V Is Due to Modification and Stabilization of Active Matriptase by Adding $\beta$ 1-6 GlcNAc Branching. <i>Journal of Biological Chemistry</i> , 2002, 277, 16960-16967.	1.6	167
1407	Heparanase and Platelet Factor-4 Induce Smooth Muscle Cell Proliferation and Migration via bFGF Release from the ECM. <i>Journal of Biochemistry</i> , 2002, 131, 913-922.	0.9	39
1408	The Fibrinolytic Defect in Adult Respiratory Distress Syndrome: A New Therapeutic Opportunity?. <i>Clinical Pulmonary Medicine</i> , 2002, 9, 13-19.	0.3	1
1409	PAI-1 Promoter Polymorphism Modulates uPA-PAI Complex Accumulation by Breast Cancer Cells. <i>Oncology</i> , 2002, 62, 286-290.	0.9	16
1410	The Role of Proteases in Fibronectin Matrix Remodeling in Thyroid Epithelial Cell Monolayer Cultures. <i>Biological Chemistry</i> , 2002, 383, 167-76.	1.2	7
1411	Expression of proteinases and inhibitors in human breast cancer progression and survival. <i>Journal of Clinical Pathology</i> , 2002, 55, 300-304.	2.1	67
1412	The Molecular Basis for Anti-Proteolytic and Non-Proteolytic Functions of Plasminogen Activator Inhibitor Type-1: Roles of the Reactive Centre Loop, the Shutter Region, the Flexible Joint Region and the Small Serpin Fragment. <i>Biological Chemistry</i> , 2002, 383, 21-36.	1.2	67
1413	The PKA Phosphorylation of Vitronectin: Effect on Conformation and Function. <i>Archives of Biochemistry and Biophysics</i> , 2002, 397, 246-252.	1.4	10
1414	Protein Kinase C Induces Motility of Breast Cancers by Upregulating Secretion of Urokinase-Type Plasminogen Activator through Activation of AP-1 and NF- $\kappa$ B. <i>Biochemical and Biophysical Research Communications</i> , 2002, 290, 552-557.	1.0	82

#	ARTICLE	IF	CITATIONS
1415	Prognostic Value of the Urokinase-Type Plasminogen Activator, and its Inhibitors and Receptor in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2002, 3, 138-146.	1.1	30
1416	Differential Regulation of Fibronectin Fibrillogenesis by Protein Kinases A and C. <i>Connective Tissue Research</i> , 2002, 43, 22-31.	1.1	14
1417	Structure and function of human sweat glands studied with histochemistry and cytochemistry. <i>Progress in Histochemistry and Cytochemistry</i> , 2002, 37, 323-386.	5.1	161
1418	Plasminogen activator activity in cortical granules of bovine oocytes during in vitro maturation. <i>Theriogenology</i> , 2002, 57, 1897-1905.	0.9	17
1419	Inhibitors of Plasmin that Extend into Both the S and S <sup>+</sup> Binding Sites: Cooperative Interactions between S1 and S2. <i>Journal of Organic Chemistry</i> , 2002, 67, 1184-1191.	1.7	12
1420	Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. <i>Gastroenterology</i> , 2002, 122, 806-819.	0.6	61
1421	Prognostic Significance of Tissue-Type Plasminogen Activator (tPA) Content in Gastric Cancer and Surrounding Mucosa. <i>International Journal of Biological Markers</i> , 2002, 17, 169-176.	0.7	6
1422	Relationship of Coagulation Test Abnormalities to Tumour Burden and Postoperative DVT in Resected Colorectal Cancer. <i>Thrombosis and Haemostasis</i> , 2002, 87, 402-408.	1.8	60
1423	Urokinase induces its own expression in Beas2B lung epithelial cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002, 283, L319-L328.	1.3	22
1424	EVALUATION OF EXTRACELLULAR MATRIX PROTEINS AND TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES-2 ON BOVINE INNER CELL MASS OUTGROWTH IN VITRO. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2002, 38, 41.	0.7	5
1425	Urokinase is required for the formation of mactinin, an $\alpha$ -actinin fragment that promotes monocyte/macrophage maturation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1591, 99-107.	1.9	16
1426	An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. <i>Journal of Immunological Methods</i> , 2002, 268, 219-231.	0.6	36
1427	A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picoyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis. <i>Biochemical Pharmacology</i> , 2002, 63, 1315-1323.	2.0	14
1428	Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2002, 39, 695-705.	2.1	49
1429	Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. <i>Cancer Detection and Prevention</i> , 2002, 26, 42-49.	2.1	58
1430	Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2268-2279.	6.7	102
1431	Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. <i>International Journal of Cancer</i> , 2002, 100, 501-506.	2.3	31
1432	Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. <i>Journal of Cellular Physiology</i> , 2002, 193, 340-348.	2.0	47



#	ARTICLE	IF	CITATIONS
1433	2,3,7,8-Tetrachlorodibenzo- p -dioxin (TCDD) induces plasminogen activator inhibitor-1 through an aryl hydrocarbon receptor-mediated pathway in mouse hepatoma cell lines. Archives of Toxicology, 2002, 76, 404-413.	1.9	30
1434	Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urological Research, 2002, 30, 301-309.	1.5	35
1435	Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells. Acta Obstetricia Et Gynecologica Scandinavica, 2002, 81, 389-397.	1.3	8
1436	Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. Apmis, 2002, 110, 630-638.	0.9	14
1437	Cytokine-induced expression of tPA is differentially modulated by NO and ROS in rat mesangial cells. Kidney International, 2002, 61, 20-30.	2.6	33
1438	Mechanisms of dexamethasone-mediated inhibition of cAMP-induced tPA expression in rat mesangial cells. Kidney International, 2002, 62, 809-821.	2.6	12
1439	Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. FEBS Journal, 2002, 269, 3945-3957.	0.2	41
1440	Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate, 2002, 51, 35-41.	1.2	40
1441	Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages. Oncogene, 2002, 21, 8830-8842.	2.6	24
1442	Expression and Functional Characterization of the Serine Protease Inhibitor Neuroserpin in Endocrine Cells. Annals of the New York Academy of Sciences, 2002, 971, 406-415.	1.8	15
1443	Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clinical and Experimental Metastasis, 2002, 19, 193-207.	1.7	94
1444	Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells. Journal of Neuro-Oncology, 2002, 59, 193-198.	1.4	5
1445	Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clinical and Experimental Metastasis, 2002, 19, 527-534.	1.7	50
1446	Localization of plasminogen in the extracellular matrix of hamster eggs: Exogenous activation by streptokinase. Molecular Reproduction and Development, 2002, 61, 528-535.	1.0	9
1447	Involvement of TGF- $\beta$ 2s/T $\beta$ 2Rs System in Tumor Progression of Murine Mammary Adenocarcinomas. Breast Cancer Research and Treatment, 2003, 80, 287-301.	1.1	7
1448	Expression of Urokinase-Type Plasminogen Activator and Its Receptor in Gastric Fibroblasts and Effects of Nonsteroidal Antiinflammatory Drugs and Prostaglandin. Digestive Diseases and Sciences, 2003, 48, 2247-2256.	1.1	16
1449	Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer. Gastric Cancer, 2003, 6, 30-38.	2.7	48
1450	Proteases in brain tumour progression. Acta Neurochirurgica, 2003, 145, 825-838.	0.9	141

#	ARTICLE	IF	CITATIONS
1451	Blood coagulation. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2003, 17, 369-383.	1.4	74
1452	Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies. Gynecologic Oncology, 2003, 90, 435-442.	0.6	11
1453	Tumor cytosol dipeptidyl peptidase III activity is increased with histological aggressiveness of ovarian primary carcinomas. Gynecologic Oncology, 2003, 91, 194-200.	0.6	49
1454	Urokinase Receptor is Up-regulated in Endothelial Cells and Macrophages Associated with Fibrinoid Deposits in the Human Placenta. Placenta, 2003, 24, 677-685.	0.7	17
1455	Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma. Cancer, 2003, 98, 66-73.	2.0	120
1456	Stromelysin-3 expression is an early event in human oral tumorigenesis. International Journal of Cancer, 2003, 107, 309-316.	2.3	50
1457	Plasminogen mediates liver regeneration and angiogenesis after experimental partial hepatectomy. British Journal of Surgery, 2003, 90, 1384-1390.	0.1	34
1458	Induction of the acrosome reaction in bull spermatozoa with plasmin. Andrologia, 2003, 35, 112-116.	1.0	15
1459	Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Science, 2003, 94, 43-49.	1.7	122
1460	Distortion of autocrine transforming growth factor $\beta$ 2 signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells. Oncogene, 2003, 22, 2309-2321.	2.6	40
1461	Molecular mechanisms of glioma invasiveness: the role of proteases. Nature Reviews Cancer, 2003, 3, 489-501.	12.8	772
1462	Polymorphonuclear proteolytic activity and milk composition change. Veterinary Research, 2003, 34, 629-645.	1.1	102
1463	Modulation of the expression of tissue plasminogen activator and its inhibitor by hypoxia in human peritoneal and adhesion fibroblasts. Fertility and Sterility, 2003, 79, 164-168.	0.5	82
1464	Invasion and metastasis in pancreatic cancer. Molecular Cancer, 2003, 2, 14.	7.9	181
1465	Proteolysis in Carcinogenesis. , 2003, , 137-149.		4
1466	The Myofibroblast Is the Predominant Plasminogen Activator Inhibitor-1-Expressing Cell Type in Human Breast Carcinomas. American Journal of Pathology, 2003, 163, 1887-1899.	1.9	63
1467	Abnormal expression of matrix metalloproteinase-2 and -9 in interspecific pregnancy of rat embryos in mouse recipients. Theriogenology, 2003, 60, 1279-1291.	0.9	6
1468	Homocysteine inhibits the proliferation and invasive potential of HT-1080 human fibrosarcoma cells. Biochemical and Biophysical Research Communications, 2003, 301, 540-544.	1.0	13

#	ARTICLE	IF	CITATIONS
1469	Vitronectin in human breast carcinomas. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2003, 1638, 72-82.	1.8	37
1470	The role of the plasminogen activation cascade in glioma cell invasion: a review. <i>Journal of Clinical Neuroscience</i> , 2003, 10, 139-145.	0.8	15
1471	Cell-surface cathepsin B: Understanding its functional significance. <i>Current Topics in Developmental Biology</i> , 2003, 54, 313-341.	1.0	52
1472	C766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancer. <i>Breast Cancer Research</i> , 2003, 5, R77-81.	2.2	35
1473	Functional Effect of Contortrostatin, a Snake Venom Disintegrin, on Human Glioma Cell Invasion In Vitro. <i>Cell Communication and Adhesion</i> , 2003, 10, 1-16.	1.0	18
1474	p11 Regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. <i>FASEB Journal</i> , 2003, 17, 235-246.	0.2	68
1475	PCR-RFLP Detection of PAI-2 Variants in Myocardial Infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 333-336.	0.7	14
1476	Syk, a Protein-tyrosine Kinase, Suppresses the Cell Motility and Nuclear Factor $\kappa$ B-mediated Secretion of Urokinase Type Plasminogen Activator by Inhibiting the Phosphatidylinositol 3 $\alpha$ -Kinase Activity in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 6209-6221.	1.6	66
1477	Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration. <i>Science Signaling</i> , 2003, 2003, pe24-pe24.	1.6	36
1478	Type II transmembrane serine proteases. <i>Thrombosis and Haemostasis</i> , 2003, 90, 185-193.	1.8	100
1479	Quantification of Elastase-Like Activity in 13 Human Cancer Cell Lines and in an Immortalized Human Epithelial Cell Line by RP-HPLC. <i>Biological Chemistry</i> , 2003, 384, 817-24.	1.2	8
1480	Epidermal Growth Factor Receptor-dependent and -independent Cell-signaling Pathways Originating from the Urokinase Receptor. <i>Journal of Biological Chemistry</i> , 2003, 278, 1642-1646.	1.6	116
1481	New Insights into the tPA-Annexin A2 Interaction. <i>Journal of Biological Chemistry</i> , 2003, 278, 5702-5709.	1.6	29
1482	Human Mast Cell $\beta$ -Tryptase Is a Gelatinase. <i>Journal of Immunology</i> , 2003, 171, 1493-1499.	0.4	72
1483	Induction of Plasminogen Activator Inhibitor-1 by Urokinase in Lung Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 18124-18131.	1.6	29
1484	Plasminogen activation at the cell surface. <i>Current Topics in Developmental Biology</i> , 2003, 54, 263-312.	1.0	36
1485	Expression and Regulation of Plasminogen Activators, Plasminogen Activator Inhibitor Type-1, and Steroidogenic Acute Regulatory Protein in the Rhesus Monkey Corpus Luteum. <i>Endocrinology</i> , 2003, 144, 3611-3617.	1.4	15
1486	Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling. <i>Current Pharmaceutical Design</i> , 2003, 9, 1545-1564.	0.9	155

#	ARTICLE	IF	CITATIONS
1487	Targeted Alpha Therapy of Prostate Cancer. , 2003, 81, 333-358.		1
1488	Multiple effects of $\alpha_1$ -antitrypsin on breast carcinoma MDA-MB 468 cell growth and invasiveness. European Journal of Cancer Prevention, 2003, 12, 117-124.	0.6	19
1489	Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis. Blood Coagulation and Fibrinolysis, 2003, 14, 369-377.	0.5	12
1490	Urokinase Plasminogen Activator System. Clinical Orthopaedics and Related Research, 2003, 415, S46-S58.	0.7	137
1491	Expression of Urokinase-type Plasminogen Activator and Its Receptor in Keloids. JAMA Otolaryngology, 2003, 129, 1334.	1.5	13
1492	Inhibitory Effects of Progesterone on Plasma Membrane Fluidity and Tumorigenic Potential of Ovarian Epithelial Cancer Cells. Experimental Biology and Medicine, 2003, 228, 308-314.	1.1	29
1493	Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. Blood, 2003, 102, 1723-1731.	0.6	57
1494	The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochemical Journal, 2003, 371, 277-287.	1.7	40
1495	Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thrombosis and Haemostasis, 2003, 90, 206-217.	1.8	46
1496	Plasminogen binding and cancer promises and pitfalls. Frontiers in Bioscience - Landmark, 2003, 8, s294-304.	3.0	56
1497	Inhibition of Retinal Neovascularization by Intravitreal Injection of Human rPAI-1 in a Rat Model of Retinopathy of Prematurity. , 2003, 44, 5423.		37
1498	Absence of Tissue Plasminogen Activator Gene or Activity Impairs Mouse Cerebellar Motor Learning. Journal of Neuroscience, 2003, 23, 7368-7375.	1.7	95
1499	The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer. Thrombosis and Haemostasis, 2004, 91, 514-521.	1.8	12
1500	Inhibition of Choroidal Neovascularization in Rats by the Urokinase-Derived Peptide A156. , 2004, 45, 635.		22
1501	Urokinase Receptor mRNA Stability Involves Tyrosine Phosphorylation in Lung Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 69-75.	1.4	16
1502	Regulation of Urokinase Receptor Expression by Phosphoglycerate Kinase. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 100-106.	1.4	35
1503	Aberrant tetranectin expression in human breast carcinomas as a predictor of survival. Journal of Clinical Pathology, 2004, 57, 417-421.	1.0	29
1504	Size, shape, structure, and direction of angiogenesis in laryngeal tumour development. Journal of Clinical Pathology, 2004, 57, 394-401.	1.0	39

#	ARTICLE	IF	CITATIONS
1505	Tumor Necrosis Factor- $\alpha$ -Induced Matrix Proteolytic Enzyme Production and Basement Membrane Remodeling by Human Ovarian Surface Epithelial Cells. <i>Cancer Research</i> , 2004, 64, 1534-1540.	0.4	59
1506	Leading-Edge Myfibroblasts in Human Colon Cancer Express Plasminogen Activator Inhibitor-1. <i>American Journal of Clinical Pathology</i> , 2004, 122, 256-265.	0.4	32
1507	Predictive Impact of Urokinase-Type Plasminogen Activator. <i>Cancer Research</i> , 2004, 64, 659-664.	0.4	41
1508	The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/ Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. <i>Biological Chemistry</i> , 2004, 385, 103-36.	1.2	86
1509	Urokinase-Deficient Mice Fail To Generate a Type 2 Immune Response following Schistosomal Antigen Challenge. <i>Infection and Immunity</i> , 2004, 72, 461-467.	1.0	34
1510	In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue. <i>Molecular Human Reproduction</i> , 2004, 10, 159-166.	1.3	31
1511	Low density lipoprotein receptor-related protein: regulation of the plasma membrane proteome. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1056-1064.	1.8	64
1512	Relationship between Urokinase-Type Plasminogen Receptor, Interleukin-8 Gene Expression and Clinicopathological Features in Gastric Cancer. <i>Oncology</i> , 2004, 66, 210-217.	0.9	45
1513	Gabexate Mesilate Inhibits Colon Cancer Growth, Invasion, and Metastasis by Reducing Matrix Metalloproteinases and Angiogenesis. <i>Clinical Cancer Research</i> , 2004, 10, 4517-4526.	3.2	44
1514	Plasminogen Is Tethered with High Affinity to the Cell Surface by the Plasma Protein, Histidine-rich Glycoprotein. <i>Journal of Biological Chemistry</i> , 2004, 279, 38267-38276.	1.6	43
1515	Osteopontin Induces AP-1-mediated Secretion of Urokinase-type Plasminogen Activator through c-Src-dependent Epidermal Growth Factor Receptor Transactivation in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 11051-11064.	1.6	93
1516	A prognostic index for operable, node-negative breast cancer. <i>British Journal of Cancer</i> , 2004, 90, 1933-1941.	2.9	18
1517	Intraocular Properties of Urokinase-Derived Antiangiogenic $\alpha$ -6 Peptide in Rabbits. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2004, 20, 439-449.	0.6	9
1518	Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro. <i>Journal of Leukocyte Biology</i> , 2004, 76, 648-656.	1.5	41
1519	Plasminogen interaction and activation on <i>Streptococcus mutans</i> surface. <i>Oral Microbiology and Immunology</i> , 2004, 19, 257-261.	2.8	3
1520	Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 769-779.	1.9	19
1521	Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients. <i>Journal of Clinical Periodontology</i> , 2004, 31, 556-561.	2.3	17
1522	Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin. <i>Journal of Periodontal Research</i> , 2004, 39, 380-387.	1.4	41

#	ARTICLE	IF	CITATIONS
1523	Soluble urokinase plasminogen activator receptor in blood transfusion components. <i>Transfusion Medicine</i> , 2004, 14, 305-312.	0.5	4
1524	Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. <i>Oral Oncology</i> , 2004, 40, 1026-1032.	0.8	20
1525	Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. <i>Gynecologic Oncology</i> , 2004, 92, 80-88.	0.6	28
1526	NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. <i>Journal of the American College of Surgeons</i> , 2004, 199, 428-435.	0.2	19
1527	Metastasis Markers in Bladder Cancer: A Review of the Literature and Clinical Considerations. <i>European Urology</i> , 2004, 46, 296-311.	0.9	66
1528	Activity of an enzyme converting single-chain tissue-type plasminogen activator to the two-chain form in preovulatory human follicular fluid. <i>Molecular Reproduction and Development</i> , 2004, 67, 178-185.	1.0	6
1529	Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. <i>Clinical and Experimental Metastasis</i> , 2004, 21, 339-346.	1.7	17
1530	Expression profiles of fibrinolytic components in nasal mucosa. <i>Histochemistry and Cell Biology</i> , 2004, 122, 61-73.	0.8	18
1533	Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas. <i>Acta Neurochirurgica</i> , 2004, 146, 111-118.	0.9	6
1534	Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma. <i>Cancer</i> , 2004, 100, 2387-2395.	2.0	11
1535	Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. <i>Cancer</i> , 2004, 101, 486-494.	2.0	35
1536	3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 2797-2805.	1.4	22
1537	Composition et physiopathologie du liquide sous-rétinien dans les décollements de rétine rhéomatogènes. <i>EMC - Ophtalmologie</i> , 2004, 1, 2-17.	0.0	0
1538	The structure-activity relationship of various YO compounds, novel plasmin inhibitors, in the apoptosis induction. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2004, 1674, 291-298.	1.1	6
1539	Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. <i>Experimental Cell Research</i> , 2004, 294, 550-558.	1.2	58
1540	Subretinal fluid in primary rhegmatogenous retinal detachment: physiopathology and composition. <i>Survey of Ophthalmology</i> , 2004, 49, 96-108.	1.7	104
1541	Effect of plasmin on movement characteristics of ejaculated bull spermatozoa. <i>Theriogenology</i> , 2004, 62, 553-561.	0.9	13
1542	Tissue Plasminogen Activator in Murine Exocrine Pancreas Cancer. <i>American Journal of Pathology</i> , 2004, 165, 1129-1139.	1.9	31

#	ARTICLE	IF	CITATIONS
1543	Involvement of the plasminogen activation system in cow endometritis. <i>Theriogenology</i> , 2004, 61, 337-349.	0.9	15
1544	Differences in the implantation rates of rat embryos developed in vivo and in vitro: possible role for plasminogen activators. <i>Fertility and Sterility</i> , 2004, 81, 780-785.	0.5	36
1545	The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. <i>Blood</i> , 2004, 103, 1069-1077.	0.6	57
1546	Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis. <i>Thrombosis and Haemostasis</i> , 2004, 91, 438-449.	1.8	152
1547	Zymographic Evaluation of Plasminogen Activators and Plasminogen Activator Inhibitors. <i>Advances in Clinical Chemistry</i> , 2004, 38, 111-133.	1.8	3
1548	PVD FOLLOWING PLASMIN BUT NOT HYALURONIDASE: Implications for Combination Pharmacologic Vitreolysis Therapy. <i>Retina</i> , 2005, 25, 38-43.	1.0	67
1549	Update on the Use of Fibrinolytics in Pleural Disease. <i>Clinical Pulmonary Medicine</i> , 2005, 12, 184-190.	0.3	14
1550	Role and Regulation of Proteases in Human Glioma. , 2005, , 151-177.		3
1551	Procedures for the Quantitative Protein Determination of Urokinase and Its Inhibitor, PAI-1, in Human Breast Cancer Tissue Extracts by ELISA. , 2006, 120, 245-266.		24
1552	3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 2773-2782.	1.4	25
1553	Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 93-98.	1.0	23
1554	Are alterations in plasma protease concentrations during labor associated with poor obstetric outcomes?. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 283-288.	0.7	0
1555	Plasminogen activator system in smokers and non-smokers with and without periodontal disease. <i>Journal of Clinical Periodontology</i> , 2005, 32, 417-424.	2.3	26
1556	Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. <i>Journal of Cellular and Molecular Medicine</i> , 2005, 9, 704-713.	1.6	55
1557	In vitro decreases of the fibrinolytic potential of cultured human fibrosarcoma cell line, HT1080, by <i>Nigella sativa</i> oil. <i>Phytomedicine</i> , 2005, 12, 100-107.	2.3	36
1558	Transcriptional expression of the genes implicated in angiogenesis and tumor invasion in cervical carcinomas. <i>Gynecologic Oncology</i> , 2005, 98, 453-461.	0.6	19
1559	Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. <i>International Journal of Cancer</i> , 2005, 113, 870-880.	2.3	67
1560	Reduced human peritoneal plasminogen activating activity: Possible mechanism of adhesion formation. <i>British Journal of Surgery</i> , 2005, 76, 382-384.	0.1	132

#	ARTICLE	IF	CITATIONS
1561	Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers. <i>British Journal of Surgery</i> , 2005, 80, 596-599.	0.1	39
1562	Plasminogen activators in oesophageal carcinoma. <i>British Journal of Surgery</i> , 2005, 83, 1152-1155.	0.1	17
1563	Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2005, 20, 245-252.	1.0	68
1564	Studies on mRNA expression of tissue-type plasminogen activator in bruises for wound age estimation. <i>International Journal of Legal Medicine</i> , 2005, 119, 16-21.	1.2	46
1565	Expression of the constitutively activated RelA/NF- $\kappa$ B in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion. <i>Brain Tumor Pathology</i> , 2005, 22, 79-87.	1.1	28
1566	Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells. <i>Molecular and Cellular Biochemistry</i> , 2005, 272, 107-118.	1.4	68
1567	Tissue-Type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 33-40.	1.1	20
1568	Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. <i>Cancer Cell International</i> , 2005, 5, 1.	1.8	69
1569	Plasminogen activation and cancer. <i>Thrombosis and Haemostasis</i> , 2005, 93, 676-681.	1.8	398
1570	The nine residue plasminogen-binding motif of the pneumococcal enolase is the major cofactor of plasmin-mediated degradation of extracellular matrix, dissolution of fibrin and transmigration. <i>Thrombosis and Haemostasis</i> , 2005, 94, 304-11.	1.8	117
1571	S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 300.	3.0	153
1572	A Urokinase-type Plasminogen Activator-inhibiting Cyclic Peptide with an Unusual P2 Residue and an Extended Protease Binding Surface Demonstrates New Modalities for Enzyme Inhibition. <i>Journal of Biological Chemistry</i> , 2005, 280, 38424-38437.	1.6	47
1573	Regulation of urokinase receptor expression by phosphoglycerate kinase is independent of its catalytic activity. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2005, 289, L591-L598.	1.3	14
1574	Protection of Plasminogen Activator Inhibitor-1-Deficient Mice from Nasal Allergy. <i>Journal of Immunology</i> , 2005, 174, 8135-8143.	0.4	43
1575	Suppression of Urokinase Receptor Expression by Thalidomide Is Associated with Inhibition of Nuclear Factor $\kappa$ B Activation and Subsequently Suppressed Ovarian Cancer Dissemination. <i>Cancer Research</i> , 2005, 65, 10464-10471.	0.4	17
1576	JNK1 Differentially Regulates Osteopontin-induced Nuclear Factor-inducing Kinase/MEKK1-dependent Activating Protein-1-mediated Promatrix Metalloproteinase-9 Activation. <i>Journal of Biological Chemistry</i> , 2005, 280, 19381-19392.	1.6	42
1577	Clinical Significance of Human Kallikrein Gene 6 Messenger RNA Expression in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2889-2893.	3.2	99
1578	Plasminogen activators promote excitotoxicity-induced retinal damage. <i>FASEB Journal</i> , 2005, 19, 1280-1289.	0.2	43



#	ARTICLE	IF	CITATIONS
1579	Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. <i>Carcinogenesis</i> , 2005, 26, 1233-1240.	1.3	41
1580	Breast Cancer Metastasis Suppressor 1 Inhibits Gene Expression by Targeting Nuclear Factor- $\kappa$ B Activity. <i>Cancer Research</i> , 2005, 65, 3586-3595.	0.4	108
1581	Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. <i>Journal of Cell Biology</i> , 2005, 169, 977-985.	2.3	127
1582	Regulation of Protease and Protease Inhibitor Gene Expression: The Role of the 3' UTR and Lessons from the Plasminogen Activating System. <i>Progress in Molecular Biology and Translational Science</i> , 2005, 80, 169-215.	1.9	0
1583	MATHEMATICAL MODELLING OF CANCER CELL INVASION OF TISSUE: THE ROLE OF THE UROKINASE PLASMINOGEN ACTIVATION SYSTEM. <i>Mathematical Models and Methods in Applied Sciences</i> , 2005, 15, 1685-1734.	1.7	245
1584	Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers. <i>Clinical Cancer Research</i> , 2005, 11, 8538-8548.	3.2	28
1585	Induction of p53 by Urokinase in Lung Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 28133-28141.	1.6	21
1586	1,25-dihydroxyvitamin D <sub>3</sub> inhibits prostate cancer cell invasion via modulation of selective proteases. <i>Carcinogenesis</i> , 2005, 27, 32-42.	1.3	103
1587	Downregulation of Human Kallikrein 10 (KLK10/NES1) by CpG Island Hypermethylation in Breast, Ovarian and Prostate Cancers. <i>Tumor Biology</i> , 2005, 26, 324-336.	0.8	59
1588	Basal release of urokinase plasminogen activator, plasminogen activator inhibitor-1, and soluble plasminogen activator receptor from separated and cultured endometriotic and endometrial stromal and epithelial cells. <i>Fertility and Sterility</i> , 2005, 83, 1155-1160.	0.5	21
1589	Proliferative effects of apical, but not basal, matrix metalloproteinase-7 activity in polarized MDCK cells. <i>Experimental Cell Research</i> , 2005, 303, 308-320.	1.2	27
1590	Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: A key phenomenon for cell invasion. <i>Experimental Cell Research</i> , 2005, 308, 479-490.	1.2	15
1591	Expression of tissue plasminogen activator during eye development. <i>Experimental Eye Research</i> , 2005, 81, 90-96.	1.2	9
1592	Plasminogen activator activity in the porcine oviduct during the oestrous cycle. <i>Theriogenology</i> , 2005, 64, 1007-1015.	0.9	12
1593	Expression of plasminogen activators in preimplantation rat embryos developed in vivo and in vitro. <i>Reproductive Biology and Endocrinology</i> , 2005, 3, 7.	1.4	22
1594	Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 783-793.	0.6	36
1595	Biomarqueurs tissulaires tumoraux. <i>Cancer du sein. Facteurs pronostiques, facteurs pronostiques</i> . Quels standards en 2005 ?. , 2006, , 83-130.		0
1596	Abnormalities in the Fibrinolytic System of the Vascular Wall Associated with Atherosclerosis. <i>Annals of the New York Academy of Sciences</i> , 1994, 748, 177-183.	1.8	16

#	ARTICLE	IF	CITATIONS
1597	Biological Effects of Disruption of the Tissueâ€”Type Plasminogen Activator, Urokinaseâ€”Type Plasminogen Activator, and Plasminogen Activator Inhibitorâ€”1 Genes in Mice<sup>a</sup>. Annals of the New York Academy of Sciences, 1994, 748, 367-381.	1.8	59
1598	The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: Relation to prognosis. Lung Cancer, 2006, 51, 193-200.	0.9	26
1599	Effects of plasmin on spermâ€”oocyte interactions during in vitro fertilization in the pig. Animal Reproduction Science, 2006, 95, 273-282.	0.5	6
1600	The emerging role of proteases in retinal ganglion cell death. Experimental Eye Research, 2006, 82, 5-12.	1.2	29
1601	Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPÎ±). Biochemical and Biophysical Research Communications, 2006, 346, 436-446.	1.0	31
1602	Molecular regulation of an invasion-related molecule â€” options for tumour staging and clinical strategies. European Journal of Cancer, 2006, 42, 811-819.	1.3	17
1603	Urokinase plasminogen activator and TGF-Î² production in immunosuppressed patients with and without P. Jiroveci infection. Microbial Pathogenesis, 2006, 41, 1-9.	1.3	3
1604	A clinical study of plasminogen activator activity in gingival tissue in dogs with gingivitis and periodontitis. Research in Veterinary Science, 2006, 80, 189-193.	0.9	8
1605	Production and purification of urokinase: A comprehensive review. Protein Expression and Purification, 2006, 45, 1-14.	0.6	19
1606	Is the Urokinase-type Plasminogen Activator System a Reliable Prognostic Factor in Gastric Cancer?. International Journal of Biological Markers, 2006, 21, 162-169.	0.7	12
1607	Pre-Treatment Prediction of Chemoresistance in Second-Line Chemotherapy of Ovarian Carcinoma: Value of Serological Tumor Marker Determination (Tetranectin, YKL-40, CASA, CA 125). International Journal of Biological Markers, 2006, 21, 141-148.	0.7	17
1608	Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinaseâ€”Aktâ€”necrosis factor kappa B signaling cascade in human melanoma cells. Melanoma Research, 2006, 16, 445-452.	0.6	14
1610	Lack of alpha2-antiplasmin improves cutaneous wound healing via over-released vascular endothelial growth factor-induced angiogenesis in wound lesions. Journal of Thrombosis and Haemostasis, 2006, 4, 1602-1610.	1.9	42
1611	Plasminogen activators and their inhibitors in human saliva and salivary gland tissue. European Journal of Oral Sciences, 2006, 114, 22-26.	0.7	15
1612	Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO Journal, 2006, 25, 2686-2697.	3.5	120
1613	Epidermal Development and Wound Healing in Matrix Metalloproteinase 13-Deficient Mice. Journal of Investigative Dermatology, 2006, 126, 486-496.	0.3	81
1614	Evaluation of t-PA, PAI-2, IL-1Î² and PGE2 in gingival crevicular fluid of rheumatoid arthritis patients with periodontal disease. Journal of Clinical Periodontology, 2006, 33, 605-611.	2.3	52
1615	Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: The influence of the ester group on their biological activity. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2886-2890.	1.0	43

#	ARTICLE	IF	CITATIONS
1616	Plasminogen Activator Inhibitor-1 Promoter Polymorphism is Not Associated With the Aggressiveness of Disease in Prostate Cancer. <i>Clinical Oncology</i> , 2006, 18, 333-337.	0.6	4
1617	Expression and Clinical Signification of Cytosolic Hyaluronan Levels in Invasive Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 97, 329-337.	1.1	17
1618	Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 601-609.	1.0	20
1619	Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression. <i>Experimental and Molecular Pathology</i> , 2006, 81, 146-156.	0.9	199
1620	Suppression of tumor growth and invasion in 9,10 dimethyl benz(a) anthracene induced mammary carcinoma by the plant bioflavonoid quercetin. <i>Chemico-Biological Interactions</i> , 2006, 162, 106-113.	1.7	40
1621	Urokinase-immobilization suppresses inflammatory responses to polyurethane tubes implanted in rabbit muscles. <i>Journal of Biomedical Materials Research - Part A</i> , 2006, 76A, 81-85.	2.1	11
1622	Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin $\beta$ -2 chain is an early coordinated event in incipient oral squamous cell carcinoma. <i>International Journal of Cancer</i> , 2006, 118, 2948-2956.	2.3	68
1623	Regional variations of urokinase-type plasminogen activator in human colorectal cancer: A quantitative study by image analysis. <i>International Journal of Cancer</i> , 1995, 60, 308-314.	2.3	16
1624	Matrix Proteinases. , 2006, , 181-198.		0
1625	Urokinase induces activation of STAT3 in lung epithelial cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2006, 291, L772-L780.	1.3	21
1626	Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and $\beta$ 2 integrin. <i>Journal of Cell Science</i> , 2006, 119, 3424-3434.	1.2	59
1627	MMP-9 Is Differentially Expressed in Primary Human Colorectal Adenocarcinomas and Their Metastases. <i>Molecular Cancer Research</i> , 2006, 4, 293-302.	1.5	88
1628	Divergence in the Plasminogen-binding Group A Streptococcal M Protein Family. <i>Journal of Biological Chemistry</i> , 2006, 281, 3217-3226.	1.6	32
1629	The Maintenance of High Affinity Plasminogen Binding by Group A Streptococcal Plasminogen-binding M-like Protein Is Mediated by Arginine and Histidine Residues within the $\alpha$ 1 and $\alpha$ 2 Repeat Domains. <i>Journal of Biological Chemistry</i> , 2006, 281, 25965-25971.	1.6	43
1630	Evidence for a Matriptase-Prostasin Proteolytic Cascade Regulating Terminal Epidermal Differentiation. <i>Journal of Biological Chemistry</i> , 2006, 281, 32941-32945.	1.6	164
1631	Autosomal Ichthyosis with Hypotrichosis Syndrome Displays Low Matriptase Proteolytic Activity and Is Phenocopied in ST14 Hypomorphic Mice. <i>Journal of Biological Chemistry</i> , 2007, 282, 36714-36723.	1.6	92
1632	Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers. <i>Journal of Molecular Endocrinology</i> , 2007, 39, 375-384.	1.1	15
1633	Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer. <i>Acta Oncologica</i> , 2007, 46, 782-791.	0.8	3

#	ARTICLE	IF	CITATIONS
1634	A system-wide analysis of differentially expressed genes in ectopic and eutopic endometrium. <i>Human Reproduction</i> , 2007, 22, 2093-2102.	0.4	41
1635	Plasmin and Matrix Metalloproteinase System in Deep Venous Thrombosis Resolution. <i>Vascular</i> , 2007, 15, 366-371.	0.4	10
1636	The Plasminogen-Binding Group A Streptococcal M Protein-Related Protein Prp Binds Plasminogen via Arginine and Histidine Residues. <i>Journal of Bacteriology</i> , 2007, 189, 1435-1440.	1.0	71
1637	Pharmacologic and Genetic Manipulation of MMP-2 and -9 Affects Retinal Neovascularization in Rodent Models of OIR. , 2007, 48, 907.		47
1638	NKT Cell-Derived Urokinase-Type Plasminogen Activator Promotes Peripheral Tolerance Associated with Eye. <i>Journal of Immunology</i> , 2007, 179, 2215-2222.	0.4	21
1639	Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1123-1132.	3.2	46
1640	Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 550-558.	3.2	13
1641	Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1212-1220.	1.5	16
1642	Increased Th1/Th2 (IFN- $\gamma$ /IL-4) Cytokine mRNA Ratio of Rat Embryos in the Pregnant Mouse Uterus. <i>Journal of Reproduction and Development</i> , 2007, 53, 219-228.	0.5	19
1643	Possible role of the plasminogen activation system in human subfertility. <i>Fertility and Sterility</i> , 2007, 87, 619-626.	0.5	25
1644	Urokinase-type plasminogen activator. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 690-694.	1.2	109
1645	Plasminogen activator system in oral squamous cell carcinoma. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2007, 45, 623-627.	0.4	29
1646	Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. <i>Journal of Structural Biology</i> , 2007, 160, 1-10.	1.3	52
1647	Inhibition of the Urokinase-Type Plasminogen Activator by Triplex-Forming Oligonucleotides in Rat Sertoli Cells: A New Contraceptive Alternative?. <i>Oligonucleotides</i> , 2007, 17, 174-188.	2.7	3
1648	PEGylated DX-1000: Pharmacokinetics and Antineoplastic Activity of a Specific Plasmin Inhibitor. <i>Neoplasia</i> , 2007, 9, 927-937.	2.3	36
1649	Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. <i>Breast Cancer Research</i> , 2007, 9, R14.	2.2	60
1650	Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: Relation to prognosis and angiogenesis. <i>Lung Cancer</i> , 2007, 56, 43-50.	0.9	49
1651	The Plasminogen Activator System and Cancer. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2007, 36, 184-194.	0.5	131

#	ARTICLE	IF	CITATIONS
1652	EGF increases expression and activity of PAs in preimplantation rat embryos and their implantation rate. <i>Reproductive Biology and Endocrinology</i> , 2007, 5, 4.	1.4	26
1653	Effect of Immunization with the Mannose-Induced <i>Acanthamoeba</i> Protein and <i>Acanthamoeba</i> Plasminogen Activator in Mitigating <i>Acanthamoeba</i> Keratitis. , 2007, 48, 5597.		27
1654	Regulation of urokinase receptor expression by protein tyrosine phosphatases. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 292, L414-L421.	1.3	8
1656	Plasminogen activators in human gastric cancers: Correlation with DNA ploidy and immunohistochemical staining. <i>International Journal of Cancer</i> , 1991, 48, 20-27.	2.3	31
1657	Co-localization of the channel activating protease prostaticin/(CAP1/PRSS8) with its candidate activator, matriptase. <i>Journal of Cellular Physiology</i> , 2007, 213, 237-245.	2.0	83
1658	Recent insights into the causes of chronic leg ulceration in venous diseases and implications on other types of chronic wounds. <i>Wound Repair and Regeneration</i> , 2007, 15, 434-449.	1.5	99
1659	Effect of Norgestomet Treatment on Plasminogen Activator Activity in the Cervical Mucus and the Endometrium in Dairy Cows. <i>Transboundary and Emerging Diseases</i> , 2007, 54, 393-397.	0.6	4
1660	Effects of plasminogen, streptokinase, and their equimolar complexes with pyruvate kinase on the human neuroblastoma IMR-32 cells. <i>Cell and Tissue Biology</i> , 2007, 1, 412-419.	0.2	0
1661	Regulation of NF- $\kappa$ B Function. , 2007, , 239-262.		2
1662	Functional structure of the somatomedin B domain of vitronectin. <i>Protein Science</i> , 2007, 16, 1502-1508.	3.1	22
1663	Anti-angiogenic therapy for osteosarcoma. <i>Cancer and Metastasis Reviews</i> , 2007, 25, 707-713.	2.7	56
1664	The molecular basis of urokinase inhibition: from the nonempirical analysis of intermolecular interactions to the prediction of binding affinity. <i>Journal of Molecular Modeling</i> , 2007, 13, 677-683.	0.8	19
1665	Testosterone upregulation of tissue type plasminogen activator expression in Sertoli cells. <i>Endocrine</i> , 2007, 32, 83-89.	2.2	13
1666	The urokinase receptor and integrins in cancer progression. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 1916-1932.	2.4	67
1667	Mitogen-activated protein kinase regulates FSH-induced expression of tissue-type plasminogen activator through an activator protein 1 response element. <i>Endocrine</i> , 2008, 34, 101-107.	1.1	6
1668	Plasminogen expression in the neonatal and adult mouse brain. <i>Journal of Neurochemistry</i> , 2008, 77, 318-325.	2.1	5
1669	The Effects of Cyclooxygenase2 $\rightarrow$ ProstaglandinE2 Pathway on <i>Helicobacter pylori</i> -Induced Urokinase $\rightarrow$ Type Plasminogen Activator System in the Gastric Cancer Cells. <i>Helicobacter</i> , 2008, 13, 174-182.	1.6	28
1670	Stromal expression of urokinase $\rightarrow$ type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. <i>Liver</i> , 1998, 18, 414-419.	0.1	20

#	ARTICLE	IF	CITATIONS
1671	Profibrinolytic Effects of Metalloproteinases during Skin Wound Healing in the Absence of Plasminogen. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2092-2101.	0.3	23
1672	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. <i>BJU International</i> , 2008, 102, 177-182.	1.3	19
1673	Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies. <i>European Journal of Clinical Investigation</i> , 1990, 20, 79-84.	1.7	13
1674	The Species-Specific Differences in the cAMP Regulation of the Tissue-Type Plasminogen Activator Gene between Rat, Mouse and Human is Caused by a One-Nucleotide Substitution in the cAMP-Responsive Element of the Promoters. <i>FEBS Journal</i> , 1995, 231, 466-474.	0.2	10
1675	Role of the plasminogen activation system in extracellular matrix degradation processes in normal or pathological conditions in sheep. <i>Small Ruminant Research</i> , 2008, 76, 120-130.	0.6	4
1676	Purification and N-terminal sequence of a serine proteinase-like protein (BMK-CBP) from the venom of the Chinese scorpion ( <i>Buthus martensii</i> Karsch). <i>Toxicon</i> , 2008, 52, 348-353.	0.8	34
1677	Pro-urokinase up-regulates the expression of urokinase-type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells. <i>Thrombosis Research</i> , 2008, 121, 485-491.	0.8	3
1678	Review of the role of the plasminogen activator system and vascular endothelial growth factor in subfertility. <i>Fertility and Sterility</i> , 2008, 90, 2340-2350.	0.5	65
1679	Evolving role of uPA/uPAR system in human cancers. <i>Cancer Treatment Reviews</i> , 2008, 34, 122-136.	3.4	371
1680	Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects. <i>Breast Care</i> , 2008, 3, 2-2.	0.8	22
1681	Mechanisms of Venous Thrombosis and Resolution. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 387-391.	1.1	322
1682	M protein-mediated plasminogen binding is essential for the virulence of an invasive <i>Streptococcus pyogenes</i> isolate. <i>FASEB Journal</i> , 2008, 22, 2715-2722.	0.2	72
1683	Allelic variants of streptokinase from <i>Streptococcus pyogenes</i> display functional differences in plasminogen activation. <i>FASEB Journal</i> , 2008, 22, 3146-3153.	0.2	55
1684	Role of Tissue-Type Plasminogen Activator in Salicylic Acid-Induced Sloughing of Human Corn Tissue. <i>Journal of the American Podiatric Medical Association</i> , 2008, 98, 345-352.	0.2	6
1685	A cyclic peptidyl inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue. <i>Biochemical Journal</i> , 2008, 412, 447-457.	1.7	25
1686	Effect of plasmin, plasminogen activators and a plasmin inhibitor on bovine in vitro embryo production. <i>Reproduction, Fertility and Development</i> , 2008, 20, 320.	0.1	21
1687	suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion. <i>International Journal of Oncology</i> , 2008, 32, 185-91.	1.4	6
1688	Binding of plasminogen to hepatocytes isolated from injured mice liver and nonparenchymal cell-dependent proliferation of hepatocytes. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 503-511.	0.5	8

#	ARTICLE	IF	CITATIONS
1689	Measurement of mRNA of 11 Biomarkers by RT-PCR to Detect Lymph Node Involvement in Cervical Cancer. <i>International Journal of Biological Markers</i> , 2008, 23, 74-82.	0.7	6
1690	Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tixaplatin in a rat stenosis model of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2008, 99, 749-758.	1.8	25
1691	QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2009, 24, 6-13.	2.5	13
1692	Defining the Structural Basis of Human Plasminogen Binding by Streptococcal Surface Enolase. <i>Journal of Biological Chemistry</i> , 2009, 284, 17129-17137.	1.6	61
1693	The Serine Protease Inhibitor Protease Nexin-1 Controls Mammary Cancer Metastasis through LRP-1-Mediated MMP-9 Expression. <i>Cancer Research</i> , 2009, 69, 5690-5698.	0.4	116
1694	Breed and seasonal variation of plasminogen activator activity and plasminogen activator inhibition in spermatozoa and seminal plasma of the ram in correlation with testosterone in the blood. <i>Andrologia</i> , 1993, 25, 101-109.	1.0	13
1695	Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. <i>Gynecologic Oncology</i> , 2009, 113, 221-227.	0.6	12
1696	Plasmin in tear fluid of patients with corneal ulcers: basis for new therapy. <i>Acta Ophthalmologica</i> , 1987, 65, 3-12.	0.6	92
1697	Elevation of tear fluid plasmin in corneal disease. <i>Acta Ophthalmologica</i> , 1988, 66, 393-399.	0.6	38
1698	Plasmin in subretinal fluid. <i>Acta Ophthalmologica</i> , 1988, 66, 647-651.	0.6	15
1699	The pathogenesis of corneal epithelial defects. <i>Acta Ophthalmologica</i> , 1989, 67, 55-64.	0.6	28
1700	On the proteolytic activity of contact lenses and bacteria. <i>Acta Ophthalmologica</i> , 1990, 68, 390-400.	0.6	5
1701	REGULATION OF THE PERICELLULAR ACTIVATION OF PLASMINOGEN AND ITS ROLE IN TISSUE-DESTRUCTIVE PROCESSES. <i>Acta Ophthalmologica</i> , 1992, 70, 34-41.	0.6	17
1702	SURFACE-ASSOCIATED ACTIVATION OF PLASMINOGEN ON GRAM-POSITIVE BACTERIA. <i>Acta Ophthalmologica</i> , 1992, 70, 42-46.	0.6	12
1703	EXPERIENCE WITH PLASMIN INHIBITORS. <i>Acta Ophthalmologica</i> , 1992, 70, 47-53.	0.6	1
1704	Secretion of plasminogen activators by cells cultured from subretinal fluid. <i>Acta Ophthalmologica</i> , 1994, 72, 218-222.	0.6	2
1705	Characteristic response of astrocytes to plasminogen/plasmin to upregulate transforming growth factor beta 3 (TGF $\beta$ 3) production/secretion through proteinase-activated receptor-1 (PAR-1) and the downstream phosphatidylinositol 3-kinase (PI3K)-Akt/PKB signaling cascade. <i>Brain Research</i> , 2009, 1305, 1-13.	1.1	24
1706	Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. <i>International Journal of Cancer</i> , 2009, 124, 1860-1870.	2.3	79

#	ARTICLE	IF	CITATIONS
1707	From Telogen to Exogen: Mechanisms Underlying Formation and Subsequent Loss of the Hair Club Fiber. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2100-2108.	0.3	81
1708	Cigarette smoke condensate stimulates urokinase production through the generation of reactive oxygen species and activation of the mitogen activated protein kinase pathways in human gingival fibroblasts. <i>Journal of Periodontal Research</i> , 2009, 44, 386-394.	1.4	12
1709	Triclosan inhibits tumor necrosis factor $\alpha$ -stimulated urokinase production in human gingival fibroblasts. <i>Journal of Periodontal Research</i> , 2009, 44, 726-735.	1.4	16
1710	Tear fluid plasmin activity of dry eye patients with Sjögren's syndrome. <i>Acta Ophthalmologica</i> , 1997, 75, 137-141.	0.4	30
1711	Dual modulation of prothrombin activation by the cyclopentapeptide plactin. <i>FEBS Journal</i> , 2009, 276, 2516-2528.	2.2	7
1712	Natural Occurring Polyphenols as Template for Drug Design. Focus on Serine Proteases. <i>Chemical Biology and Drug Design</i> , 2009, 74, 1-15.	1.5	44
1713	Degradation behaviors of nerve guidance conduits made up of silk fibroin in vitro and in vivo. <i>Polymer Degradation and Stability</i> , 2009, 94, 2213-2220.	2.7	56
1714	Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone. <i>Journal of Bone and Mineral Research</i> , 1991, 6, 1081-1090.	3.1	28
1715	The effect of transforming growth factor $\beta$ 2 on the plasminogen activator activity of normal human osteoblast-like cells and a human osteosarcoma cell line MG-63. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 1363-1371.	3.1	18
1716	Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones. <i>Journal of Bone and Mineral Research</i> , 1994, 9, 891-902.	3.1	28
1717	Role of selectins and fibrinolysis in VTE. <i>Thrombosis Research</i> , 2009, 123, S35-S40.	0.8	31
1718	Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells. <i>Blood</i> , 2009, 113, 1699-1709.	0.6	13
1719	Cytokines and Growth Factors in Implantation. <i>Journal of Reproductive and Stem Cell Biotechnology</i> , 2010, 1, 219-243.	0.1	5
1720	Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 3947-3960.	2.4	21
1723	Urokinase receptor expression involves tyrosine phosphorylation of phosphoglycerate kinase. <i>Molecular and Cellular Biochemistry</i> , 2010, 335, 235-247.	1.4	5
1724	Long term increased expression of the short form 1b prolactin receptor in PC $\beta$ human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity. <i>Prostate</i> , 2010, 70, 37-47.	1.2	11
1725	Enhanced cell-associated plasminogen activator pathway but not coagulation pathway activity contributes to motility in metastatic breast cancer cells. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1323-1332.	1.9	4
1726	Small molecule modulators of zymogen activation in the fibrinolytic and coagulation systems. <i>FEBS Journal</i> , 2010, 277, 3675-3687.	2.2	49



#	ARTICLE	IF	CITATIONS
1727	Immunocytochemical and immunoelectron microscopic demonstration of cathepsin B in human malignant melanoma. <i>British Journal of Dermatology</i> , 2010, 132, 867-875.	1.4	13
1728	Leptospiral Endostatin-Like Protein A Is a Bacterial Cell Surface Receptor for Human Plasminogen. <i>Infection and Immunity</i> , 2010, 78, 2053-2059.	1.0	78
1729	Targeted Toxins in Brain Tumor Therapy. <i>Toxins</i> , 2010, 2, 2645-2662.	1.5	41
1730	Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. <i>Protein Engineering, Design and Selection</i> , 2010, 23, 261-269.	1.0	12
1731	Post-Transcriptional Regulation of Plasminogen Activator Inhibitor Type-1 Expression in Human Pleural Mesothelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2010, 43, 358-367.	1.4	15
1732	Matriptase/epithin participates in mammary epithelial cell growth and morphogenesis through HGF activation. <i>Mechanisms of Development</i> , 2010, 127, 82-95.	1.7	23
1733	Serum tetranectin is a significant prognostic marker in ovarian cancer patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 190-198.	1.3	6
1734	Induction of Bystander Response in Human Glioma Cells using High-Energy Electrons: A Role for TGF- $\beta$ 1. <i>Radiation Research</i> , 2010, 173, 769-778.	0.7	52
1735	Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques. <i>Journal of Proteome Research</i> , 2010, 9, 4721-4731.	1.8	21
1736	Gingival status, crevicular fluid tissue-type plasminogen activator, plasminogen activator inhibitor-2 levels in pregnancy versus post-partum. <i>Australian Dental Journal</i> , 2010, 55, 292-297.	0.6	10
1737	Prevention of intra-peritoneal adhesions in gynaecological surgery: theory and evidence. <i>Reproductive BioMedicine Online</i> , 2010, 21, 290-303.	1.1	55
1738	Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 947-962.	1.5	43
1739	Modulators of the urokinase-type plasminogen activation system for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 641-652.	1.9	64
1740	Intraocular Properties of a Repository Urokinase Receptor Antagonist Å...36 Peptide in Rabbits. <i>Current Eye Research</i> , 2010, 35, 742-750.	0.7	1
1741	A modified Tat peptide for selective intracellular delivery of macromolecules. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 611-618.	1.2	1
1742	Urokinase Plasminogen Activator Inhibits HIV Virion Release from Macrophage-Differentiated Chronically Infected Cells via Activation of RhoA and PKC $\mu$ . <i>PLoS ONE</i> , 2011, 6, e23674.	1.1	14
1743	Fascin Is a Key Regulator of Breast Cancer Invasion That Acts via the Modification of Metastasis-Associated Molecules. <i>PLoS ONE</i> , 2011, 6, e27339.	1.1	88
1744	Cell Surface Receptors in Malignant Glioma. <i>Neurosurgery</i> , 2011, 69, 980-994.	0.6	7

#	ARTICLE	IF	CITATIONS
1745	The Expression of Fibrinolytic Components in Chronic Paranasal Sinus Disease. American Journal of Rhinology and Allergy, 2011, 25, 1-6.	1.0	31
1746	Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. Biochemical Journal, 2011, 438, 39-51.	1.7	14
1747	VEGF non-angiogenic functions in adult organ homeostasis: therapeutic implications. Journal of Molecular Medicine, 2011, 89, 635-645.	1.7	24
1748	GATA Factors in Gastrointestinal Malignancy. World Journal of Surgery, 2011, 35, 1757-1765.	0.8	25
1749	The plasminâ€“antiplasmin system: structural and functional aspects. Cellular and Molecular Life Sciences, 2011, 68, 785-801.	2.4	123
1750	Mastitis impact on technological properties of milk and quality of milk productsâ€”a review. Dairy Science and Technology, 2011, 91, 247-282.	2.2	140
1751	Metals affect the structure and activity of human plasminogen activator inhibitorâ€“1. I. Modulation of stability and protease inhibition. Protein Science, 2011, 20, 353-365.	3.1	20
1752	Design and synthesis of a near-infrared fluorescent nanofiber precursor for detecting cell-secreted urokinase activity. Analytical Biochemistry, 2011, 412, 26-33.	1.1	16
1753	Plasmin Treatment Accelerates Vascular Endothelial Growth Factor Clearance from Rabbit Eyes. , 2011, 52, 6162.		6
1754	Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145. Oncology Reports, 2011, 26, 1407-13.	1.2	11
1755	Annexin A2 Promotes Glioma Cell Invasion and Tumor Progression. Journal of Neuroscience, 2011, 31, 14346-14360.	1.7	99
1756	Streptococcus pyogenes M49 Plasminogen/Plasmin Binding Facilitates Keratinocyte Invasion via Integrin-Integrin-linked Kinase (ILK) Pathways and Protects from Macrophage Killing. Journal of Biological Chemistry, 2011, 286, 21612-21622.	1.6	56
1757	Overexpression of MMP-9 Contributes to Invasiveness of Prostate Cancer Cell Line LNCaP. Immunological Investigations, 2011, 40, 447-464.	1.0	72
1758	Bacterial Plasminogen Receptors: Mediators of a Multifaceted Relationship. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-14.	3.0	102
1759	Bacterial Plasminogen Receptors Utilize Host Plasminogen System for Effective Invasion and Dissemination. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-19.	3.0	125
1760	Molecular Alterations Associated with Osteosarcoma Development. Sarcoma, 2012, 2012, 1-12.	0.7	23
1761	Levels of Components of the Urokinase-Type Plasminogen Activator System are Related to Chronic Obstructive Pulmonary Disease Parenchymal Destruction and Airway Remodelling. Journal of International Medical Research, 2012, 40, 976-985.	0.4	25
1762	Place des biomarqueurs dans la prise en charge du cancer du sein. , 2012, , 315-434.		0

#	ARTICLE	IF	CITATIONS
1763	Role of Urokinase Plasminogen Activator Receptor in Gastric Cancer: A Potential Therapeutic Target. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 285-290.	0.7	7
1764	Micronutrient Synergy in the Fight against Hepatocellular Carcinoma. <i>Cancers</i> , 2012, 4, 323-339.	1.7	8
1765	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines. <i>Oncology Reports</i> , 2012, 28, 768-776.	1.2	22
1766	Staurosporine induces ganglion cell differentiation in part by stimulating urokinase-type plasminogen activator expression and activation in the developing chick retina. <i>Biochemical and Biophysical Research Communications</i> , 2012, 423, 67-72.	1.0	9
1767	Blockade of VEGF-induced GSK/ $\beta$ -catenin signaling, uPAR expression and increased permeability by dominant negative p38 $\beta$ . <i>Experimental Eye Research</i> , 2012, 100, 101-108.	1.2	10
1768	Humoral innate immune response and disease. <i>Clinical Immunology</i> , 2012, 144, 142-158.	1.4	67
1769	Multiplex Sensing of Protease and Kinase Enzyme Activity via Orthogonal Coupling of Quantum Dot-Peptide Conjugates. <i>ACS Nano</i> , 2012, 6, 851-857.	7.3	134
1770	Immunohistochemical detection of uPA, tPA, and PAI-1 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation. <i>International Journal of Legal Medicine</i> , 2012, 126, 421-425.	1.2	23
1772	Molecular profiling of functional interactions between pre-osteoblastic and breast carcinoma cells. <i>Genes To Cells</i> , 2012, 17, 302-315.	0.5	1
1773	Diphtheria toxin-based targeted toxin therapy for brain tumors. <i>Journal of Neuro-Oncology</i> , 2013, 114, 155-164.	1.4	22
1774	u-Plasminogen Activator. , 2013, , 2938-2945.		2
1775	BBA70 of <i>Borrelia burgdorferi</i> Is a Novel Plasminogen-binding Protein. <i>Journal of Biological Chemistry</i> , 2013, 288, 25229-25243.	1.6	57
1776	Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase. <i>Molecular Cancer</i> , 2013, 12, 54.	7.9	31
1777	Three are better than one: plasminogen receptors as cancer theranostic targets. <i>Experimental Hematology and Oncology</i> , 2013, 2, 12.	2.0	33
1778	Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. <i>Clinica Chimica Acta</i> , 2013, 415, 138-144.	0.5	5
1779	uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1221-1228.	1.2	17
1780	The interaction between bacterial enolase and plasminogen promotes adherence of <i>Streptococcus pneumoniae</i> to epithelial and endothelial cells. <i>International Journal of Medical Microbiology</i> , 2013, 303, 452-462.	1.5	88
1781	Probing Binding and Cellular Activity of Pyrrolidinone and Piperidinone Small Molecules Targeting the Urokinase Receptor. <i>ChemMedChem</i> , 2013, 8, 1963-1977.	1.6	21

#	ARTICLE	IF	CITATIONS
1782	LRP-1: A Checkpoint for the Extracellular Matrix Proteolysis. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	92
1783	Proteomic Analysis of the Cerebrospinal Fluid of Parkinson's Disease Patients Pre- and Post-Deep Brain Stimulation. <i>Cellular Physiology and Biochemistry</i> , 2013, 31, 625-637.	1.1	833
1784	Plasminogen Activator Inhibitor-1. <i>Circulation</i> , 2013, 128, 2286-2288.	1.6	6
1785	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in adult human sarcoma cell lines. <i>International Journal of Oncology</i> , 2013, 43, 39-49.	1.4	10
1786	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human lung cancer and mesothelioma cell lines. <i>International Journal of Oncology</i> , 2013, 42, 1883-1889.	1.4	10
1787	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in pediatric human sarcoma cell lines. <i>International Journal of Oncology</i> , 2013, 43, 1027-1035.	1.4	9
1788	Interaction of streptococcal plasminogen binding proteins with the host fibrinolytic system. <i>Frontiers in Cellular and Infection Microbiology</i> , 2013, 3, 85.	1.8	50
1789	Adhesion Prevention Strategies in Laparoscopic Surgery. , 0, , .		7
1790	Anticancer Effects of Grape Seed Extract on Human Cancers: A Review. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2014, s8, .	0.3	13
1791	Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves. <i>Biochemistry Research International</i> , 2014, 2014, 1-5.	1.5	9
1792	Periodicity in the levels of serum plasminogen activator inhibitor-1 is a robust prognostic factor for embryo implantation and clinical pregnancy in ongoing IVF cycles. <i>Journal of Human Reproductive Sciences</i> , 2014, 7, 198.	0.4	4
1793	A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility. <i>PLoS ONE</i> , 2014, 9, e115872.	1.1	22
1794	Grape seed extract suppresses MDA-MB231 breast cancer cell migration and invasion. <i>European Journal of Nutrition</i> , 2014, 53, 421-431.	1.8	28
1795	Disease Manifestations and Pathogenic Mechanisms of Group A Streptococcus. <i>Clinical Microbiology Reviews</i> , 2014, 27, 264-301.	5.7	668
1796	New markers in pelvic inflammatory disease. <i>Clinica Chimica Acta</i> , 2014, 431, 118-124.	0.5	18
1797	The emerging role of MMP14 in brain tumorigenesis and future therapeutics. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 113-120.	3.3	40
1798	Protease Nexin-1 affects the migration and invasion of C6 glioma cells through the regulation of urokinase Plasminogen Activator and Matrix Metalloproteinase-9/2. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 2631-2644.	1.9	33
1799	The plasminogen activation system in periodontal tissue (Review). <i>International Journal of Molecular Medicine</i> , 2014, 33, 763-768.	1.8	21

#	ARTICLE	IF	CITATIONS
1800	Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human glioblastoma cell lines. <i>International Journal of Oncology</i> , 2014, 45, 887-894.	1.4	13
1801	Diphtheria toxin-based targeted toxins that target glioblastoma multiforme. <i>Toxin Reviews</i> , 2014, 33, 119-124.	1.5	1
1802	Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors. <i>Radiology and Oncology</i> , 2015, 49, 357-364.	0.6	28
1803	Enzymatic Vitrectomy and Pharmacologic Vitreodynamics. <i>Developments in Ophthalmology</i> , 2016, 55, 357-364.	0.1	4
1804	Serum level of Urokinase Plasminogen Activator (uPA) Correlates with the Survival of Patients with Pancreatic Ductal Adenocarcinoma (PDAC). <i>Pancreatic Disorders &amp; Therapy</i> , 2015, 05, .	0.3	2
1805	What drives "fibrinolysis"? <i>Hamostaseologie</i> , 2015, 35, 303-310.	0.9	11
1806	HGF Modulates Actin Cytoskeleton Remodeling and Contraction in Testicular Myoid Cells. <i>Biomedicines</i> , 2015, 3, 89-109.	1.4	3
1807	Translation Elongation Factor Tuf of <i>Acinetobacter baumannii</i> Is a Plasminogen-Binding Protein. <i>PLoS ONE</i> , 2015, 10, e0134418.	1.1	37
1808	First-in-human uPAR PET: Imaging of Cancer Aggressiveness. <i>Theranostics</i> , 2015, 5, 1303-1316.	4.6	92
1809	The source of matrix-degrading enzymes in human cancer: Problems of research reproducibility and possible solutions. <i>Journal of Cell Biology</i> , 2015, 209, 195-198.	2.3	34
1810	Modulation of CD44 Activity by A6-Peptide. <i>Frontiers in Immunology</i> , 2015, 6, 135.	2.2	33
1811	Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human colorectal, pancreatic and hepatic carcinoma cell lines. <i>International Journal of Oncology</i> , 2015, 47, 370-376.	1.4	11
1812	A New Class of Orthosteric uPAR-uPA Small-Molecule Antagonists Are Allosteric Inhibitors of the uPAR-Vitronectin Interaction. <i>ACS Chemical Biology</i> , 2015, 10, 1521-1534.	1.6	22
1813	Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 627-631.	1.2	12
1814	D-dimer. <i>Advances in Clinical Chemistry</i> , 2015, 69, 1-46.	1.8	142
1815	Periodontitis associated with plasminogen deficiency: a case report. <i>BMC Oral Health</i> , 2015, 15, 59.	0.8	11
1816	A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 464, 848-854.	1.0	22
1817	Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 62, 88-92.	1.2	2

#	ARTICLE	IF	CITATIONS
1818	Post-infectious group A streptococcal autoimmune syndromes and the heart. <i>Autoimmunity Reviews</i> , 2015, 14, 710-725.	2.5	91
1819	<i>Porphyromonas gingivalis</i> -derived RgpA-Kgp Complex Activates the Macrophage Urokinase Plasminogen Activator System. <i>Journal of Biological Chemistry</i> , 2015, 290, 16031-16042.	1.6	21
1820	GM-CSF and uPA are required for <i>Porphyromonas gingivalis</i> -induced alveolar bone loss in a mouse periodontitis model. <i>Immunology and Cell Biology</i> , 2015, 93, 705-715.	1.0	19
1821	Fibroblast growth factor-2 did not restore plasminogen system activity in endothelial cells on glycated collagen. <i>Biochemistry and Biophysics Reports</i> , 2015, 4, 104-110.	0.7	1
1822	Effects of Addition of Tissue-Type Plasminogen Activator in <i>In Vitro</i> Fertilization Medium on Bovine Embryo Development and Quality. <i>Reproduction in Domestic Animals</i> , 2015, 50, 112-120.	0.6	11
1823	<i>Streptococcus pyogenes</i> . , 2015, , 675-716.		8
1824	Complement Evasion by Pathogenic <i>Leptospira</i> . <i>Frontiers in Immunology</i> , 2016, 7, 623.	2.2	63
1825	Anticancer Efficacy of Polyphenols and Their Combinations. <i>Nutrients</i> , 2016, 8, 552.	1.7	371
1826	Plasmin-Antiplasmin System. , 2016, , 31-51.		2
1827	Cutaneous (tPA) and Skeletal (TnI) mRNA as Markers of Aging in Contused Wound. <i>Journal of Forensic Sciences</i> , 2016, 61, 1007-1010.	0.9	7
1828	Penicillin binding protein 3 of <i>Staphylococcus aureus</i> NCTC 8325-4 binds and activates human plasminogen. <i>BMC Research Notes</i> , 2016, 9, 389.	0.6	2
1829	MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 31.	3.5	55
1830	A CCR2 macrophage endocytic pathway mediates extravascular fibrin clearance in vivo. <i>Blood</i> , 2016, 127, 1085-1096.	0.6	33
1831	MMP-14 promotes VSMC migration via up-regulating CD44 expression in cardiac allograft vasculopathy. <i>Pathology Research and Practice</i> , 2016, 212, 1119-1125.	1.0	4
1832	Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. <i>Biomarker Insights</i> , 2016, 11, BMI.S33372.	1.0	23
1833	Adenovirus-mediated artificial microRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth. <i>Journal of Gene Medicine</i> , 2016, 18, 102-111.	1.4	14
1834	The Effect of Levonorgestrel on Fibrinolytic Factors in Human Endometrial Endothelial Cells. <i>Reproductive Sciences</i> , 2016, 23, 1536-1541.	1.1	7
1835	Modulation of urokinase plasminogen activator system by poly(ADP-ribose)polymerase-1 inhibition. <i>Cytotechnology</i> , 2016, 68, 783-794.	0.7	2

#	ARTICLE	IF	CITATIONS
1836	Plasmin cleaves fibrinogen and the human complement proteins C3b and C5 in the presence of <i>Leptospira interrogans</i> proteins: A new role of LigA and LigB in invasion and complement immune evasion. <i>Immunobiology</i> , 2016, 221, 679-689.	0.8	72
1837	The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 551-566.	1.5	121
1838	Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. <i>Scientific Reports</i> , 2017, 7, 3385.	1.6	27
1839	Proteases and Protease Inhibitors in Male Reproduction. , 2017, , 195-216.		3
1840	Plasminogenâ€“receptor KT: plasminogen activation and beyond. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 150-154.	1.9	9
1841	Proteases as prognostic markers in human and canine cancers. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 669-683.	0.8	16
1842	Tumor-Associated Macrophages Derived from Circulating Inflammatory Monocytes Degrade Collagen through Cellular Uptake. <i>Cell Reports</i> , 2017, 21, 3662-3671.	2.9	99
1843	Biophysical Mechanisms Mediating Fibrin Fiber Lysis. <i>BioMed Research International</i> , 2017, 2017, 1-17.	0.9	51
1844	SERPINA3 induced by astroglia/microglia coâ€“culture facilitates glioblastoma stemâ€“like cell invasion. <i>Oncology Letters</i> , 2017, 15, 285-291.	0.8	16
1845	Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2077-2085.	1.0	10
1846	Computational Approaches and Analysis for a Spatio-Structural-Temporal Invasive Carcinoma Model. <i>Bulletin of Mathematical Biology</i> , 2018, 80, 701-737.	0.9	9
1847	Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro. <i>Molecular Medicine Reports</i> , 2018, 17, 4273-4280.	1.1	11
1848	Diversity and functional evolution of the plasminogen activator system. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 886-898.	2.5	43
1849	Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1. <i>Biological Chemistry</i> , 2018, 399, 1091-1097.	1.2	5
1850	Protein moonlighting: what is it, and why is it important?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20160523.	1.8	218
1851	PLOD3 promotes lung metastasis via regulation of STAT3. <i>Cell Death and Disease</i> , 2018, 9, 1138.	2.7	33
1852	The plasminogen binding protein PbsP is required for brain invasion by hypervirulent CC17 Group B streptococci. <i>Scientific Reports</i> , 2018, 8, 14322.	1.6	26
1853	Increased TIMP-3 expression alters the cellular secretome through dual inhibition of the metalloprotease ADAM10 and ligand-binding of the LRP-1 receptor. <i>Scientific Reports</i> , 2018, 8, 14697.	1.6	23

#	ARTICLE	IF	CITATIONS
1854	Genetically-engineered Salmonella typhimurium expressing TIMP-2 as a therapeutic intervention in an orthotopic glioma mouse model. <i>Cancer Letters</i> , 2018, 433, 140-146.	3.2	24
1855	The Complement Binding and Inhibitory Protein CbiA of <i>Borrelia miyamotoi</i> Degrades Extracellular Matrix Components by Interacting with Plasmin(ogen). <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 23.	1.8	22
1856	Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. <i>Frontiers in Oncology</i> , 2018, 8, 24.	1.3	305
1857	Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases. <i>RSC Advances</i> , 2018, 8, 28189-28197.	1.7	12
1858	A Perspective of Coagulation Dysfunction in Multiple Sclerosis and in Experimental Allergic Encephalomyelitis. <i>Frontiers in Neurology</i> , 2018, 9, 1175.	1.1	23
1859	Fibrin and Fibrinolysis in Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 413-422.	1.5	81
1860	Lymphâ€circulating tumor cells show distinct properties to bloodâ€circulating tumor cells and are efficient metastatic precursors. <i>Molecular Oncology</i> , 2019, 13, 1400-1418.	2.1	19
1861	Implementing TIMERS: the race against hard-to-heal wounds. <i>Journal of Wound Care</i> , 2019, 28, S1-S50.	0.5	142
1862	The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe?. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1489-1506.	2.4	23
1863	Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system. <i>Cellular Signalling</i> , 2020, 65, 109432.	1.7	11
1864	Serpina3n: Potential drug and challenges, mini review. <i>Journal of Drug Targeting</i> , 2020, 28, 368-378.	2.1	39
1865	Moonlighting Proteins in the Fuzzy Logic of Cellular Metabolism. <i>Molecules</i> , 2020, 25, 3440.	1.7	25
1866	Pharmacological interventions part II. , 2020, , 309-333.		0
1867	Surface Protein Dispersin of Enterococcal <i>Escherichia coli</i> Binds Plasminogen That Is Converted Into Active Plasmin. <i>Frontiers in Microbiology</i> , 2020, 11, 1222.	1.5	6
1868	The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPAâ€uPAR peptide inhibitors. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 3570-3583.	1.3	19
1869	A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling. <i>Frontiers in Immunology</i> , 2020, 11, 616188.	2.2	7
1870	Interaction between <i>Borrelia miyamotoi</i> variable major proteins Vlp15/16 and Vlp18 with plasminogen and complement. <i>Scientific Reports</i> , 2021, 11, 4964.	1.6	8
1871	Plasmin and Plasminogen System in the Tumor Microenvironment: Implications for Cancer Diagnosis, Prognosis, and Therapy. <i>Cancers</i> , 2021, 13, 1838.	1.7	53



#	ARTICLE	IF	CITATIONS
1872	Plasminogen Activators in Neurovascular and Neurodegenerative Disorders. International Journal of Molecular Sciences, 2021, 22, 4380.	1.8	11
1873	Endogenous and Borrowed Proteolytic Activity in the <i>Borrelia</i>. Microbiology and Molecular Biology Reviews, 2021, 85, .	2.9	3
1874	SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 759-771.	1.8	1
1875	Urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 1851-1859.	0.6	5
1876	Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention. Frontiers in Cell and Developmental Biology, 2021, 9, 732015.	1.8	16
1877	Inhibitors of Collagenase IV and Cell Adhesion Reduce the Invasive Activity of Malignant Tumour Cells. Novartis Foundation Symposium, 1988, 141, 193-210.	1.2	7
1878	Plasminogen/Plasminogen Activator and Growth Factor Activation. Novartis Foundation Symposium, 1997, 212, 105-118.	1.2	11
1881	Prognostic factors in gastric cancer. British Journal of Surgery, 1997, 84, 1651-1664.	0.1	80
1883	Serine Proteases. , 2007, , 409-443.		1
1884	The Cancer Degradome. , 2008, , .		17
1885	Physiological Functions of Plasminogen Activation: Effects of Gene Deficiencies in Humans and Mice. , 2008, , 183-201.		2
1886	Engineered Antagonists of uPA and PAI-1. , 2008, , 721-758.		2
1887	The Role of Plasminogen-Plasmin System in Cancer. Cancer Treatment and Research, 2009, 148, 43-66.	0.2	123
1888	Plasminogen Activator Inhibitor-1. , 1997, , 65-78.		2
1889	Enzyme Markers. , 1992, , 117-133.		1
1890	Follicular Rupture During Ovulation: Activation of Collagenolysis. , 1990, , 103-112.		8
1891	Epidermal growth factor receptors in human breast cancer. Cancer Treatment and Research, 1988, 40, 93-118.	0.2	17
1892	Pulmonary Embolism Associated with Dialysis Access Procedure. , 2014, , 195-211.		1

#	ARTICLE	IF	CITATIONS
1893	Human Plasminogen: Structure, Activation, and Function. , 2003, , 3-17.		6
1894	Mechanisms of invasion by head and neck cancers. Cancer Treatment and Research, 1995, 74, 117-130.	0.2	4
1895	Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): Regulators of proteolysis during cancer invasion and prognostic parameters in Breast cancer. Cancer Treatment and Research, 1994, 71, 299-309.	0.2	27
1896	Effect of Host Proteases on Early Steps of Enterovirus Infection. , 1992, , 191-200.		1
1897	Extracellular Matrix Degradation. , 1991, , 255-302.		137
1898	Effects of Structural Modifications on the Properties of Tissue Plasminogen Activator (tPA). Advances in Experimental Medicine and Biology, 1990, 281, 185-194.	0.8	2
1899	The role of metalloproteinases in tumor cell metastasis. Cancer Treatment and Research, 1991, 54, 119-133.	0.2	4
1900	Extracellular matrix metalloproteinases in tumor invasion and metastasis. Cancer Treatment and Research, 1991, 53, 421-440.	0.2	22
1901	Of Mice and Men. Advances in Experimental Medicine and Biology, 1997, , 131-141.	0.8	25
1902	Proteases, Their Inhibitors and the Extracellular Matrix: Factors in Nerve-Muscle Development and Maintenance. , 1987, 209, 25-39.		6
1903	Induction of the Urokinase-Type Plasminogen Activator Gene by Cytoskeleton-Disrupting Agents. , 1990, , 105-114.		3
1904	Plasminogen Activator in the Developing Nervous System. , 1990, , 173-184.		12
1905	Plasminogen Activators in Development, Injury and Pathology of the Neuromuscular System. , 1990, , 219-228.		3
1906	Relationship Between Plasminogen Activators and Regeneration Capacities of Rat Skeletal Muscles. , 1990, , 229-241.		3
1907	A Key Molecule Dictating and Regulating Surface Plasmin Formation : The Receptor for Urokinase Plasminogen Activator. , 1990, , 21-30.		2
1908	Structure and Function of Tissue-Type Plasminogen Activator. , 1990, , 51-68.		4
1909	Biology of Liver Metastases. Cancer Treatment and Research, 2001, 109, 183-206.	0.2	14
1910	Cerebellar Granule Cell Migration Involves Proteolysis. Advances in Experimental Medicine and Biology, 1990, 265, 169-178.	0.8	40

#	ARTICLE	IF	CITATIONS
1911	Targeting of Drugs to Tumors: The Use of the Plasminogen Activator Inhibitor as a Ligand. , 1994, , 67-79.		1
1912	Human Tumor Cell Urokinase-Type Plasminogen Activator (uPA): Degradation of the Proenzyme form (pro-uPA) by Granulocyte Elastase Prevents Subsequent Activation by Plasmin. Advances in Experimental Medicine and Biology, 1991, 297, 111-128.	0.8	6
1913	Proteolytic Mechanisms Operating at the Surface of Invasive Cells. Advances in Experimental Medicine and Biology, 1988, 233, 187-199.	0.8	14
1914	Molecular analysis of amoeboid chemotaxis: Parallel observations in amoeboid phagocytes and metastatic tumor cells. Exs, 1991, 59, 1-16.	1.4	7
1915	Vascular permeability factor/vascular endothelial growth factor:A multifunctional angiogenic cytokine. Exs, 1997, 79, 233-269.	1.4	353
1916	Streptococcal Superantigens. SpringerBriefs in Microbiology, 2015, , 1-41.	0.1	1
1917	PACAP in the Reproductive System. Current Topics in Neurotoxicity, 2016, , 405-420.	0.4	4
1918	Cooperation Between Proteolysis and Endocytosis in Collagen Turnover. , 2011, , 53-74.		3
1919	Molecular and Cellular Hemostasis and Fibrinolysis. , 2002, , 287-318.		1
1920	Agents which Increase Synthesis and Release of Tissue-Type Plasminogen Activator. Handbook of Experimental Pharmacology, 2001, , 521-556.	0.9	2
1921	Different Roles for Plasminogen Activators and Metalloproteinases in Melanoma Metastasis. Current Topics in Microbiology and Immunology, 1996, 213 ( Pt 1), 65-80.	0.7	29
1922	The E-cadherin/Catenin Complex in Invasion and Metastasis. Current Topics in Microbiology and Immunology, 1996, 213 ( Pt 1), 123-161.	0.7	121
1923	Intratumoral Fibrin Stabilization. , 1988, , 339-349.		6
1924	Plasminogen Activators: Molecular Properties, Biological Cell Function and Clinical Application. Progress in Clinical Biochemistry and Medicine, 1988, , 101-146.	0.5	2
1925	Fibrinolysis and Fibrinolytic Drugs. Handbook of Experimental Pharmacology, 1989, , 279-300.	0.9	1
1926	Comparative Study of the Effect of Various Fibres on the Secretion of Plasminogen Activator by Murine Peritoneal Macrophages. , 1989, , 93-100.		7
1927	Cell Surface Plasminogen Activation. , 1989, , 98-107.		4
1928	Urokinase-Catalyzed Plasminogen Activation at the Monocyte/Macrophage Cell Surface: A Localized and Regulated Proteolytic System. Current Topics in Microbiology and Immunology, 1992, 181, 65-86.	0.7	55

#	ARTICLE	IF	CITATIONS
1929	Properties of Metastasizing and Nonmetastasizing Human Melanoma Cells. Recent Results in Cancer Research, 1995, 139, 105-122.	1.8	18
1930	Effect of Antisense Inhibition of Urokinase Receptor on Malignancy. Current Topics in Microbiology and Immunology, 1996, 213 ( Pt 3), 101-112.	0.7	8
1931	Epidermal Growth Factor Receptor in Human Breast Cancer. Recent Results in Cancer Research, 1989, 113, 70-77.	1.8	12
1932	Extracellular Matrix and Its Enzymatic Degradation in Tumor Invasion. , 1989, , 72-83.		5
1933	The regulation of urokinase plasminogen activator gene expression in macrophages. , 1992, , 233-240.		2
1934	Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clinical and Experimental Metastasis, 1996, 14, 297-307.	1.7	103
1935	Fibronectin and Malignant Transformation. , 1989, , 255-271.		6
1936	Malignant Cell Properties Important in the Organ Preference of Metastasis. , 1994, , 467-494.		1
1937	Urokinase and Its Related Proteases in Human Urine. , 1989, , 77-87.		1
1938	Fibrinogen-Fibrin: Preparation and Use of Monoclonal Antibodies as Diagnostics. , 1991, 19, 281-313.		3
1939	Molecular Mechanism of Prostate Cancer Invasion and Metastasis. , 2003, , 11-27.		2
1940	Regulation of Arterial Smooth Muscle Growth. , 1995, , 271-295.		8
1941	Persistent Epithelial Defects. , 2008, , 749-759.		4
1942	Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants. Journal of Biological Chemistry, 1990, 265, 20293-20301.	1.6	118
1943	Rat Oocyte Tissue Plasminogen Activator Is a Catalytically Efficient Enzyme in the Absence of Fibrin. Journal of Biological Chemistry, 1989, 264, 630-634.	1.6	5
1944	Regulation of plasminogen activation by human U937 promonocytic cells.. Journal of Biological Chemistry, 1994, 269, 21353-21357.	1.6	27
1945	Vitronectin gene expression in vivo. Evidence for extrahepatic synthesis and acute phase regulation.. Journal of Biological Chemistry, 1994, 269, 19836-19842.	1.6	61
1946	Multiple transforming growth factor-beta-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells.. Journal of Biological Chemistry, 1991, 266, 1092-1100.	1.6	140

#	ARTICLE	IF	CITATIONS
1947	Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.. Journal of Biological Chemistry, 1986, 261, 4352-4357.	1.6	62
1948	Localization of vitronectin binding domain in plasminogen activator inhibitor-1.. Journal of Biological Chemistry, 1994, 269, 15223-15228.	1.6	112
1949	Monomeric 55-kDa guanidinobenzoate switches to a serine proteinase activity upon tetramerization. Tetrameric proteinase SP 220 K appears as the native form.. Journal of Biological Chemistry, 1994, 269, 14666-14671.	1.6	8
1950	Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). Journal of Biological Chemistry, 1994, 269, 9416-9419.	1.6	198
1951	The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.. Journal of Biological Chemistry, 1994, 269, 2659-2666.	1.6	108
1952	Okadaic acid-dependent induction of the urokinase-type plasminogen activator gene associated with stabilization and autoregulation of c-Jun.. Journal of Biological Chemistry, 1994, 269, 2887-2894.	1.6	31
1953	Isolation and characterization of a pepsin C zymogen produced by human breast tissues.. Journal of Biological Chemistry, 1992, 267, 24725-24731.	1.6	39
1954	One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.. Journal of Biological Chemistry, 1988, 263, 11189-11195.	1.6	205
1955	Separation and characterization of nonphosphorylated and serine-phosphorylated urokinase. Catalytic properties and sensitivity to plasminogen activator inhibitor type 1.. Journal of Biological Chemistry, 1992, 267, 19369-19372.	1.6	17
1956	Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response.. Journal of Biological Chemistry, 1992, 267, 15086-15091.	1.6	97
1957	Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells.. Journal of Biological Chemistry, 1992, 267, 13617-13622.	1.6	54
1958	Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation.. Journal of Biological Chemistry, 1992, 267, 13020-13027.	1.6	34
1959	Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments.. Journal of Biological Chemistry, 1992, 267, 5070-5077.	1.6	72
1960	Osteonectin in matrix remodeling. A plasminogen-osteonectin-collagen complex.. Journal of Biological Chemistry, 1994, 269, 30147-30153.	1.6	43
1961	Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase.. Journal of Biological Chemistry, 1987, 262, 17467-17474.	1.6	237
1962	In vivo and in vitro interaction of high and low molecular weight single-chain urokinase-type plasminogen activator with rat liver cells.. Journal of Biological Chemistry, 1992, 267, 1589-1595.	1.6	25
1963	Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.. Journal of Biological Chemistry, 1994, 269, 27657-27662.	1.6	121
1964	Inactivation of human anaphylatoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line.. Journal of Biological Chemistry, 1994, 269, 25529-25533.	1.6	6

#	ARTICLE	IF	CITATIONS
1965	Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.. Journal of Biological Chemistry, 1994, 269, 25668-25676.	1.6	125
1966	Degradation of type I collagen by rat mucosal keratinocytes. Evidence for secretion of a specific epithelial collagenase.. Journal of Biological Chemistry, 1987, 262, 6823-6831.	1.6	46
1967	Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.. Journal of Biological Chemistry, 1991, 266, 2824-2830.	1.6	141
1968	Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. Journal of Biological Chemistry, 1991, 266, 1926-1933.	1.6	519
1969	Fibrin affinity of urokinase-type plasminogen activator. Evidence that Zn <sup>2+</sup> mediates strong and specific interaction of single-chain urokinase with fibrin.. Journal of Biological Chemistry, 1993, 268, 8574-8579.	1.6	16
1970	Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin.. Journal of Biological Chemistry, 1993, 268, 5985-5989.	1.6	40
1971	Potential of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation.. Journal of Biological Chemistry, 1993, 268, 4806-4813.	1.6	77
1972	Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells.. Journal of Biological Chemistry, 1991, 266, 17845-17849.	1.6	59
1973	Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo.. Journal of Biological Chemistry, 1990, 265, 15560-15563.	1.6	134
1974	The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.. Journal of Biological Chemistry, 1987, 262, 4437-4440.	1.6	452
1975	Kunitz-type inhibitors in human serum. Identification and characterization.. Journal of Biological Chemistry, 1987, 262, 3586-3589.	1.6	23
1976	Monovalent cation dependence of tissue plasminogen activator synthesis by HeLa cells.. Journal of Biological Chemistry, 1987, 262, 3017-3021.	1.6	3
1977	Plasminogen activators and their inhibitors in a human mammary cell line (HBL-100). Modulation by glucocorticoids.. Journal of Biological Chemistry, 1986, 261, 9309-9315.	1.6	75
1978	Purification and properties of a single-chain urokinase-type plasminogen activator form produced by subcultured human umbilical vein endothelial cells.. Journal of Biological Chemistry, 1988, 263, 15139-15145.	1.6	25
1979	Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells.. Journal of Biological Chemistry, 1988, 263, 3111-3115.	1.6	228
1980	A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification.. Journal of Biological Chemistry, 1988, 263, 2358-2363.	1.6	253
1981	Human Ovarian Tumor-associated Trypsin. Journal of Biological Chemistry, 1989, 264, 14095-14099.	1.6	89
1982	Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.. Journal of Biological Chemistry, 1990, 265, 14093-14099.	1.6	36

#	ARTICLE	IF	CITATIONS
1983	A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2 binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol ester and cAMP.. Journal of Biological Chemistry, 1990, 265, 14618-14626.	1.6	129
1984	Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Journal of Biological Chemistry, 1989, 264, 7862-7868.	1.6	84
1985	Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. Journal of Biological Chemistry, 1989, 264, 8375-8383.	1.6	40
1986	Plasminogen activators in the mouse mammary gland. Journal of Biological Chemistry, 1989, 264, 7455-7457.	1.6	37
1987	Interaction of Plasminogen Activator Inhibitor (PAI-1) with Vitronectin. Journal of Biological Chemistry, 1989, 264, 6339-6343.	1.6	176
1988	Structure of the Gene for Human Plasminogen Activator Inhibitor-2. Journal of Biological Chemistry, 1989, 264, 5495-5502.	1.6	84
1989	Down-regulation of Plasmin Receptors on Human Sarcoma Cells by Glucocorticoids. Journal of Biological Chemistry, 1989, 264, 5628-5632.	1.6	24
1990	Binding of Type 1 Plasminogen Activator Inhibitor to the Extracellular Matrix of Cultured Bovine Endothelial Cells. Journal of Biological Chemistry, 1989, 264, 5058-5063.	1.6	90
1991	Plasminogen Activation Initiated by Single-chain Urokinase-type Plasminogen Activator. Journal of Biological Chemistry, 1989, 264, 2185-2188.	1.6	305
1992	The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. Journal of Biological Chemistry, 1991, 266, 15240-15243.	1.6	71
1993	Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. Journal of Biological Chemistry, 1991, 266, 14580-14584.	1.6	100
1994	SPARC induces the expression of type 1 plasminogen activator inhibitor in cultured bovine aortic endothelial cells. Journal of Biological Chemistry, 1991, 266, 13178-13184.	1.6	61
1995	Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. Journal of Biological Chemistry, 1991, 266, 12329-12336.	1.6	130
1996	Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. Journal of Biological Chemistry, 1991, 266, 12752-12758.	1.6	448
1997	Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.. Journal of Biological Chemistry, 1992, 267, 18224-18229.	1.6	213
1998	Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells.. Journal of Biological Chemistry, 1988, 263, 15688-15693.	1.6	41
1999	Disruption of cytoskeletal structures results in the induction of the urokinase-type plasminogen activator gene expression.. Journal of Biological Chemistry, 1990, 265, 13327-13334.	1.6	68
2000	Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.. Journal of Biological Chemistry, 1990, 265, 9904-9908.	1.6	233

#	ARTICLE	IF	CITATIONS
2001	Alveolar epithelial cell plasminogen activator. Characterization and regulation.. Journal of Biological Chemistry, 1990, 265, 8198-8204.	1.6	55
2002	The human receptor for urokinase plasminogen activator. NH <sub>2</sub> -terminal amino acid sequence and glycosylation variants.. Journal of Biological Chemistry, 1990, 265, 6453-6460.	1.6	250
2003	Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.. Journal of Biological Chemistry, 1990, 265, 2865-2872.	1.6	102
2004	The structure of the TATA-less rat tissue-type plasminogen activator gene. Species-specific sequence divergences in the promoter predict differences in regulation of gene expression.. Journal of Biological Chemistry, 1990, 265, 2022-2027.	1.6	61
2005	Isolation and characterization of the rat plasminogen activator inhibitor-1 gene.. Journal of Biological Chemistry, 1990, 265, 2078-2085.	1.6	74
2006	Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters.. Journal of Biological Chemistry, 1990, 265, 1333-1338.	1.6	45
2007	Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.. Journal of Biological Chemistry, 1992, 267, 15595-15602.	1.6	65
2008	Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.. Journal of Biological Chemistry, 1992, 267, 14151-14156.	1.6	214
2009	Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.. Journal of Biological Chemistry, 1992, 267, 12098-12105.	1.6	124
2010	Regulatory sequences and protein-binding sites involved in the expression of the rat plasminogen activator inhibitor-1 gene.. Journal of Biological Chemistry, 1992, 267, 12202-12210.	1.6	31
2011	Cell- and gene-specific interactions between signal transduction pathways revealed by okadaic acid. Studies on the plasminogen activating system.. Journal of Biological Chemistry, 1992, 267, 12220-12226.	1.6	33
2012	Pulmonary epithelial cell urokinase-type plasminogen activator. Induction by interleukin-1 beta and tumor necrosis factor-alpha.. Journal of Biological Chemistry, 1992, 267, 11462-11469.	1.6	55
2013	Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.. Journal of Biological Chemistry, 1992, 267, 9129-9133.	1.6	155
2014	Regulation of plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes. Correlation with production of the protein.. Journal of Biological Chemistry, 1992, 267, 7089-7094.	1.6	27
2015	Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis.. Journal of Biological Chemistry, 1992, 267, 3438-3444.	1.6	79
2016	Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation.. Journal of Biological Chemistry, 1988, 263, 1563-1569.	1.6	145
2017	Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.. Journal of Biological Chemistry, 1986, 261, 7644-7651.	1.6	208
2018	The human tissue plasminogen activator gene.. Journal of Biological Chemistry, 1986, 261, 6972-6985.	1.6	207



#	ARTICLE	IF	CITATIONS
2019	Isolation of a prokaryotic plasmin receptor. Relationship to a plasminogen activator produced by the same micro-organism.. Journal of Biological Chemistry, 1991, 266, 4922-4928.	1.6	57
2020	Isolation and characterization of a 70-kDa metalloprotease (gelatinase) that is elevated in Rous sarcoma virus-transformed chicken embryo fibroblasts.. Journal of Biological Chemistry, 1991, 266, 5113-5121.	1.6	71
2021	Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).. Journal of Biological Chemistry, 1991, 266, 5147-5152.	1.6	294
2022	Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells.. Journal of Biological Chemistry, 1991, 266, 5177-5181.	1.6	96
2023	Actin is a noncompetitive plasmin inhibitor.. Journal of Biological Chemistry, 1991, 266, 5273-5278.	1.6	24
2024	Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequences.. Journal of Biological Chemistry, 1988, 263, 9129-9141.	1.6	152
2025	Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells.. Journal of Biological Chemistry, 1988, 263, 18220-18224.	1.6	88
2026	Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2. Journal of Biological Chemistry, 1989, 264, 18180-18187.	1.6	47
2027	Characterization of the Cellular Binding Site for the Urokinase-type Plasminogen Activator. Journal of Biological Chemistry, 1989, 264, 1180-1189.	1.6	223
2028	Isolation and characterization of an intracellular serine proteinase inhibitor from a monkey kidney epithelial cell line.. Journal of Biological Chemistry, 1993, 268, 21560-21568.	1.6	29
2029	Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase.. Journal of Biological Chemistry, 1993, 268, 21862-21867.	1.6	166
2030	The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator.. Journal of Biological Chemistry, 1991, 266, 7842-7847.	1.6	230
2031	BIOCHEMISTRY OF BLADDER CANCER INVASION AND METASTASIS. Urologic Clinics of North America, 1992, 19, 621-627.	0.8	14
2032	8 Advances in Clinical Fibrinolysis. Clinics in Haematology, 1986, 15, 443-463.	2.2	10
2033	Myeloid leukaemic cells can lyse fibrin directly. British Journal of Haematology, 2000, 111, 524-529.	1.2	7
2034	Fibrin Deposition in Squamous Cell Carcinomas of the Larynx and Hypopharynx. Thrombosis and Haemostasis, 1998, 80, 767-772.	1.8	29
2035	Mechanisms of Signaling through Urokinase Receptor and the Cellular Response. Thrombosis and Haemostasis, 1999, 82, 305-311.	1.8	42
2036	Plasma Levels of Lipoprotein(a) Are Elevated in Patients with the Antiphospholipid Antibody Syndrome. Thrombosis and Haemostasis, 1994, 71, 424-427.	1.8	49

#	ARTICLE	IF	CITATIONS
2037	Inhibition of the Metastasis of Lewis Lung Carcinoma by Antibody Against Urokinase-Type Plasminogen Activator in the Experimental and Spontaneous Metastasis Model. <i>Thrombosis and Haemostasis</i> , 1994, 71, 474-480.	1.8	53
2038	Quantitation of Plasma Levels of Tetraneotin - Effects of Oral Contraceptives, Pregnancy, Treatment with L-Asparaginase and Liver Cirrhosis. <i>Thrombosis and Haemostasis</i> , 1989, 62, 792-796.	1.8	12
2039	Localization of Fibrinolytic Activators and Inhibitors in Normal and Atherosclerotic Vessels. <i>Thrombosis and Haemostasis</i> , 1996, 75, 933-938.	1.8	27
2040	Cytokine Regulation of the Synthesis of Plasminogen Activator Inhibitor-2 by Human Vascular Endothelial Cells. <i>Thrombosis and Haemostasis</i> , 1993, 69, 135-140.	1.8	28
2041	Localization of a Vitronectin Binding Region of Plasminogen Activator Inhibitor-1. <i>Thrombosis and Haemostasis</i> , 1995, 73, 829-834.	1.8	29
2042	Plasminogen Activation by Invasive Human Pathogens. <i>Thrombosis and Haemostasis</i> , 1997, 77, 001-010.	1.8	166
2043	The Urokinase-receptor (CD87) Is Expressed in Cells of the Megakaryoblastic Lineage. <i>Thrombosis and Haemostasis</i> , 1997, 77, 540-547.	1.8	31
2044	Depression of Tissue-Type Plasminogen Activator and Enhancement of Urokinase-Type Plasminogen Activator as an Expression of Local Inflammation. <i>Thrombosis and Haemostasis</i> , 1992, 68, 180-184.	1.8	34
2045	Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy. <i>Thrombosis and Haemostasis</i> , 1997, 78, 285-296.	1.8	309
2046	Polyoma Middle T-induced Vascular Tumor Formation: The Role of the Plasminogen Activator/Plasmin System. <i>Journal of Cell Biology</i> , 1997, 137, 953-963.	2.3	65
2047	Plasminogen Activation System in Human Milk. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1997, 25, 159-166.	0.9	32
2048	Plasminogen Activator Inhibitor-1 in Brain Tumors. <i>Neurosurgery</i> , 1995, 36, 375-381.	0.6	3
2049	IMMUNOLocalization of FGF-1 AND RECEPTORS IN GLOMERULAR LESIONS ASSOCIATED WITH CHRONIC HUMAN RENAL ALLOGRAFT REJECTION1. <i>Transplantation</i> , 1996, 62, 190-200.	0.5	28
2050	Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. <i>Clinical Orthopaedics and Related Research</i> , 2003, , 546-58.	0.7	87
2051	Purification of native $\epsilon$ -enolase from <i>Streptococcus pneumoniae</i> that binds plasminogen and is immunogenic. <i>Journal of Medical Microbiology</i> , 2002, 51, 837-843.	0.7	36
2052	The Major N-Linked Carbohydrate Chains from Human Urokinase. The Occurrence of 4-O-sulfated, (alpha2-6)-sialylated or (alpha1-3)-fucosylated N-acetylgalactosamine(beta1-4)-N-acetylglucosamine Elements. <i>FEBS Journal</i> , 1995, 228, 1009-1019.	0.2	52
2053	The Species-Specific Differences in the cAMP Regulation of the Tissue-Type Plasminogen Activator Gene between Rat, Mouse and Human is Caused by a One-Nucleotide Substitution in the cAMP-Responsive Element of the Promoters. <i>FEBS Journal</i> , 1995, 231, 466-474.	0.2	23
2054	Penetration of fimbriate enteric bacteria through basement membranes: A hypothesis. <i>FEMS Microbiology Letters</i> , 1992, 100, 307-312.	0.7	29

#	ARTICLE	IF	CITATIONS
2055	Penetration of fimbriate enteric bacteria through basement membranes: A hypothesis. FEMS Microbiology Letters, 1992, 100, 307-312.	0.7	37
2056	Identification of a specific receptor for plasmin on a group A streptococcus. Infection and Immunity, 1987, 55, 1914-1918.	1.0	124
2057	Tissue-type plasminogen activator-mediated activation of plasminogen on the surface of group A, C, and G streptococci. Infection and Immunity, 1992, 60, 196-201.	1.0	83
2058	Bacterial plasminogen receptors: in vitro evidence for a role in degradation of the mammalian extracellular matrix. Infection and Immunity, 1995, 63, 3659-3664.	1.0	77
2059	Borrelia burgdorferi induces secretion of pro-urokinase-type plasminogen activator by human monocytes. Infection and Immunity, 1996, 64, 4307-4312.	1.0	36
2060	Identification of Two Laminin-Binding Fimbriae, the Type 1 Fimbria of <i>Salmonella enterica</i> Serovar Typhimurium and the G Fimbria of <i>Escherichia coli</i> , as Plasminogen Receptors. Infection and Immunity, 1998, 66, 4965-4970.	1.0	46
2061	Plasminogen Binding and Activation at the Surface of <i>Helicobacter pylori</i> CCUG 17874. Infection and Immunity, 1998, 66, 4976-4980.	1.0	41
2062	Plasmin-Coated <i>Borrelia burgdorferi</i> Degrades Soluble and Insoluble Components of the Mammalian Extracellular Matrix. Infection and Immunity, 1999, 67, 3929-3936.	1.0	86
2063	Induction of Urokinase-Type Plasminogen Activator by UV Light in Human Fetal Fibroblasts is Mediated through a UV-Induced Secreted Protein. Molecular and Cellular Biology, 1987, 7, 622-631.	1.1	17
2064	The effect of tissue type-plasminogen activator deletion and associated fibrin(ogen) deposition on macrophage localization in peritoneal inflammation. Thrombosis and Haemostasis, 2006, 95, 659-667.	1.8	12
2065	Inhibitors of Fibrinolysis Are Elevated in Atherosclerotic Plaque. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 539-545.	1.1	96
2066	Antagonists of the Mannose Receptor and the LDL Receptor-Related Protein Dramatically Delay the Clearance of Tissue Plasminogen Activator. Circulation, 1997, 95, 46-52.	1.6	39
2067	Migration of Arterial Wall Cells. Circulation Research, 1996, 78, 405-414.	2.0	83
2068	Urokinase Anchors uPAR to the Actin Cytoskeleton. , 2004, 45, 2967.		30
2069	Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangial cells.. Journal of Clinical Investigation, 1988, 82, 1992-2000.	3.9	30
2070	Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.. Journal of Clinical Investigation, 1989, 83, 1747-1752.	3.9	192
2071	Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.. Journal of Clinical Investigation, 1991, 87, 962-970.	3.9	148
2072	The plasminogen activator/plasmin system.. Journal of Clinical Investigation, 1991, 88, 1067-1072.	3.9	1,091

#	ARTICLE	IF	CITATIONS
2073	Differential protease expression by cutaneous squamous and basal cell carcinomas.. Journal of Clinical Investigation, 1991, 88, 1073-1079.	3.9	87
2074	Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin.. Journal of Clinical Investigation, 1991, 88, 1680-1684.	3.9	48
2075	The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.. Journal of Clinical Investigation, 1993, 92, 978-983.	3.9	26
2076	A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.. Journal of Clinical Investigation, 1993, 92, 2160-2167.	3.9	107
2077	The urokinase receptor is required for human monocyte chemotaxis in vitro.. Journal of Clinical Investigation, 1994, 93, 1380-1387.	3.9	287
2078	Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion.. Journal of Clinical Investigation, 1995, 96, 639-645.	3.9	123
2079	Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.. Journal of Clinical Investigation, 1995, 96, 2593-2600.	3.9	138
2080	The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells.. Journal of Clinical Investigation, 1996, 97, 1705-1714.	3.9	169
2081	Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model.. Journal of Clinical Investigation, 1996, 97, 1818-1826.	3.9	172
2082	Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator.. Journal of Clinical Investigation, 1996, 97, 2440-2451.	3.9	184
2083	Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury.. Journal of Clinical Investigation, 1996, 98, 2666-2673.	3.9	124
2084	Exacerbation of antigen-induced arthritis in urokinase-deficient mice.. Journal of Clinical Investigation, 1998, 102, 41-50.	3.9	126
2085	The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis. Journal of Clinical Investigation, 1999, 103, 81-87.	3.9	100
2086	Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood, 1989, 74, 1396-1402.	0.6	91
2087	Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon. Blood, 1992, 79, 678-687.	0.6	22
2088	Growth and Dissemination of Lewis Lung Carcinoma in Plasminogen-Deficient Mice. Blood, 1997, 90, 4522-4531.	0.6	100
2089	Growth and Dissemination of Lewis Lung Carcinoma in Plasminogen-Deficient Mice. Blood, 1997, 90, 4522-4531.	0.6	7
2090	Tissue Factor Regulates Plasminogen Binding and Activation. Blood, 1998, 91, 1987-1998.	0.6	1

#	ARTICLE	IF	CITATIONS
2091	Plasminogen Deficiency Differentially Affects Recruitment of Inflammatory Cell Populations in Mice. <i>Blood</i> , 1998, 91, 2005-2009.	0.6	8
2092	Plasminogen activator expression in F9 teratocarcinoma embryoid bodies and their endoderm derivatives. <i>Development (Cambridge)</i> , 1989, 106, 195-201.	1.2	14
2093	Mouse neural crest cells secrete both urokinase-type and tissue-type plasminogen activators <i>in vitro</i>. <i>Development (Cambridge)</i> , 1989, 106, 685-690.	1.2	30
2094	Proteinase expression in early mouse embryos is regulated by leukaemia inhibitory factor and epidermal growth factor. <i>Development (Cambridge)</i> , 1995, 121, 1005-1014.	1.2	171
2095	Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. <i>Development (Cambridge)</i> , 1996, 122, 181-193.	1.2	465
2096	Differential expression of plasminogen activators and their inhibitors in an organotypic skin coculture system. <i>Journal of Cell Science</i> , 1993, 106, 45-53.	1.2	40
2097	Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. <i>Journal of Cell Science</i> , 1994, 107, 2381-2391.	1.2	140
2098	Receptor-mediated endocytosis of urokinase-type plasminogen activator is regulated by cAMP-dependent protein kinase. <i>Journal of Cell Science</i> , 1997, 110, 1395-1402.	1.2	36
2099	Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. <i>Journal of Cell Science</i> , 1997, 110, 1091-1098.	1.2	91
2100	Cloned cDNA sequence for the human mesothelial protein <i>mesosecrin</i> <sup>™</sup> discloses its identity as a plasminogen activator inhibitor (PAI-1) and a recent evolutionary change in transcript processing. <i>Journal of Cell Science</i> , 1989, 94, 1-10.	1.2	22
2101	Neutralisation of uPA with a Monoclonal Antibody Reduces Plasmin Formation and Delays Skin Wound Healing in tPA-Deficient Mice. <i>PLoS ONE</i> , 2010, 5, e12746.	1.1	25
2102	Blood Peptidome-Degradome Profile of Breast Cancer. <i>PLoS ONE</i> , 2010, 5, e13133.	1.1	54
2103	Phenotypic Overlap between MMP-13 and the Plasminogen Activation System during Wound Healing in Mice. <i>PLoS ONE</i> , 2011, 6, e16954.	1.1	26
2104	BRMS1 Suppresses Glioma Progression by Regulating Invasion, Migration and Adhesion of Glioma Cells. <i>PLoS ONE</i> , 2014, 9, e98544.	1.1	24
2105	Tetranectin expression in gastric adenocarcinomas. <i>Histology and Histopathology</i> , 2002, 17, 471-5.	0.5	13
2106	Heparin decreases mesangial matrix accumulation after selective antibody-induced mesangial cell injury.. <i>Journal of the American Society of Nephrology: JASN</i> , 1992, 3, 921-929.	3.0	4
2107	Soluble Urokinase-Type Plasminogen Activator Receptor and Ferritin Concentration in Patients with Advanced Alimentary Tract Carcinoma. Relationship to Localization, Surgical Treatment and the Stage of the Disease <i>“ Preliminary Report. Advances in Clinical and Experimental Medicine</i> , 2014, 23, 959-967.	0.6	10
2108	Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.. <i>Acta Biochimica Polonica</i> , 2000, 47, 191-199.	0.3	23

#	ARTICLE	IF	CITATIONS
2109	Cell surface protease activation during RAS transformation: Critical role of the plasminogen receptor, S100A10. <i>Oncotarget</i> , 2016, 7, 47720-47737.	0.8	17
2110	Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells. <i>Oncotarget</i> , 2017, 8, 18712-18725.	0.8	47
2111	Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors. <i>Frontiers in Bioscience - Landmark</i> , 1999, 4, d178.	3.0	34
2112	Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. <i>World Journal of Gastroenterology</i> , 2005, 11, 1251.	1.4	151
2113	Estradiol agonists inhibit human LoVo colorectal-cancer cell proliferation and migration through p53. <i>World Journal of Gastroenterology</i> , 2014, 20, 16665.	1.4	22
2114	Intracellular proteins moonlighting as bacterial adhesion factors. <i>AIMS Microbiology</i> , 2018, 4, 362-376.	1.0	61
2115	Intracellular/surface moonlighting proteins that aid in the attachment of gut microbiota to the host. <i>AIMS Microbiology</i> , 2019, 5, 77-86.	1.0	25
2116	Mathematical modelling of cancer invasion of tissue: dynamic heterogeneity. <i>Networks and Heterogeneous Media</i> , 2006, 1, 399-439.	0.5	219
2117	The fibrinolytic system: Recent advances. <i>Cleveland Clinic Journal of Medicine</i> , 1988, 55, 531-541.	0.6	8
2119	Is the urokinase-type plasminogen activator system a reliable prognostic factor in gastric cancer?. <i>International Journal of Biological Markers</i> , 2006, 21, 162-169.	0.7	4
2120	Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). <i>International Journal of Biological Markers</i> , 2006, 21, 141-148.	0.7	7
2121	Protease Expression in Dedifferentiated Parosteal Osteosarcoma. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 213-221.	1.2	12
2124	GLIPR1 Protects Against Cigarette Smoke-Induced Airway Inflammation via PLAU/EGFR Signaling. <i>International Journal of COPD</i> , 2021, Volume 16, 2817-2832.	0.9	6
2125	Pulmonary Embolism Associated with Dialysis Access Procedure. , 2022, , 195-211.		0
2126	Host Proteinases as Targets for Therapeutic Intervention. <i>Handbook of Experimental Pharmacology</i> , 2000, , 207-219.	0.9	0
2127	The cJun N-terminal kinase (JNK) signaling pathway mediates induction of urokinase-type plasminogen activator (uPA) by the alkylating agent MNNG. <i>Blood</i> , 2000, 96, 1415-1424.	0.6	0
2129	Tissue-type Plasminogen Activator (tPA). <i>Handbook of Experimental Pharmacology</i> , 2001, , 57-89.	0.9	0
2130	Changes in Localization of Type I, III and IV Collagens and Their mRNA Expression During Follicular Atresia in Bovine and Porcine Ovaries.. <i>Journal of Reproduction and Development</i> , 2001, 47, 27-36.	0.5	3

#	ARTICLE	IF	CITATIONS
2131	Pathogenic Mechanisms in Streptococcal Diseases. , 2001, , 717-749.		1
2132	Thrombolytika. , 2002, , 158-177.		0
2134	The Role of RNA Binding Proteins in Tumorigenesis. Growth Hormone, 2002, , 271-284.	0.2	0
2136	The Plasminogen Activation System in Cell Invasion. , 2002, , 138-157.		0
2138	Molecular Regulation of Urokinase-Receptor Gene Expression as One Potential Concept for Molecular Staging and Therapy. Recent Results in Cancer Research, 2003, 162, 15-30.	1.8	1
2139	Plasminogen-Directed Phenotypes in Mice. , 2003, , 177-188.		0
2140	Fibrin Turnover in Pulmonary Fibrosis. Lung Biology in Health and Disease, 2003, , 397-418.	0.1	1
2141	Urokinase Inhibitor Design Based on Pharmacophore Model Derived from Diverse Classes of Inhibitors. Interdisciplinary Bio Central, 2006, 1, 115-122.	0.1	0
2142	Interactions entre les cellules tumorales et le microenvironnement tissulaire : Â« Quand le dialogue remplace le monologue Â». , 2007, , 97-123.		0
2143	ã,çãf-ãf«ã,®ãf¼ãâ¿œã•ç•sæª¶ç³»ã• Japanese Journal of Thrombosis and Hemostasis, 2007, 18, 302-308.	0.1	0
2144	Functional Role of Specific Secreted and Cell Surface Molecules inc Tumour Cell Invasion and Metastasis. Novartis Foundation Symposium, 1988, 141, 22-47.	1.2	0
2145	Role of Fibrinolysis in the Nasal System. , 2008, , 328-335.		0
2146	Measurement of mRNA of 11 biomarkers by RT-PCR to detect lymph node involvement in cervical cancer. International Journal of Biological Markers, 2008, 23, 74-82.	0.7	5
2147	Thrombosis in Childhood Cancer. Cancer Treatment and Research, 2009, 148, 223-242.	0.2	0
2151	Recent Insights into the Molecular and Cellular Contributions to Venous Thrombosis. , 2012, , 71-102.		1
2153	Tumor progression of the breast cancer mediated by plasminogen activation system. Japanese Journal of Thrombosis and Hemostasis, 2013, 24, 496-500.	0.1	0
2154	Interaction of Microglia with Neurons and Astrocytes Under Lesioned Neuronal Conditions. , 2013, , .		0
2155	Proteases and Their Role in Drug Development with an Emphasis in Cancer. , 2014, , 227-244.		0

#	ARTICLE	IF	CITATIONS
2156	Plasminogen Activator (PA) in Muscle, Its Activation Post-Denervation. Proceedings in Life Sciences, 1986, , 162-166.	0.5	1
2157	Adhesive Basement Membrane (BM) Proteins are Degraded by Plasminogen Activator in the Presence of Plasminogen. Proceedings in Life Sciences, 1986, , 167-171.	0.5	1
2158	The Role of Lipid Mediators in Blood Fibrinolysis. , 1987, , 241-248.		1
2159	Enzymatic and immunological properties of urokinase-converting protease obtained from urine.. Blood & Vessel, 1987, 18, 93-95.	0.0	0
2160	The placental type plasminogen activator inhibitor, PAI-2.. Blood & Vessel, 1989, 20, 121-130.	0.0	1
2161	Fibrinolysis. , 1989, , 179-215.		0
2162	The Role of Extracellular Proteases in Cell Proliferation and Differentiation. , 1989, , 187-213.		12
2163	Serpins and Brain Tumors: Roles in Pathogenesis. , 1990, , 301-311.		0
2164	Plasminogen activator inhibitors: Biological effects. , 1990, , 221-231.		2
2165	Urokinase-type plasminogen activator gene regulation as a model system for studying transcriptional activation by the cAMP-dependent protein kinase pathway. Molecular Aspects of Cellular Regulation, 1991, , 197-222.	1.4	0
2166	Production of Plasminogen Activators and Matrix Metalloproteinases by Endothelial Cells: Their Role in Fibrinolysis and Local Proteolysis. , 1992, , 111-126.		0
2167	Cathepsin B Efficiently Activets the Soluble and the Tumor Cell Receptor-Bound Form of the Proenzyme Urokinase-Type Plasminogen Activator (Pro-Upa). , 1992, , 115-120.		1
2168	Mechanisms of fibrinolysis and clinical use of thrombolytic agents. , 1992, 39, 197-217.		5
2169	Two Current Topics in Coagulation and Fibrinolysis. Japanese Journal of Thrombosis and Hemostasis, 1992, 3, 73-94.	0.1	0
2170	Binding and Activation of Plasminogen on the Surface of Staphylococcus Aureus and Group A, C, and G Streptococci. , 1992, , 153-162.		2
2171	Growth Factors and Cellular Proteolysis. Japanese Journal of Thrombosis and Hemostasis, 1992, 3, 95-105.	0.1	0
2172	Growth Factor Regulation of Brain Protease Inhibitors. Advances in Behavioral Biology, 1992, , 123-133.	0.2	0
2173	Plasminogen Activator Contained in Secretions of a Keratinocyte Cell Line and in the Fluid of Intraepidermal Pemphigus vulgaris Blisters Is Activated by Sodium dodecyl sulfate. , 1993, , 183-188.		0



#	ARTICLE	IF	CITATIONS
2174	Biological and Clinical Relevance of the Tumor-Associated Serine Protease uPA. , 1993, , 129-149.		0
2175	A Dominant Metastogene Confers Metastatic Potential to Tumor Cells. , 1993, , 87-95.		0
2176	Transcriptional regulation of the rat tissue type plasminogen activator gene: localization of DNA elements and nuclear factors mediating constitutive and cyclic AMP-induced expression. Molecular and Cellular Biology, 1993, 13, 266-275.	1.1	12
2177	Tumorassoziierte Fibrinolyse unter besonderer Berücksichtigung der klinischen und prognostischen Bedeutung von u-PA, t-PA und PAI-1 bei gynäkologischen Tumorerkrankungen. , 1993, , 163-173.		0
2178	Evidence for an extra-cellular function for protein kinase A. , 1993, 127-128, 283-291.		6
2179	SDS-Induced Activation of the Cutaneous Plasminogen Activator System: A Molecular Pathway Possibly Involved in SDS-Induced Skin Irritation. , 1993, , 348-354.		0
2180	Activation of Receptor-bound Single-chain Urokinase-type Plasminogen Activator by Plasmin. Japanese Journal of Thrombosis and Hemostasis, 1993, 4, 170-178.	0.1	0
2181	Differential Modulation of Plasminogen Activator Gene Expression by Oncogene-Encoded Protein Tyrosine Kinases. Molecular and Cellular Biology, 1993, 13, 5888-5897.	1.1	9
2182	Studies on the Regulatory System Governing Tissue Type-plasminogen Activator Gene Expression in Primary Cultured Rat Hepatocytes. Japanese Journal of Thrombosis and Hemostasis, 1994, 5, 49-53.	0.1	0
2183	Role of matrix metalloproteinases in invasion and metastasis: biology, diagnosis and inhibitors. , 1994, , 367-384.		5
2184	Electrostatic Cell to-Cell Adhesion by a Non-Proteolytic Component in a Protease Preparation.. Cell Structure and Function, 1994, 19, 165-172.	0.5	0
2185	Tumor invasion, proteolysis, and angiogenesis. , 1994, , 1-15.		0
2186	Studies on dynamics of collagenase and plasminogen activator in domestic rabbits bearing VX2 lingual carcinoma.. Nihon Koku Geka Gakkai Zasshi, 1994, 40, 1058-1070.	0.0	0
2187	Molecular Biology of Endocrine Receptors in the Ovary. , 1994, , 153-205.		1
2188	Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood, 1994, 83, 1883-1891.	0.6	16
2189	Plasmin-Mediated Pericellular Proteolysis by Keratinocytes: Extracellular Matrix Reorganization vs Tissue Damage. , 1995, , 201-211.		0
2190	Regulation of Vascular Fibrinolysis by Type 1 Plasminogen Activator Inhibitor. , 1995, , 205-209.		0
2191	Urokinasetypl-Plasminogenaktivator (uPA), sein Inhibitor PAI-1 und sein Rezeptor (CD87) sind an Tumorinvasion und Metastasierung solider maligner Tumoren beteiligt. , 1996, , 167-188.		0

#	ARTICLE	IF	CITATIONS
2192	Proteinases. , 1996, , 139-165.		4
2194	Roles of Î±2-Macroglobulin and its Receptor in the Regulation of the Plasminogen-Plasmin System. Japanese Journal of Thrombosis and Hemostasis, 1997, 8, 459-483.	0.1	0
2195	The Role of Cysteine and Serine Proteases in Gastric Carcinogenesis and Their Prognostic Impact in Gastric Cancer. , 1997, , 175-185.		0
2196	Cysteine and Serine Proteases in Duodenal Ulcer. , 1997, , 259-269.		0
2197	Inhibition of Metastasis of Intraocular Melanomas by Adenovirus-Mediated Gene Transfer of Plasminogen Activator Inhibitor Type 1 (PAI-1) in an Athymic Mouse Model. Blood, 1997, 90, 2738-2746.	0.6	26
2198	Role of Endothelial Plasminogen Activators in Fibrinolysis and Repair-Associated Angiogenesis. , 1998, , 77-97.		0
2199	Apposition-Dependent Induction of Plasminogen Activator Inhibitor Type 1 Expression: A Mechanism for Balancing Pericellular Proteolysis During Angiogenesis. Blood, 1998, 92, 939-945.	0.6	0
2200	The Urokinase Plasminogen Activation System in Breast Cancer. , 1999, , 325-345.		1
2201	Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition. Protein and Peptide Letters, 2014, 21, 1209-1229.	0.4	14
2202	Urokinase Plasminogen Activator System and Hematologic Malignancies: Potential Role in Diagnosis and Therapy. Journal of Hematology & Thromboembolic Diseases, 0, s1, .	0.1	0
2203	13 Tumor-specific imaging and photodynamic therapy targeting the urokinase receptor. Series in Cellular and Clinical Imaging, 2017, , 259-274.	0.2	0
2204	The Role of Stromelysin-3 (ST-3) in Progression of Oral Squamous Cell Carcinoma- A Narrative Review. Journal of Scientific Dentistry, 2018, 8, 29-31.	0.1	0
2205	Gene Expression and Function of the Cellular Receptor for u-PA (u-PAR). , 2019, , 30-42.		0
2206	Plasminogen Activator Enzymes and Inhibitors in Epithelial Biology and Pathology. , 2019, , 260-263.		0
2207	Molecular Basis for Plasminogen Activation, Surface Proteolysis, and Their Relation to Cancer. , 2020, , 133-148.		0
2209	Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration. Science Signaling, 2003, 2003, pe24-pe24.	1.6	1
2210	Biomarqueurs pronostiques LOE I/UC+++ . , 2007, , 185-195.		0
2211	A Novel Trypsin-like Serine Proteinase from the Venom of the Chinese Scorpion Buthus martensii Karsch. IFMBE Proceedings, 2008, , 829-832.	0.2	1

#	ARTICLE	IF	CITATIONS
2213	Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells. <i>Molecular and Cellular Biology</i> , 1987, 7, 3021-3025.	1.1	24
2214	Expression of Human Recombinant Plasminogen Activators Enhances Invasion and Experimental Metastasis of H-ras-Transformed NIH 3T3 Cells. <i>Molecular and Cellular Biology</i> , 1989, 9, 2133-2141.	1.1	48
2215	Activation of Plasmin in Mastitic Milk. <i>Acta Veterinaria Scandinavica</i> , 1988, 29, 485-491.	0.5	7
2216	Effects of Tissue Plasminogen Activator on Glaucoma Filter Blebs in Rabbits. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 1989, 20, 663-667.	0.4	14
2225	The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. <i>EMBO Journal</i> , 1994, 13, 3983-91.	3.5	43
2226	Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. <i>EMBO Journal</i> , 1989, 8, 3287-94.	3.5	34
2227	Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. <i>EMBO Journal</i> , 1991, 10, 3399-407.	3.5	23
2228	Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. <i>EMBO Journal</i> , 1990, 9, 467-74.	3.5	137
2229	A plasminogen activator is induced during goldfish optic nerve regeneration. <i>EMBO Journal</i> , 1990, 9, 2471-7.	3.5	9
2230	Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. <i>EMBO Journal</i> , 1987, 6, 1281-6.	3.5	83
2231	Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. <i>EMBO Journal</i> , 1992, 11, 4825-33.	3.5	167
2232	A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. <i>EMBO Journal</i> , 1992, 11, 4573-82.	3.5	38
2233	Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells. <i>EMBO Journal</i> , 1986, 5, 855-61.	3.5	22
2234	Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells. <i>Biochemical Journal</i> , 2000, 345 Pt 3, 595-601.	1.7	14
2235	Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma. <i>Transactions of the American Ophthalmological Society</i> , 1998, 96, 721-52.	1.4	13
2236	Murine lymphocytes with natural killer activity express CTL-derived serine protease genes. <i>Immunology</i> , 1989, 67, 269-73.	2.0	1
2237	Rapid appearance of plasmin in tear fluid after ocular allergen exposure. <i>Clinical and Experimental Immunology</i> , 1988, 73, 146-8.	1.1	19
2238	Modification of beta-2-microglobulin in sera from patients with small cell lung cancer: evidence for involvement of a serine protease. <i>Clinical and Experimental Immunology</i> , 1987, 67, 425-32.	1.1	30

#	ARTICLE	IF	CITATIONS
2239	Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. <i>American Journal of Human Genetics</i> , 1992, 50, 492-7.	2.6	36
2240	Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells. <i>American Journal of Pathology</i> , 1997, 151, 1655-61.	1.9	27
2241	Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms. <i>American Journal of Pathology</i> , 1998, 152, 703-10.	1.9	32
2242	In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas. <i>American Journal of Pathology</i> , 1997, 150, 283-95.	1.9	8
2243	Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. <i>American Journal of Pathology</i> , 1997, 150, 359-69.	1.9	35
2244	Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. <i>American Journal of Pathology</i> , 1995, 146, 1150-60.	1.9	70
2245	Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. <i>American Journal of Pathology</i> , 1995, 146, 1029-39.	1.9	2,275
2246	Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. <i>American Journal of Pathology</i> , 1995, 147, 183-92.	1.9	25
2247	Prognostic role of urokinase-type plasminogen activator in human gliomas. <i>American Journal of Pathology</i> , 1995, 147, 114-23.	1.9	66
2248	Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. <i>American Journal of Pathology</i> , 1995, 147, 1559-66.	1.9	10
2249	Human skin in organ culture. Elaboration of proteolytic enzymes in the presence and absence of exogenous growth factors. <i>American Journal of Pathology</i> , 1995, 146, 210-7.	1.9	25
2250	High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. <i>American Journal of Pathology</i> , 1990, 136, 1339-48.	1.9	183
2251	Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix. <i>American Journal of Pathology</i> , 1989, 135, 631-6.	1.9	29
2252	Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. <i>American Journal of Pathology</i> , 1991, 138, 1059-67.	1.9	322
2253	Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. <i>American Journal of Pathology</i> , 1991, 138, 111-7.	1.9	142
2254	Basic fibroblast growth factor promotes proliferation of rat glomerular visceral epithelial cells in vitro. <i>American Journal of Pathology</i> , 1992, 141, 107-16.	1.9	38
2255	Plasminogen activator inhibitor-1 deposition in the extracellular matrix of cultured human mesangial cells. <i>American Journal of Pathology</i> , 1992, 141, 117-28.	1.9	24
2256	Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone. <i>American Journal of Pathology</i> , 1992, 141, 611-21.	1.9	37

#	ARTICLE	IF	CITATIONS
2257	Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. American Journal of Pathology, 1993, 142, 359-65.	1.9	204
2258	Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. American Journal of Pathology, 1994, 144, 70-81.	1.9	110
2259	Plasminogen activation in healing human wounds. American Journal of Pathology, 1994, 144, 1269-80.	1.9	95
2260	Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion. American Journal of Pathology, 1994, 145, 561-73.	1.9	13
2261	Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development (Cambridge), 1996, 122, 181-93.	1.2	183
2262	Matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Journal of Chemical Sciences, 1999, 111, 239-254.	0.7	2
2263	Inflammatory Endotypes and Tissue Remodeling Features in Antrochoanal Polyps. Allergy, Asthma and Immunology Research, 2021, 13, 863.	1.1	9
2264	Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer. Cancers, 2022, 14, 498.	1.7	16
2265	Simulated in vitro hypoxic conditions from psoriatic arthritis cartilage change plasminogen activating system urokinase and serpine functionality. Reversal of antiapoptotic protection suggests common homeostatic buffering. Postepy Dermatologii i Alergologii, 0, , .	0.4	0
2266	Role of Serine Proteases at the Tumor-Stroma Interface. Frontiers in Immunology, 2022, 13, 832418.	2.2	18
2267	Activation of plasmin in mastitic milk. Acta Veterinaria Scandinavica, 1988, 29, 485-91.	0.5	4
2268	The significance of Fas, tumor necrosis factor-related apoptosis-inducing ligand and fibrinolytic factors in the assessment of malignant pleural effusion. Archives of Biological Sciences, 2022, 74, 119-126.	0.2	0
2269	The C-Terminal Domain of Staphylococcus aureus Zinc Transport Protein AdcA Binds Plasminogen and Factor H In Vitro. Pathogens, 2022, 11, 240.	1.2	1
2270	Plasminogen activator activity and plasminogen activator inhibition in the uterus of ewes after the induction of oestrus synchronization or superovulation, involving eCG. Small Ruminant Research, 2022, 210, 106672.	0.6	1
2284	The urokinase-system--role of cell proliferation and apoptosis. Histology and Histopathology, 2008, 23, 227-36.	0.5	63
2285	Corneal Wound Healing, Recurrent Corneal Erosions, and Persistent Epithelial Defects. , 2022, , 331-360.		1
2290	Urokinase-Type Plasminogen Activator Triggers Wingless/Int1-Independent Phosphorylation of the Low-Density Lipoprotein Receptor-Related Protein-6 in Cerebral Cortical Neurons. Journal of Alzheimer's Disease, 2022, 89, 877-891.	1.2	1
2291	Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk. Frontiers in Pediatrics, 0, 10, .	0.9	0

#	ARTICLE	IF	CITATIONS
2292	Suppression of the Invasive Capacity of Human Breast Cancer Cells by Inhibition of Urokinase Plasminogen Activator via Amiloride and B428. <i>American Surgeon</i> , 2000, 66, 460-464.	0.4	19
2293	The Mast Cell as Site of Tissue-Type Plasminogen Activator Expression and Fibrinolysis. <i>Journal of Immunology</i> , 1999, 162, 1032-1041.	0.4	76
2294	Moonlighting proteins [ML proteins]: The pandora's box of insidious oro-dental diseases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2023, 1870, 119435.	1.9	0
2295	Microparticle Phosphatidylserine Mediates Coagulation: Involvement in Tumor Progression and Metastasis. <i>Cancers</i> , 2023, 15, 1957.	1.7	3
2297	Multifunctional Proteins and their Role in the Vital Activity of Cells. <i>Russian Journal of Bioorganic Chemistry</i> , 2023, 49, 448-461.	0.3	1
2304	<i>Streptococcus pyogenes</i> . , 2024, , 705-753.		0